### What is the effectiveness of community diagnostic centres: a rapid review

**Authors:** Alesha Wale<sup>1</sup>, Chukwudi Okolie<sup>1</sup>, Jordan Everitt<sup>1</sup>, Amy Hookway<sup>1</sup>, Hannah Shaw<sup>1</sup>, Kirsty Little<sup>1</sup>, Ruth Lewis<sup>2</sup>, Alison Cooper<sup>2</sup>, Adrian Edwards<sup>2</sup>

1 Public Health Wales, Wales, United Kingdom 2 Wales COVID-19 Evidence Centre, Wales, United Kingdom

**Abstract:** The COVID-19 pandemic directly impacted diagnostic services in the UK and globally. This exacerbated the rapid rise in demand for diagnostics that existed before the pandemic, resulting in significant numbers of patients requiring various diagnostic services and increased waiting times for diagnostics and treatment. In 2021, community diagnostic centres were launched in England. As diagnostic services account for over 85% of clinical pathways within the NHS and cost over six billion pounds per year, diagnostic centres across a broader range of diagnostic services may be effective, efficient, and cost-effective in the UK health sector.

This rapid review aimed to identify and examine the evidence on the effectiveness of community diagnostic centres. A prior Research Evidence Map was used, along with the stakeholder input, to select a substantive focus for the rapid review. Comparative studies examining community diagnostic centres that accept referrals from primary care as a minimum were included. Prioritised outcomes included those relating to impact on capacity and pressure on secondary care, ensuring equity in uptake or access, and economic outcomes

The review included evidence available up until August 2022. Twenty primary studies were included. Twelve individual diagnostic centres were evaluated across the 20 studies. Most studies evaluated diagnostic centres located within hospital settings. One study evaluated a mobile diagnostic ultrasound service. Most studies were specific to cancer diagnoses. Six studies covered multiple health conditions, which will have also included cancer. Other conditions reported included: severe anaemia, fever of uncertain nature, and multiple sclerosis. A range of outcomes was identified. 11 studies conducted in Spain evaluated the same type of clinic i.e. Quick Diagnostic Unit and seven studies evaluated the same centre at different time intervals. No evidence relating to equity of access was identified.

The evidence relating to effectiveness appeared mixed. There is evidence to suggest that diagnostic centres can reduce various waiting times, including time to surgical consultation, time from consultation to treatment, time from cancer suspicion to treatment, time from diagnosis to specialist consultation and time from diagnosis to treatment. Diagnostic centres could help reduce pressure on secondary care by avoiding hospitalisations in stable patients.

Cost-effectiveness may depend on whether the diagnostic centre is running at full capacity. Factors that could determine the costs incurred by a centre include the diagnostic and clinical complexity of patients, and the characteristics of the unit including the number of staff and contribution of staff time.

**Funding statement:** Public Health Wales was funded for this work by the Wales COVID-19 Evidence Centre, itself funded by Health & Care Research Wales on behalf of Welsh Government.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.









## Wales COVID-19 Evidence Centre (WCEC) Rapid Review

## What is the effectiveness of community diagnostic centres: a rapid review Report number – RR00043 (November 2022)

#### **Rapid Review Details**

Review conducted by: Public Health Wales (PHW)

#### **Review Team:**

- Alesha Wale, Public Health Wales, <u>Alesha.Wale@wales.nhs.uk</u>
- Chukwudi Okolie, Public Health Wales, <u>Chukwudi.Okolie@wales.nhs.uk</u>
- Jordan Everitt, Public Health Wales, Jordan. Everitt2@wales.nhs.uk
- Amy Hookway, Public Health Wales, amy.hookway2@wales.nhs.uk
- Hannah Shaw, Public Health Wales, <u>Hannah.Shaw@wales.nhs.uk</u>
- Kirsty Little, Public Health Wales, Kirsty.Little@wales.nhs.uk

Review submitted to the WCEC: November 2022

Stakeholder consultation meeting: 22<sup>nd</sup> November 2023

Rapid Review report issued by the WCEC: December 2022

#### **WCEC Team:**

Ruth Lewis, Adrian Edwards, Alison Cooper involved in drafting the Topline Summary and editing.

**This review should be cited as:** RR00043\_Wales COVID-19 Evidence Centre\_What is the effectiveness of community diagnostic centres: a rapid review. November 2022

**Disclaimer:** The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The WCEC and authors of this work declare that they have no conflict of interest.

# What is the effectiveness of community diagnostic centres: a rapid review Report number – RR00043 (November 2022)

#### **TOPLINE SUMMARY**

#### What is a Rapid Review?

Our rapid reviews (RR) use a variation of the systematic review approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. They follow the methodological recommendations and minimum standards for conducting and reporting rapid reviews, including a structured protocol, systematic search, screening, data extraction, critical appraisal, and evidence synthesis to answer a specific question and identify key research gaps. They take 1- 2 months, depending on the breadth and complexity of the research topic/ question(s), extent of the evidence base, and type of analysis required for synthesis.

This report is linked to a **rapid evidence map** published as: <u>REM00043</u> Wales COVID-19 Evidence Centre. A rapid evidence map of what evidence is available on the effectiveness of community diagnostic centres. September 2022

#### Who is this summary for?

**Diagnostics Strategy Board** 

#### **Background / Aim of Rapid Review**

The COVID-19 pandemic directly impacted diagnostic services in the UK and globally. This exacerbated the rapid rise in demand for diagnostics that existed before the pandemic, resulting in significant numbers of patients requiring various diagnostic services and increased waiting times for diagnostics and treatment. In 2021, community diagnostic centres were launched in England. As diagnostic services account for over 85% of clinical pathways within the NHS and cost over £6 billion per year, diagnostic centres across a broader range of diagnostic services may be effective, efficient, and cost-effective in the UK health sector. This rapid review aimed to identify and examine the evidence on the effectiveness of community diagnostic centres. The prior REM was used, along with the stakeholder input, to select a substantive focus for the RR. It was decided that only comparative studies examining community diagnostic centres that accept referrals from primary care as a minimum would be included. Prioritised outcomes included those relating to impact on capacity and pressure on secondary care, ensuring equity in uptake or access, and economic outcomes.

#### **Key Findings**

Extent of the evidence base

- Twenty primary studies were included: 16 quasi-experimental studies (all comparative studies using cross sectional post-test only designs), three economic evaluations and one randomised controlled trial (the latter published in 1998, and now superseded by more recent research).
- Twelve individual diagnostic centres were evaluated across the 20 studies.
- Most studies (n=19) evaluated diagnostic centres located within hospital settings. One study evaluated a mobile diagnostic ultrasound service.
- Most studies (n=10) were specific to cancer diagnoses. Six studies covered multiple health conditions, which will have also included cancer. Other conditions reported

included: severe anaemia (n=1), fever of uncertain nature (n=1), and multiple sclerosis (n=1). One study did not report a particular health condition of interest.

- A range of outcomes was identified from studies conducted in Canada (n=4), UK (n=5). and Spain (n=11). The 11 studies conducted in Spain evaluated the same type of clinic -Quick Diagnostic Unit (QDU), and seven of these studies evaluated the same centre at different time intervals.
- No evidence relating to equity of access was identified.
- No comparative ongoing studies were identified.

#### Recency of the evidence base

The review included evidence available up until August 2022. Included studies were published between 1998 and 2021, with data collection between 1995 and 2018.

#### Evidence of effectiveness

- The evidence relating to effectiveness appeared mixed.
- There is evidence to suggest that diagnostic centres can reduce various waiting times. including time to surgical consultation, time from consultation to treatment, time from cancer suspicion to treatment, time from diagnosis to specialist consultation and time from diagnosis to treatment.
- Diagnostic centres could help reduce pressure on secondary care by avoiding hospitalisations in stable patients, reducing the number of visits required to receive a definite diagnosis, and increasing the number of patients in whom a definite outcome (discharged or scheduled for surgery) was reached.
- Cost-effectiveness may depend on whether the diagnostic centre is running at full capacity. Factors that could determine the costs incurred by a diagnostic centre include the diagnostic and clinical complexity of patients, and the characteristics of the unit including the number of staff and contribution of staff time.

#### Best quality evidence

All studies had considerable methodological limitations. The three economic evaluation studies (Bosch et al 2021, Sewell et al 2020, Sanclemente-Ansó et al 2016) were considered the most robust.

#### **Policy Implications**

- This rapid review highlighted possible benefits of diagnostic centres, particularly with regards to reducing waiting times and pressure on hospitals.
- As the data collection dates of included studies are wide-ranging, and many of the diagnostic centres included were from other countries where the healthcare system is different to that of the UK, the results may not be generalisable.
- Further research is needed to determine the optimum location for diagnostic centres.
- Further research is required to evaluate the effectiveness of diagnostic centres for conditions other than cancer.
- Further well-designed robust research from the UK and other comparable countries is needed to better understand the effectiveness and accessibility of diagnostic centres within Wales. (Only one UK study was published after 2013)
- Comparative impact evaluations should be incorporated into service development plans from the onset, to assess the effectiveness of newly opened diagnostic centres in the UK over time.

#### Strength of Evidence

Most study designs used weak methods that may be less appropriate for inferring effectiveness. Studies varied by countries, designs, definitions and often had inconsistent findings, so results should be interpreted with caution.

#### TABLE OF CONTENTS

TABLE OF CONTENTS......5 BACKGROUND ......8 1.1 Who is this review for?......8 1.2 Purpose of this review ......8 1.3 Definition of community diagnostic centres......9 RESULTS......9 2. 2.1 2.2 Impact of diagnostic centres on waiting times......10 2.2.1 Bottom line results for the impact of diagnostic centres on waiting times ......14 2.3 Impact of diagnostic centres on capacity and pressure on secondary care......14 2.3.1 Bottom line results for the impact of diagnostic centres on capacity and pressure on secondary care ......16 2.4 Economic impact of diagnostic centres and other economic outcomes......16 2.4.1 Economic evaluations.......17 2.4.2 Generic economic outcomes derived from quasi-experimental studies......17 2.4.3 Bottom line results for the economic effectiveness of diagnostic centres............20 DISCUSSION......56 3.1 Summary of the findings.......56 3.3 Implications for policy and practice .......57 3.4 Strengths and limitations of this rapid review.......57 4. RAPID REVIEW METHODS......60 5.1 Eligibility criteria ......60 5.2 Literature search......60 5.4 Data extraction......61 5.5 Study design categorisation ......61 5.6 Quality appraisal ......61 EVIDENCE .......62 6.2 Study selection flow chart.......63 6.3 Quality appraisal tables ......64 ADDITIONAL INFORMATION......66 7.2 Information available on request .......66 

8.	ABOUT THE WALES COVID-19 EVIDENCE CENTRE (WCEC)	67
9.	APPENDIX	68

#### **Abbreviations:**

Acronym	Full Description
2WW	Two-Week Wait
COVID-19	Coronavirus Disease 2019
CMV	Cytomegalovirus
CNS	Clinical Nurse Specialist
CT	Computed Tomography
DDC	Demyelinating Disease Diagnostic Clinic
DES	Discrete-Event Simulation
D.F.	Degrees Of Freedom
EBV	Epstein-Barr Virus
ED	Emergency Department
EUS	Upper Gastrointestinal Endoscopic Ultrasound
FDG-PET	Fluorodeoxyglucose-Positron Emission Tomography
FNA	Fine-Needle Aspiration
FUN	Fever of Uncertain Nature
HCSW	Healthcare Support Worker
JBI	Joanna Briggs Institute
LRDC	Lymphoma Rapid Diagnosis Clinic
MS	Multiple Sclerosis
PHC	Primary Healthcare Centres
RABC	Rapid Access Breast Clinic
RADS	Rapid Diagnosis And Support
RCT	Randomised Controlled Trial
RDC	Rapid Diagnostic Centre/clinic
RDU	Rapid Diagnostic Unit
REM	Rapid Evidence Map
RO	Radiation Oncology
RR	Rapid Review
RT	Radiotherapy Treatment
SD	Standard Deviation
TAC	Technical Advisory Cell
TS	Traditional System
QALYs	Quality Adjusted Life Years
QDU	Quick Diagnostic Unit
UHN	University Health Network
UK	United Kingdom
WCEC	Wales COVID-19 Evidence Centre

#### 1. BACKGROUND

#### 1.1 Who is this review for?

This Rapid Review (RR) was conducted as part of the Wales COVID-19 Evidence Centre Work Programme (WCEC). The above question was suggested by the Welsh Government Technical Advisory Cell (TAC) to inform the Diagnostics Strategy Board and support the implementation of community diagnostic centres across Wales.

#### 1.2 Purpose of this review

The COVID-19 pandemic has had a direct impact on diagnostic services in the United Kingdom (UK) and globally. This, in addition to the rapid rise in demand for diagnostics that existed prior to the pandemic, has resulted in a significant backlog of patients requiring various diagnostic services and increased waiting times for diagnostics and treatment. The most recently published data shows that in Wales, the number of patients waiting longer than the target of eight weeks for diagnostics rose from 10.8% (7,964) in March 2020 to 41.5% (44,489) in August 2022 (StatsWales 2022). An Independent Review of Diagnostic Services for NHS England chaired by Professor Sir Mike Richards, called for significant reform and investment in diagnostic services, and recommended the establishment of community diagnostic centres to aid in tackling the backlog and delays to diagnostic services (National Health Service England 2020). Community diagnostic centres aim to provide patients with quicker and more convenient direct access to diagnostic services than is currently available, and reduce pressure on hospitals (Department of Health and Social Care 2021). With an emphasis on direct patient access to services from primary care, these centres can be located within hospital settings or within the community. In Wales, community diagnostic centres are generally referred to as Regional Diagnostic Hubs (but are referred to here as Community Diagnostic Centres, for the purpose of this report).

In England, community diagnostic centres were first launched in 2021 in a range of settings including hospitals, football stadiums, and repurposed retail outlets (Department of Health and Social Care 2021). At present, over 90 community diagnostic centres have been opened, with plans to open up to 160 centres by 2025 (National Health Service England 2022). In Wales, a plan to create a network of community diagnostic centres was outlined by the Welsh Government in April 2022 (Welsh Government 2022). As diagnostic services currently account for over 85% of clinical pathways within the NHS and cost over £6 billion a year (National Health Service 2022), community diagnostic centres across a broader range of diagnostic services may be an effective, efficient, and cost-effective introduction to the UK health sector. These services could ensure timely diagnoses and reduced waiting times in a convenient location, ensuring people receive the treatment they need. Furthermore, community diagnostic centres could help address inequalities by providing accessible diagnostic services to people from particular social groups who may be less likely to engage with the healthcare system (The King's Fund 2022).

The purpose of this RR is to draw on the earlier work undertaken to identify and examine the evidence on the effectiveness of community diagnostic centres. This preliminary work included a rapid evidence map (REM) that identified a large body of evidence relevant to community diagnostic centres: REM00043\_Wales COVID-19 Evidence Centre. A rapid evidence map of what evidence is available on the effectiveness of community diagnostic centres. September 2022. In order to measure effectiveness as part of the current RR, stakeholders prioritised outcomes, identified during the REM, that evaluated whether community diagnostic centres can impact capacity and pressure on secondary care, as well as ensuring equity in uptake or access as most important, along with economic outcomes. Therefore, our RR focussed on outcomes that were best able to demonstrate this. Due to the

large number of studies identified during the initial investigation into this topic, **only comparative studies examining community diagnostic centres that accept referrals from primary care as a minimum, were included in this RR**. Comparative studies are defined here as studies that investigated some aspect of a diagnostic centre and compared it with usual care, another diagnostic centre or some other service.

#### 1.3 Definition of community diagnostic centres

Community diagnostic centres are described within the international literature using a variety of terms and definitions. For the purposes of this RR, community diagnostic centres are defined as health services aimed at improving population health outcomes by providing quicker and easily accessible diagnostic services in the community, which are accessible to primary care practitioners/services, thereby relieving pressure on secondary care services. In Wales, community diagnostic centres are generally referred to as Regional Diagnostic Hubs to avoid confusion with the descriptors or acronyms used for other similar services. For the purposes of this RR, we use the descriptor 'community diagnostic centres' to incorporate the range of terms used for these services. However, the different descriptors used within individual studies are also outlined and discussed in this report.

#### 2. RESULTS

#### 2.1 Overview of the Evidence Base

A total of 20 primary studies met our inclusion criteria. Sixteen of these were quasi-experimental studies comprising cross sectional post-test only designs, three were economic evaluations and one was a randomised controlled trial (RCT). Included studies were conducted in Spain (n=11), UK (n=5), and Canada (n=4), and were published between 1998 and 2021. Ten studies were specific to cancer diagnoses, six studies reported on multiple health conditions (rather than a specific condition) and three studies covered a single health condition including severe anaemia (n=1), fever of uncertain nature (FUN) (n=1), and multiple sclerosis (MS) (n=1). One study did not report a particular health condition of interest. Included studies varied in their reporting of outcomes, with some being purely descriptive and others offering inferential statistical findings. A detailed matrix of the outcomes reported by each study presented in this RR can be found in Figure 1. A detailed summary of included studies organised by country, diagnostic centre and comparator, can be found in Table 1.

Twelve individual diagnostic centres were assessed across the 20 included studies. Details on the characteristics of each diagnostic centre can be found in Appendix 1. The majority of studies reported on diagnostic centres located within hospital settings (n=19). Only one study (Pallan et al 2005) reported findings from a diagnostic service located within the community setting. As outlined in our eligibility criteria (Table 2 in Section 5), all diagnostic centres accepted referrals from primary care as a minimum. The diagnostic centres in five studies accepted referrals solely from primary care while the remaining 15 studies accepted referrals from primary care and other referral sources such as emergency departments (ED) and hospital outpatient clinics.

The methodological quality of the included studies was assessed using the appropriate Joanna Briggs Institute (JBI) critical appraisal tool (for quasi-experimental studies, RCTs and economic evaluations) (see Tables 3, 4, 5). The JBI tool contains a set of signalling questions for particular domains of bias, including bias in selection of participants, bias in measurement of outcomes, and bias in selection of the reported results. Critical appraisal of the economic evaluation studies showed that all three studies measured outcomes and costs accurately. However, appraisal determined that none reported results that were

generalisable to the setting of interest in our review. The single RCT measured all outcomes in a reliable way across groups but had issues with blinding of participants and outcome assessors. In the quasi-experimental studies, participants received similar treatment/care however, there appeared to be differences between participants included in compared groups. While all studies had some methodological issues, none were excluded from the review after quality appraisal.

#### 2.2 Impact of diagnostic centres on waiting times

Nineteen included studies reported a range of outcomes relevant to waiting times. These included outcomes such as time to first visit, time to examination and time to diagnosis. In addition, some outcome measures relating to waiting times were specific to cancer studies, such as time from cancer suspicion to diagnosis, and time to surgical/specialist consultation. Some outcome measures relating to waiting times may have been measured at the same time intervals across the diagnostic pathway, but as they were often poorly defined across the studies, we have reported them separately.

#### Time to first visit

Time to first visit (the interval between referral and first visit to the diagnostic centre) was reported in 10 studies covering five diagnostic centres (three from Spain and two from the UK). The findings from the most recent studies are reported below for each diagnostic centre. Two studies covered the same diagnostic centre (Montori-Palacín et al 2017; Bosch et al 2020). However, one of these compared outcomes between patients referred to the diagnostic centre and patients hospitalised in inpatient wards (Bosch et al 2020), while the other compared the diagnostic performance of two diagnostic centres of different levels of complexity (secondary vs tertiary) (Montori-Palacín et al 2017). The findings of both studies are reported below. Study findings were generally mixed.

- A reduction in time to first visit was reported in two studies (Choudhury et al 2013, Porter et al 2003). Choudhury et al (2013) assessed the efficacy of a newly established rapid diagnostic clinic (RDC) for patients with suspected head and neck cancer by conducting an audit of new referrals made to a head and neck clinic during a six-month period before the new clinic was established (pre-RDC) and compared this with findings from the RDC period. The study reported a **statistically significant reduction in the time from referral to the patients being seen between pre-RDC period and RDC period** for both patients referred via the two-week wait (2WW) source (11.2 vs 9.2 days; p = 0.0002) and for patients referred via all other referral sources (33.5 vs 23.3 days; p = 0.0015).
- Porter et al (2003) compared a newly established demyelinating disease diagnostic clinic (DDC) with two existing clinical settings in the management of MS and reported that **the mean waiting time to first visit was shorter for the patients attending the DDC** (5.9 weeks) compared to the general neurology clinic (7.7 weeks) and the inpatient investigation unit (10.0 weeks) operating within the same hospital.
- Bosch et al (2020) compared outcomes between patients referred to a quick diagnostic unit (QDU) and patients hospitalised in inpatient wards and reported that the time to first QDU visit (outpatients) was found to be significantly longer than the time to admission in hospitalised patients (1.2 vs 0.7 days; p<0.001).
- Bosch et al (2018) compared outcomes between patients referred to two QDUs and patients hospitalised in inpatient wards and reported that the **time to first QDU visit** (outpatients) was found to be significantly longer than the time to admission in hospitalised patients (1.7 vs 0.6 days; p<0.001). It should be noted that two QDUs were combined and analysed as a single outpatient unit in this study.

- Montori-Palacín et al (2017) compared the diagnostic performance of two QDUs of different levels of complexity (secondary vs tertiary) and found that the median time to first visit was longer in the QDU of a secondary hospital than that of the QDU of its reference general tertiary hospital (5 vs 3 days; p=0.008). The study authors suggested that this difference could be due to direct appointments to the tertiary hospital QDU from the ED and a lack of administrative support of the secondary hospital QDU. This study, however, did not provide any non-QDU comparator data.

#### Time to diagnostic examination

Time to examination (the interval between diagnostic centre physician's order and the examination being actually performed) was reported in four studies covering four different diagnostic centres (three from Spain and one from the UK). Two studies reported findings from the same diagnostic centre (Bosch et al 2012c; Bosch et al 2018), however one of these studies compared outcomes between patients referred to the diagnostic centre and patients hospitalised in inpatient wards (Bosch et al 2012c), while the other study combined two diagnostic centres into a single unit and compared outcomes with patients hospitalised in inpatient wards (Bosch et al 2018). The findings of both studies are therefore reported below. Similarly, Montori-Palacín et al (2017) and Bosch et al (2018) reported findings from the same diagnostic centre. However, unlike the latter, Montori-Palacín et al (2017) compared the diagnostic performance of the diagnostic centre with that of another diagnostic centre of a different level of complexity. Study findings were generally mixed.

- Pallan et al (2005) assessed the effectiveness of a primary care-based mobile diagnostic ultrasound service provided by an independent radiographer compared to an NHS Trust diagnostic ultrasound service and found that the mean waiting time for an ultrasound scan appointment was shorter for the community service than for the hospital service (17.44 days vs 44.53 days).
- Bosch et al (2018) compared waiting times of patients attending two outpatient QDUs versus conventional hospitalisation for the diagnosis of lymphoma and found that the mean time to biopsy was significantly longer in the outpatient QDUs than in inpatient settings (7.4 vs 3.5 days; p< 0.001). Two QDUs were combined and analysed as a single outpatient unit in this study.
- Bosch et al (2012c) compared waiting times of patients attending a QDU versus conventional hospitalisation for those with severe anaemia and found that the mean waiting time to gastroscopy was shorter in the QDU than in inpatient settings (3.23 vs 3.47 days) while the mean waiting time to colonoscopy was longer in the QDU than in inpatient settings (4.45 vs 4.24 days). However, these differences were not statistically significant.
- Montori-Palacín et al (2017) compared waiting times of two QDUs of different levels of complexity. Significant differences were observed in the waiting times to computed tomography (CT) scan (2 vs 3 days; p=0.03) and cytology/biopsy studies (3 vs 4 days; p=0.03), which were longer in patients attending the QDU of the tertiary hospital, and in the waiting times to ultrasonography (3 vs 2 days; p=0.04), endoscopy (12 vs 5 days; p<0.001), scintigraphy (7 vs 2 days; p<0.001), and body fluorodeoxyglucose-positron emission tomography (FDG-PET) (6 vs 3 days; p<0.001), compared to patients attending the QDU of the secondary hospital. However, this study did not provide non-QDU comparator data.</p>

Time to diagnosis

Time to diagnosis (the time elapsed between the request of the decisive diagnostic procedure and the cyto/pathological diagnosis) was reported in 14 studies covering six diagnostic centres (three from Spain, two from Canada, and one from the UK). The findings from the most recent studies for each diagnostic centre are reported below. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2021), however the former compared outcomes between patients referred to the diagnostic centre and patients hospitalised in inpatient wards, while the latter compared the diagnostic performance of two diagnostic centres of different levels of complexity. Both studies are reported below. Findings were generally mixed.

- Nixon et al (2020) examined the impact of a nurse practitioner-led lymphoma rapid diagnosis clinic (LRDC) by comparing findings from the initial 30-month experience of the LRDC with those prior to its implementation. The time from initial assessment to lymphoma diagnosis was found to be significantly shorter for the patients attending the LRDC compared to historical controls (16 vs 28 days; p<0.001).</p>
- Sethukavalan et al (2013) compared wait time intervals for patients with prostate cancer diagnosed at a rapid diagnostic unit (RDU) versus the usual community process. The results showed **that time from urologist visit to diagnosis was significantly shorter in the RDU patients** compared to community patients (29 vs 100 days; p=0.0094).
- Sewell et al (2020) found that patients diagnosed directly at a RDC had a shorter time to diagnosis than patients receiving usual care (5.9 days vs 84.2 days).
   However, this study was conducted using patient-level discrete-event simulation (DES) and decision analytic modelling.
- Bosch et al (2020) found **no significant differences** between admission time to diagnosis (hospitalised patients) and the QDU time to diagnosis (4.1 vs 4.3 days; p=0.163).
- Bosch et al (2018) found that the **time to diagnosis of QDU outpatients was significantly longer than the admission time to diagnosis among inpatients** (hospitalised) (16.2 vs 12.3 days; p<0.001). Two QDUs were combined and analysed as a single outpatient unit in this study.
- Bosch et al (2021) compared the diagnostic performance of two QDUs of different levels of complexity (secondary vs tertiary) and found that the **time to diagnosis** was significantly longer in the QDU of a secondary hospital than in QDU of its reference general tertiary hospital (12 vs 8 days; p<0.0001). This study, however, does not provide any non-QDU comparator data.

#### Wait time from abnormal imaging to biopsy and from biopsy to pathology verification

One study conducted in Canada reported on the wait time from abnormal imaging to biopsy and from biopsy to pathology verification.

- Arnaout et al (2013) assessed the impact of a Rapid Diagnosis and Support (RADS) programme on diagnostic and treatment wait times for patients with a high probability of breast cancer compared to patients who had BI-RADS 5 diagnostic imaging in the year before the programme (PRE-RADS). Significant reductions were found in the mean wait time from abnormal imaging to biopsy (7.1 days vs 3 days; p<0.01) and from biopsy to pathology verification (3.9 days vs 3.4 days; p<0.01) for patients attending the RADS programme compared to PRE-RADS.</p>

#### Time to surgical consultation

Time to surgical consultation (the time from presentation to seeing the surgeon/ the interval between pathology verification to surgical consultation) was reported by two Canadian studies investigating two different rapid diagnostic services. It should be noted that these studies use different start points to measure this outcome, as described above. Both studies identified a statistically significant reduction in wait times compared to their comparators.

- McKevitt et al (2017) reported that **patients seen at a Rapid Access Breast Clinic** (RABC) had a significantly decreased time from presentation to surgical consultation (33 vs 86 days; p<0.0001) for both malignant (36 vs 59 days; p=0.0007) and benign diagnoses (31 vs 95 days; p<0.0001) compared to patients diagnosed through the traditional system (TS).
- Arnaout et al (2013) reported that the time from pathology verification to surgical consultation had been reduced significantly from 16.1 to 5.9 days (p<0.01) in patients who took part in a RADS programme compared to patients who had BI-RADS 5 diagnostic imaging in the year before the programme (PRE-RADS).

#### Time from cancer suspicion to treatment

One study conducted in Canada reported the time from cancer suspicion to treatment (the time from suspicion of cancer to radiotherapy).

- Sethukavalan et al (2013) compared wait time intervals for patients with prostate cancer diagnosed at a multidisciplinary RDU versus the usual community referral process. The results showed a **statistically significant difference in the time** interval from cancer suspicion to treatment (158 days vs 218; p = 0.046) in favour of the patients attending the RDU.

#### Time from consultation to treatment

Time from consultation to therapy (the time interval from consultation to treatment/surgery) was reported in five studies covering five different diagnostic centres (four from Canada and one from UK). All studies identified a reduction in time from consultation to treatment compared to their comparators, but only two identified a statistically significant difference.

- Nixon et al (2020) found that the time from initial assessment to treatment of aggressive lymphomas and Hodgkin's lymphoma was significantly shorter for patients attending a LRDC compared to historical controls (29 days vs 48 days; p<0.001).</li>
- Arnaout et al (2013) reported that **time from surgical consultation to treatment** was reduced significantly from 31.5 to 24.1 days (p=0.04) for patients who took part in a RADS programme compared to patients who had BI-RADS 5 diagnostic imaging in the year before the programme (PRE-RADS).
- McKevitt et al (2017) reported that patients seen at a RABC had a **decreased time from surgical consultation to surgery** compared to patients diagnosed through the TS (31 days vs 33 days). However, this difference was not statistically significant (p=0.78).
- Choudhury et al (2013) reported that patients seen during the RDC period had a **decreased time from initial consultation to date of surgery** compared to patients seen during the pre-RDC period (32.5 vs 38.9 days) however this difference was not statistically significant (p = 0.307).

Sethukavalan et al (2013) found **the time from consultation to treatment to be shorter for patients attending a RDU compared** to the usual community referral process (60 vs 62 days), however this difference was not statistically significant (p = 0.52).

#### Time from diagnosis to specialist consultation

One study conducted in Canada reported the outcome time from diagnosis to specialist consultation (the time from diagnosis to radiation oncology consult).

- Sethukavalan et al (2013) found the **time from diagnosis to specialist consultation was significantly shorter for patients attending a RDU** compared to the usual community referral process (27 days vs 49 days; p=0.0019).

#### Time from diagnosis to treatment

One study conducted in Canada reported the outcome time from diagnosis to treatment.

- Sethukavalan et al (2013) found the **time from diagnosis to treatment was significantly shorter for patients attending a RDU** compared to the usual community referral process (mean 91 days vs 120; p=0.016).

#### 2.2.1 Bottom line results for the impact of diagnostic centres on waiting times

Evidence relating to the impact of diagnostic centres on waiting times appears to be mixed. There is evidence to suggest that the utilisation of diagnostic centres can reduce various waiting times, including time to surgical consultation and time from consultation to treatment. However, the evidence was mixed for other wait time outcomes including the time to first visit, time to diagnostic examination and time to diagnosis.

Reductions in waiting times were also reported for the time to biopsy, from cancer suspicion to treatment, from diagnosis to specialist consultation and from diagnosis to treatment, for patients attending diagnostic centres. However, these outcomes were reported by individual studies and as such firm conclusions cannot be made. Furthermore, the methodological limitations across included studies and variations in healthcare systems of the countries of origin of included studies, could limit the applicability of all findings.

#### 2.3 Impact of diagnostic centres on capacity and pressure on secondary care

Thirteen studies reported a range of outcomes relevant to the impact of diagnostic centres on capacity and pressure on secondary care. These included outcomes such as the number of visits required to obtain a definite diagnosis, number of biopsies required to arrive at a diagnosis, onward referrals and referral patterns over time.

#### Number of visits required to receive a diagnosis

The number of visits to the diagnostic centre required to obtain a definite diagnosis was reported by four studies covering three diagnostic centres (two from Spain and one from the UK). The findings from the most recent studies are reported below for each diagnostic centre. Findings were unclear.

- Bosch et al (2021) investigated the costs incurred by two QDUs of tertiary and secondary hospitals and found that significantly fewer visits were required to achieve a diagnosis at the secondary unit compared to the tertiary unit (2.123)

vs 3.098 visits; p = 0.0064). However, this study does not provide any non-QDU comparator data.

 Porter et al (2003) compared a newly established DDC to two existing clinical settings in the management of MS. They found that patients attending the DDC required two visits (one initial and one follow-up appointment) before receiving a definite diagnosis compared to one to four visits, and two to five visits respectively, for the other clinical settings.

#### Number of biopsies to arrive at a diagnosis

One study conducted in Canada reported the number of biopsies required to arrive at a definitive diagnosis.

- Nixon et al (2020) examining the effectiveness of a nurse-led LRDC, found that significantly fewer patients required two or more biopsies to arrive at a diagnosis of lymphoma after institution of a LRDC compared with patients diagnosed prior to the implementation of the clinic (40% vs 12%; p<0.001).

#### Referral patterns over time and onward referrals

One study conducted in Spain reported referral patterns over time.

- Bosch, Jordán and López-Soto (2013) conducted a study to determine whether QDUs could be used to safely and efficiently avoid ED visits and hospitalisations. This study compared the referral trends over time of patients with suspected serious disease, from primary care and EDs to the QDU. They found statistically significantly more direct referrals to the QDU (from 36% to 64%) and less to the ED (from 65% to 35%) respectively during the 25 month study period (p<0.0001). In addition, at least 84% of hospitalised patients were found to be stable and their hospitalisations might have been avoided.

Onward referrals after attending a diagnostic centre were reported by nine studies covering four diagnostic centres (three from Spain and one from UK). The findings from the most recent studies are reported below for each diagnostic centre. Two studies reported findings from the same diagnostic centre (Montori-Palacín et al 2017; Bosch et al 2018). However, Montori-Palacín et al (2017) compared the diagnostic performance of the diagnostic centre with that of another diagnostic centre of a different level of complexity, while Bosch et al (2018) combined two diagnostic centres into a single unit and compared outcomes with patients hospitalised in inpatient wards. Both are reported below.

- Bosch et al (2018) reported onward referrals for patients attending one of two QDUs and compared this to hospitalised patients. The study found the majority of QDU patients were referred to outpatient specialist clinics (95.1% and 96% respectively, compared to 92% of controls). Patients were also referred to primary care (3.1% and 3% respectively compared to 2.1% of controls) and to palliative care (1.9% and 1% compared to 6% of controls). The patients attending the QDUs were significantly more likely to be referred to outpatient specialist clinics (p=0.046) and were significantly less likely to be referred to palliative care (p<0.001). However, authors reported this significant difference is likely related to the fact that the inpatient cohort were generally older and likely to have more aggressive lymphoma subtypes than those attending the diagnostic centres.
- Montori-Palacín et al (2017) assessed the diagnostic performance of a QDU of a secondary hospital by assessing patients with potentially serious disorders and compared it with a tertiary hospital QDU. The study found that after diagnosis, most

secondary hospital QDU patients were referred to the outpatient clinics of the secondary hospital and primary care centres (42% each), and 8% referred to specialist outpatient clinics at the tertiary hospital. In contrast, 60% of the tertiary hospital QDU patients were referred onward to primary care centres and 35% to the hospital outpatient clinics. However, this study does not provide any non-QDU comparator data.

Choudhury et al (2013) assessed the efficacy of a newly established RDC by conducting an audit of new referrals to a head and neck clinic during a six-month pre-RDC period and compared this with findings from the RDC period. The study reported an increase in the number of patients in whom a definitive outcome was reached (discharged or being listed for surgery) from the RDC. In the pre-RDC period, one-third (33%) of patients reached a clear management plan including one of these two definitive outcomes, compared to almost one half (48 %) of all patients who attended the RDC, who were either discharged or scheduled for surgery. Similarly, the number of patients that needed to be referred for an investigation fell by more than half, from 37 % in the pre-RDC period, to 15 % from the RDC period.

### 2.3.1 Bottom line results for the impact of diagnostic centres on capacity and pressure on secondary care

Evidence relating to the impact of diagnostic centres on capacity and pressure in secondary care appears to be unclear. There is evidence to suggest that diagnostic centres could reduce the number of visits needed to receive a definite diagnosis. The evidence also suggest diagnostic centres could reduce the number of biopsies needed to arrive at a diagnosis and reduce the number of stable patients being referred for hospitalisation overtime however, these outcomes were only reported by individual studies and as such firm conclusions cannot be made.

Onward referrals were made to a range of settings including primary care centres, palliative care, outpatient clinics and referrals for surgery. The evidence suggests onward referrals differed in diagnostic centres when compared with hospitalisation (however this is likely to be due to the differences of the patients who are able to attend a diagnostic centre and those who require hospitalisation). The evidence suggests that diagnostic centres can increase the number of patients reaching a clear management plan (discharged or scheduled for surgery) and reduce the need to be referred for further investigations. However, these findings were only reported by individual studies and as such firm conclusions cannot be made. Onward referrals appeared to differ between diagnostic centre patients and inpatients, possibly due to the fact that inpatients were generally older and more unwell than those attending diagnostic centres. The methodological limitations across included studies and variations in healthcare systems of the countries of origin of included studies could further limit the applicability of these findings.

#### 2.4 Economic impact of diagnostic centres and other economic outcomes

Fourteen studies covering seven diagnostic centres (three from UK, three from Spain, and one from Canada) reported economic outcomes. Of these, three studies were economic evaluations: one cost-minimisation analysis (Sanclemente-Ansó et al 2016), one cost-effectiveness study (Sewell et al 2020), and one comparative cost analysis (Bosch et al 2021), while the other studies (11 quasi-experimental studies) reported more generic economic outcomes.

#### 2.4.1 Economic evaluations

Bosch et al (2021) conducted a comparative cost analysis using micro-costing, to compare the costs incurred by two QDUs of different levels of complexity (tertiary vs secondary). The results showed that the mean total cost per patient of the tertiary unit was €577.50 ± 219.60, while the mean cost of the secondary unit was €394.70 ± 92.58 per patient (p value for difference between the two units = 0.0559). The mean cost per visit of both units was similar (€182.8 ± 41.47 in the tertiary vs €184.6 ± 29.41 in the secondary unit; p = 0.9056). An analysis of general costs revealed that direct and structural costs per patient of the two units were not significantly different. Conversely, indirect costs of the tertiary unit were significantly higher than those of the secondary unit (€49.93 ± 19.90 vs €12.42 ± 2.344, respectively; p = 0.0018). The main driver of the cost differences between the two QDUs was found to be the total number of visits and successive/first visits ratio. However, this study does not provide any non-QDU comparator data.

Sewell et al (2020) used patient-level DES and decision analytic modelling to estimate the cost-effectiveness of a pilot RDC in its first year of operation compared with standard clinical practice. The results showed that during the start-up phase of the service, the RDC was seeing a mean number of 2.78 patients per clinic and was more costly and more effective compared to standard clinical practice. However, when run at near or full capacity (80% or higher, seeing a mean number of 4.65 patients/clinic), the RDC was found to outperform usual care, i.e. being less costly and more effective.

Sanclemente-Ansó et al (2016) conducted a cost-minimisation analysis to assess the costs of the QDU approach compared with the costs of conventional hospitalisation for the diagnosis of cancer and severe anaemia. For this analysis, three groups of QDU patients (with a final diagnosis of severe anaemia, lymphoma, and lung cancer) were compared with hospitalised patients with the same final diagnoses. The results showed a significant cost saving of care delivered by a QDU service compared with traditional inpatient care. The QDU savings from hospitalisation for the three diagnostic groups were related to fixed direct costs of hospital stays (66% of total savings). Savings related to fixed non-direct costs of structural and general functioning were 33% of total savings. Savings related to variable direct costs of diagnostic investigations were 1% of total savings. Overall savings from hospitalisation of all patients were €867,719.31.

#### 2.4.2 Generic economic outcomes derived from quasi-experimental studies

Eleven quasi-experimental studies reported a range of generic economic outcomes including patient costs (such as the mean cost per visit to the diagnostic centre, cost of diagnostic test per patients and the mean costs per patient), costs associated with running a diagnostic centre (such as the average cost per process, staffing costs and direct, indirect and structural costs) and cost savings.

#### **Patient costs**

#### Cost per visit to the diagnostic centre

Nine studies covering three different diagnostic centres (two from Spain and one from the UK) reported the mean cost per diagnostic centre visit. The findings from the most recent studies are reported below for each diagnostic centre. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2018), however Bosch et al 2018 combined the cohort of patients in this centre with another diagnostic centre to form a single unit, and as such both studies are reported below. The findings were generally unclear.

- Bosch et al (2020) compared the costs of outpatients (QDU patients) and inpatients and found the cost per hospital stay was less expensive than cost per visit to the QDU at the same hospital (€154.72 vs €340.90).
- Bosch et al (2018) compared the associated costs of outpatient (QDU) and inpatient (hospitalised) settings and found the total cost per one day stay as an inpatient was less expensive than the cost per visit to outpatients (€328.42 vs €432.05). However, it is worth noting that two QDUs were combined and analysed as a single unit in this study.
- Porter et al (2003) compared a newly established DDC with two existing clinical settings in the management of MS. They found that the cost per appointment to the DDC was £395, compared to £95 per visit to another outpatient clinic. For inpatients, the length of stay ranged from one to five days and patients in this group also attended outpatient appointments on two to five occasions before receiving a definite diagnosis. The collective price of admission and outpatient visits ranged from £1940 to £2700.

#### Cost of diagnostic test per patient

Three studies covering three diagnostic centres (two from Spain and one from the UK) reported the cost of diagnostic tests per patient. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2018), however the latter combined the cohort of patients from this centre with another diagnostic centre to form a single unit, and as such both studies are reported below. The findings indicate costs of diagnostic tests may be cheaper in diagnostic centres situated within hospital grounds. Findings for mobile-based diagnostic services are unclear.

- Bosch et al (2020) compared the costs incurred by outpatient (QDU) and inpatient (hospitalised) settings and reported the total cost of diagnostic examinations per patient to be significantly cheaper for patients attending the QDU compared to hospitalised patients (€231.88 vs €280.60; p<0.001).
- Bosch et al (2018), compared the associated costs of outpatient (QDU) and inpatient (hospitalised) settings and found the total cost of diagnostic examinations per patient was significantly cheaper for patients attending the QDUs compared to hospitalised patients (€713.19 vs €1,026.80; p<0.001). Two QDUs were combined and analysed as a single unit in this study.
- Pallan et al (2005) compared a primary care-based mobile diagnostic ultrasound service to a NHS Trust diagnostic ultrasound service and found the cost of diagnostic tests was more expensive per patient attending the mobile diagnostic ultrasound service in the community compared to the NHS Trust hospital service (cost per ultrasound £30 vs £20.62 £27.51 respectively).

#### Total cost per patient

Three studies conducted in Spain reported on the total cost per patient for two diagnostic centres. The findings from the most recent studies are reported below for each diagnostic centre. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2018), however the latter combined the cohort of patients from this centre with another diagnostic centre to form a single unit, and as such both studies are reported below. Both studies identified statistically significant reductions in cost per patient attending a QDU compared to hospitalisation.

- Bosch et al (2020), reported that **the total cost per patient at a QDU was significantly less than the total cost per hospitalised patient** (€347.76 [SD 48.69] vs €634.36 [SD 80.56]; p<0.001). Total cost per QDU patient included 66.7% being attributable to diagnostic tests, 18.2% to ambulatory visits, and 13.7% to salaries, and total cost per hospitalised patient included 46.4% being attributable to personnel salaries and 44.2% to diagnostic tests.
- Bosch et al (2018) reported that the total cost per patient was significantly less for outpatients (QDU patients) than the cost per hospitalised patient (€1,408.48 [197.32] vs €4,039.56 [513.02]; p<0.001). Two QDUs were combined and analysed as a single unit in this study.

#### Costs of running a diagnostic centre

#### Average cost per process (from admission to discharge)

Five studies covering one diagnostic centre reported the average cost per process. All five studies were conducted in Spain. The findings of the most recent study is reported below.

- Bosch, Jordán and López-Soto (2013) compared patients attending a QDU with hospitalised patients and found the average cost per process was more expensive for hospitalised patients compared to patients attending the QDU (€3,241.11 [standard deviation (SD), 915] vs €726.47 [SD, 617] respectively).

#### Direct, indirect and structural costs

Two studies conducted in Spain (Brito-Zerón et al 2014; Bosch et al 2020) reported on the direct, indirect and structural costs of one diagnostic centre. Therefore, only the findings from the most recent study is reported below.

- Bosch et al (2020) described mean **non-direct costs per patient** in QDU and hospitalised patients. These costs mainly corresponded to structural and general functioning costs such as costs related to maintenance (€0.05 [SD, 0.01] vs €0.66 [SD, 0.07]), laundry (€0.26 [SD, 0.02] vs €5.17 [SD, 0.36]), cleaning services (€0.73 [SD, 0.05] vs €8.36 [SD, 0.67]), administrative costs (€0.02 [SD, 0.01] vs €0.37 [SD, 0.03]), as well as depreciation of fixed costs (€3.10 [SD, 0.61] vs €4.43 [SD, 0.89]). All were found to **cost significantly less for patients attending the QDU** compared to hospitalised patients (p<0.001).

#### **Staffing costs**

Two studies conducted in Spain covering two diagnostic centres, reported on staffing costs. The two studies covered the same diagnostic centre (Bosch 2020; Bosch 2018) however one study combined the findings for this centre with another diagnostic centre and as such, both studies are reported below. Both studies identified a statistically significant reduction in staff costs compared to controls.

- Bosch et al (2020) reported that the mean staff wages per patient attending the QDU was significantly lower than the staff wages for hospitalised patients (€47.71 [SD, 4.15] vs €294.50 [SD, 18.26] respectively; p<0.001).
- Bosch et al (2018) reported that the mean staff wages per patient attending the QDU was significantly lower than the staff wages for hospitalised patients (€262.50 [SD,22.92] vs €2,806.49 [SD,174]; p<0.001). Two QDUs were combined and analysed as a single unit in this study.

#### Cost saving from hospitalisation

One study conducted in Spain reported on the cost saving from hospitalisation.

Bosch et al (2018) compared associated costs of outpatient (QDU) and inpatient (hospitalised) settings and found that the total cost saving from hospitalisation was €2,631.08 per patient. However, two QDUs were combined and analysed as a single unit in this study.

#### 2.4.3 Bottom line results for the economic effectiveness of diagnostic centres

There is evidence to suggest that diagnostic centres are cost-saving and a more costeffective resource than traditional inpatient care. However, it appears that overall costeffectiveness may be dependent on whether or not the diagnostic centre is running at full capacity. Factors that could determine the costs incurred by a diagnostic centre include the diagnostic and clinical complexity of the patients managed at the unit, as well as the characteristics of the unit including the number of staff and contribution of staff time. Additionally, there is evidence to suggest that utilisation of diagnostic centres can reduce staffing costs, costs incurred per patient, and the costs of diagnostic tests. However, the methodological limitations across included studies and variations in healthcare systems of the countries of origin of included studies could limit the applicability of these findings.

Figure 1. Outcomes matrix of included studies as reported in the RR (all outcomes reported by each study can be seen in the rapid evidence map (REM)).

Authors in Dold donote concer	1	1	1	1	1		ı	1	1	1	1	1	1	1		1	ı	1	1	I	
Authors in <b>Bold</b> denote cancer						_															
diagnostic centres						2013															
						20															
						9															
						Bosch, Jordán and López-Soto															_
						2-Z													~		Total no of studies (n=20)
						pe'					~			2017				16	2013		Ĭ
						<u>_</u> ó_				7	7.	~		2				20	7		)
	13		~	q		b		_		20	7	36	17	it e				ý	a		ies
	50	11	125	12	120	an	18	20	21	al	al	15	20	) e	50	35	33	\range VIS	et	22	pr
	Arnaout et al 2013	et al 2011	2012a	Bosch et al 2012b	Bosch et al 2012c	я́и	Bosch et al 2018	Bosch et al 2020	Bosch et al 2021	Brito-Zerón, et al 2014	Choudhury et al 2013	Harcourt et al 1998	McKevitt et al 2017	Montori-Palacín et al	Nixon et al 2020	Pallan et al 2005	Porter et al 2003	Sanclemente-Ansó 2016	Sethukavalan	Sewell et al 2020	stı
	et é	7/8	al 2	al	12	ζģ	al	al	12	n,	>	et	et	ala	<del> </del>	1 2	12	nte	ale	al	)f :
	ıt e	¥ 5	et s	et	) <del>t</del> 9	9	et	et	€ €	ž	hu	ıt	itt	٩	) t (	) <del>t</del> 9	3¢ 9	пе	à	et	0
	70	h e	h e	i,	h e	h,	i,	ų;	h e	Ϋ́	p	70	) A	ori	u e	n e	7.	le/	¥	₩	u l
	na	SC	SC	SC	SC	SC	SC	SC	SC	.j.	0	Z	Š	nt	8	lla	rte	nc	ŧ	Š	ta
	Ą	Bosch	Bosch	BG	Bo	Bo	BC	BC	Bo	Bri	Ö	Ha	×	M	Ž	Ра	Po	Sa	Se	Se	70
Performance outcomes																					
Wait time from confirmation of BI-RADS	Х																				1
5 status of abnormal diagnostic	, ,																				•
mammogram to biopsy																					
Time from biopsy to pathology	Х																				1
	^																				'
verification		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\ <u>'</u>	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\ \		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\ \									\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				40
Time to first visit		Х	Х	Х	Х	X	Х	Х			Х			X			X				10
Number of visits required to receive						Χ			Χ					Χ			Х				4
diagnosis																					
Number of biopsies to arrive at															Χ						1
diagnosis																					
Time to diagnostic examination					Χ		Х							Χ		Χ					4
Time to surgical consultation/	Х												Х								2
assessment	, ,												, ,								_
Time from consultation to treatment	Х										Χ		Χ		Χ				Χ		5
Time from cancer suspicion to																			X		1
treatment																			^		ı
		V	V	V	V	V	V	V	V	V				V	V			V	V	V	4.4
Time to diagnosis		Х	Х	Х	Х	Х	Х	Х	Х	Х				Х	Х			Х	X	Х	14
Time from diagnosis to treatment																			Χ		1
Time from diagnosis to specialist																			Χ		1
consultation																					
Referral patterns over time						Χ															1
Onward referral		Χ	X	X	Χ	Χ	Χ			Χ	Χ			Χ							9
Economic outcomes																					
Mean cost per hospital stay		Х	Х	Х	Χ		Х	Х		Х							Х	Х			9
Mean cost per visit to the diagnostic		X	X	X	X	Χ	X	X	Χ	X							X				10
centre		^	^	^			^		^	^							^				10
Average cost per process (from		Х	Х	Х	Х	Х															5
		^	^	^	^	^															5
admission to discharge)							V	V	V	V								V		. V	_
Total cost per patient							X	X	Х	Х								Х		Х	6
Cost of diagnostic tests per patient							Χ	Χ								Χ					3
Cost saving related to diagnostic																		Χ			1
investigation																					
Cost saving from hospitalisation							Χ											Χ			2
Cost saving per patient related to																		Х			1
structural and general functioning costs																					
of hospitalisation																					
Mean cost saving per patient																		Х			1
Overall cost saving																		X			1
							V	V	V												
Staffing costs							Х	X	Χ									Χ			4
Costs of catering/ cleaning/laundry/								X													1
travel/maintenance/																					
				1																	
administrative/depreciation/consultation																				_	
								Х	Х	Х		Χ						Х		Χ	2

Table 1: Summary of included studies

	of included studies			
Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
		Diagnostic centre vs u	sual care	
		Canada		
	Clinic (LRDC) at Princess Mar	garet Cancer Centre, Toronto, Ont	ario	
Nixon et al (2020).	Study Design:	Sample size: 126 patients	Of 129 patients referred to LRDC with suspected	Cancer-related study
Evaluation of	Cross-sectional post-test	referred to the LRDC (no data	lymphoma, 126 were included in the current analysis.	(lymphoma)
lymphadenopathy and	only quasi-experimental	on historical controls)	Median age was 55 years (range, 18 to 95 years),	
suspected lymphoma in a			and 67 patients (53%) were female.	Some of the
lymphoma rapid diagnosis	Intervention/comparator:	Participants: Patients with		included participants
clinic. JCO Oncology	Nurse-practitioner-led LRDC	lymphadenopathy on the basis	Primary Findings:	had a prior cancer
Practice. 16(1). e29-e36	vs usual care at University	of clinical assessment or	After evaluation, 66 patients (52%) had confirmation	diagnosis.
	Health Network (UHN) (i.e.,	imaging, biopsy results	of a diagnosis of lymphoma - indolent (n = 34),	<b>-</b> , , ,
	care given at the centre	suspicious for lymphoma, or	aggressive (n = 18), Hodgkin lymphoma (HL) (n =14),	The authors'
	before the LRDC was	peripheral blood abnormalities.	acute leukaemia (n = 2), metastatic carcinoma (n	acknowledge the
	implemented.	Catting The LDDC et a	=14), and non-malignant diagnoses (n = 44).	small sample size
	Aim. To investigate if weit	Setting: The LRDC at a	Madian time from initial apparament to hypothesis	used as a limitation
	Aim: To investigate if wait times can be reduced for a	tertiary cancer centre (Princess	Median time from initial assessment to lymphoma	of the study.
	definitive diagnosis of	Margaret Cancer Centre), part of University Health Network	diagnosis was 16 days (9-24 days) for the patients assessed in LRDC and 28 days (19-48 days) for	This study does not
	lymphoma and initiation of	(UHN), Toronto, Ontario,	historical controls (P< 0.001). Median time from initial	give the patient
	treatment by implementing a	Canada.	LRDC assessment to treatment of aggressive	characteristics of the
	nurse practitioner-led LRDC	Cariaua.	lymphomas and HL was 29 days (21-43 days)	controls or even the
	in a tertiary care cancer	Staffing/facilities: The LRDC	compared with 48 days (28-78 days) for historical	number of patients
	centre	was led by a nurse practitioner,	controls (P< 0.001).	in the control group.
	Contro	weekly operating room time	001111013 (1 < 0.001).	m the control group.
	Data collection methods	was needed and commitments	Significantly fewer patients required two or more	
	and dates:	from surgeons and radiologists	biopsies to arrive at a diagnosis of lymphoma after	
	Data were collected from	were needed to perform the	institution of the LRDC compared with patients	
	patients referred to LRDC	biopsies.	previously diagnosed at UHN (40% v 12%; P<0.001,	
	from June 1, 2015 to Nov		Fisher's exact test). Lymph node size greater than	
	30, 2017. Pre-RDC data	Services provided:	3.4 cm and presence of mediastinal or abdominal	
	collected in 2008 and 2012.	Laboratory tests, peripheral	adenopathy increased the likelihood of a diagnosis of	
		blood flow cytometry,	malignancy, whereas younger age, being a non-	
	Outcomes reported:	tuberculosis skin testing,	smoker, and prior rheumatologic condition were	
	Number of biopsies to arrive	abdominal ultrasound, CT	associated with a non-malignant diagnosis.	
	at diagnosis	scans, bone marrow biopsy, or		
	Time from consultation to	fine-needle aspiration (FNA).		
	diagnosis			

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Time from assessment to			
	treatment			
	Predictive factors for benign			
	diagnoses			
4.5	(5450) (44			
	ic (RABC) at Mount St Joseph I		In the atual array 000/ of national ware female with	Canaar ralatad atudu
McKevitt et al (2017). Reduced time to breast	Study Design: Cross-sectional post-test	Sample size: 373 Patients	In the study group, 99% of patients were female with one male seen in the TS and two males seen in the	Cancer-related study (breast cancer)
cancer diagnosis with	only quasi-experimental	Participants: Patients	RABC. In the RABC the surgeons saw 24 (38%)	(Dreast Caricer)
coordination of radiological	only quasi-experimental	presenting with a new breast	patients with a known cancer diagnosis and 40 (62%)	The study authors
and clinical care. Cureus,	Intervention/comparator:	problem who were referred to	patients with a benign or indeterminate diagnosis. In	reported a total
9(12).	RABC vs traditional system	the clinic with either an	the office, 44 (25%) patients were referred with a	sample size of 373
9(12).	(TS) i.e., standard care	abnormal screening	known cancer diagnosis and 134 (75%) patients were	patients, however
	(10) i.c., standard care	mammogram or were referred	referred with a benign diagnosis, indeterminate	there are disparities
	Aim: To investigate if the	by their family physician for	diagnosis, or an incomplete diagnostic workup.	in the numbers
	RABC will decrease wait	assessment of a breast	alagnosis, or an incomplete diagnosis workapi	reported for the
	times to diagnosis and	symptom.	Primary Findings:	intervention and
	minimise duplication of		Patients seen at the RABC had a decreased time to	control group
	services compared to usual	Setting: The RABC at Mount	surgical consultation (33 vs 86 days, p < 0.0001) for	
	care	St Joseph Hospital, University	both malignant (36 vs 59 days, p=0.0007) and benign	The study authors
		of British Columbia Vancouver,	diagnoses (31 vs 95 days, p<0.0001). Seventeen	acknowledge the
	Data collection methods	Canada	(13%) of the patients referred to the surgeon in the	retrospective nature
	and dates: A retrospective		traditional system without a diagnosis were	of the data collected,
	review of a prospectively	Staffing/facilities: The clinic	eventually diagnosed with a malignancy and waited a	as well as the
	maintained breast clinic	provided triple evaluation of	mean of 84 days for initial surgical assessment. Of	inability to accurately
	database was undertaken to	patients with close	the patients seen at the RABC, 5% required	determine the breast
	look at diagnostic wait	collaboration between	investigation at more than one institution compared to	problem
	times, treatment times, and	clinicians and radiologists,	39% patients seen in usual care (p<0.0001). Cancer	presentation date,
	the number of preoperative	facilitated by clinical pathways	patients had a shorted time from presentation to	as limitations for this
	diagnostic centres involved	and nurse navigation	surgery in the RABC (64 vs 92 days, p=0.009).	study.
	for consecutive patients	Complete annual de de	Additional Findings	
	seen by the three breast	Services provided:	Additional Findings:	
	surgeons in November and December 2009.	Single site for coordinated clinical and radiological	For the patients presenting with breast cancer and	
	December 2009.	assessment of breast	having initial treatment with surgery, the time from surgical consultation to surgery was 33 days in usual	
	Outcomes reported:	problems. Offers on-site	care and 31 days in the RABC (p=0.78). However,	
	Time from presentation to	mammography, breast	the time from presentation to surgery for cancer	
	surgical	ultrasound, ultrasound-guided	patients was decreased for patients managed	
	consultation/assessment	biopsy, and mammographic	through the RABC (64 vs 92 days, p=0.009). For	
	CO. TOURIGITO IT GOOD STITLE IT	Siepoy, and maniningrapino	cancer patients that had a core biopsy prior to seeing	
			Toditor patients that had a core biopsy prior to seeing	l

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Time from surgical consultation to surgery Time from presentation to surgery	and ultrasound-guided fine wire localisation.	the surgeon, the time from presentation to core biopsy was shorter in the RABC (18 vs 38 days, p=0.002) as was the time from core biopsy to seeing the surgeon (15 vs 25 days, p=0.01).	
	Number of diagnostic centres visited in order to obtain a diagnosis.		In the RABC, 61 (95%) patients had their diagnosis at one centre and three (5%) patients had diagnostic studies at other centres. In contrast, in the usual care group only 61% attended a single diagnostic centre with 39% attending two or more diagnostic centres (p<0.0001).	
			A patient attending four diagnostic centres had a mammogram at one centre, an ultrasound at a different centre, an ultrasound-guided biopsy at a third centre, and a stereotactic core biopsy at a fourth centre. Of the patients having only mammograms, ultrasound, and ultrasound-guided biopsy in usual care, 31.5% of the patients attended more than one diagnostic imaging centre and were more likely to have attended one diagnostic centre for these tests in the RABC (p<0.0001). Patients referred with a breast cancer diagnosis were more likely to have been seen in a single diagnostic centre for mammogram, ultrasound, and ultrasound-guided core biopsy when seen at the RABC than in usual care (p=0.021).	
Rapid Access Diagnostic an	□ nd Support (RADS) at The Wom	ı en's Breast Health Centre, Ottawa	l Hospital, Ottawa, Ontario	
Arnaout et al (2013).  Improving Breast  Diagnostic Services with a	Study Design: Cross- sectional post-test only quasi-experimental	Sample size: 211 RADS patients and 225 historical controls	The mean age of patients enrolled in the RADS programme was 62 years. Fourteen percent (10 patients) of the biopsies performed on the RADS	Cancer-related study (breast cancer)
Rapid Access Diagnostic and Support (RADS)		Participants: Women referred	patients were benign. Overall, 91 % of the biopsies resulted in invasive (ductal or lobular) carcinoma or	The authors acknowledge a
Annals of surgical oncology, 20(10), pp.3335-3340.	Intervention/comparator: RADS clinic vs pre-RADS period	to the breast centre with a high probability of breast cancer (i.e., patients with an initial diagnostic imaging classified	DCIS. An additional 2 % of the biopsies resulted in either lymphoma (1 %) or metaplastic carcinoma (1 %).	limitation of the study was the inability to address whether or not the
	Aim: To pilot a rapid diagnosis and support clinic programme for patients	as BI-RADS 5)	Primary Findings: The mean wait time from abnormal imaging to biopsy decreased by 4.1 days (from 7.1 to 3 days; 58%	RADS program had an impact in the diagnostic wait times

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Citation	referred to the breast centre with a high probability of breast cancer  Data collection methods and dates: Data for wait times and patient satisfaction was analysed before (for 1 year) and after 1 year of RADS clinic implementation (2011).  Outcomes reported: Wait times from date of diagnostic imaging workup and confirmation of the BIRADS 5 status to biopsy date  Time from biopsy to pathological verification of malignancy Time from verification to initial surgical consultation Time from consultation to operative management Patient satisfaction Personnel costs	Setting: The RADS clinic, at the Women's Breast Health Centre of the Ottawa Hospital in Ottawa, Ontario, Canada (a university-affiliated tertiary care centre)  Staffing/facilities: A multidisciplinary team of breast cancer specialists (five radiologists, five surgeons, two pathologists, one nurse manager, two nurse navigators, and a diagnostic imaging manager)  Services provided: Routine screening mammography, initial diagnostic imaging workup (mammogram and/or breast ultrasound) for a breast problem (e.g., palpable mass, breast pain, nipple discharge), or additional diagnostic imaging and biopsy workup following an abnormal mammogram performed at another institution	reduction, p<0.01), biopsy to pathology verification by 0.6 days (from 3.9 to 3.3 days; 15% reduction, p<0.01), pathology verification to surgical consult by 10.1 days (from 16.1 to 5.9 days; 63% reduction, p<0.01), and operative wait time from initial consultation by 7.5 days (from 31.5 to 24.1 days; 24% reduction, p = 0.04)  Significant improvements in patient satisfaction was in the understanding of the diagnostic and treatment plan (p = 0.03), as well as timeliness of diagnostic tests (p = 0.04) and timeliness provision of results (0.04). There was a trend towards an improvement in overall satisfaction of the diagnostic testing experience but it was not statistically significant (p = 0.16).  Additional Findings: There was an average of 4.5 RADS patients per week at the breast centre. The nursing cost was equivalent to a 0.2 FTE nurse annual salary (CAD \$20,730.80), and there were 10 additional biopsy days added in total (CAD \$6,100, including radiology technician time and equipment; not including fees for radiologist), which accommodated 70 of 234 diagnostic biopsies. The remaining 164 biopsies were fitted into previously routinely reserved biopsies slots in addition to last minute unused gaps in scheduling.	Observations/Notes of breast cancer patients with BI- RADS 4 mammograms. However, findings for these patients will be reported in a future publication.
Rapid Diagnostic Unit (RDU)	 ) at The Gale and Graham Wrig	ht Prostate Centre, North York Ge	neral Hospital Toronto, Ontario	
Sethukavalan et al (2013).	Study Design: Cross-	Sample size: The study aimed	There were no significant differences between the	Cancer-related study
Improved wait time	sectional post-test only	to include 100 patients,	RDU and community cohorts with respect to	(prostate cancer)
intervals for prostate	quasi-experimental	however only 87 patients (44	demographic (not all data shown) or tumour	The authors
cancer patients in a multidisciplinary rapid		RDU patients and 43 community patients) were	variables.	acknowledged that
diagnostic unit compared	Intervention/comparator:	included in the study	Primary Findings:	the retrospective
to a community-based	A multidisciplinary RDU vs a	included in the study	The median overall wait time interval from suspicion	nature of the data
referral pattern. Canadian	7 mandasoipiinary 1100 vs a		of prostate cancer to RT, the "overall interval," was	collected and the

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Urological Association	community based referral	Participants: A convenience	138 days for the RDU cohort and 183 days for the	use of a modest
journal. 7;7, 244-250.	pattern	sample of 100 consenting	community cohort (p = 0.046). The median wait time	sample size over a
	Aim: To document intervals	patients who were treated with radical radiotherapy at the	interval from suspicion of prostate cancer to diagnosis, the "diagnostic interval," for patients in the	limited timeframe, could limit the study
	between key wait time	Odette Cancer Centre at	RDU and community cohorts was 49 days and 67	findings.
	milestones within the	Sunnybrook Health Sciences	days, respectively (p = 0.29). The median wait time	iiriuirigs.
	prostate cancer care	Centre, in 2011 and 2012.	interval from diagnosis to radiation oncology (RO)	
	pathway from suspicion to	Centre, in 2011 and 2012.	consult for patients in the RDU and community	
	the start of definitive therapy	Setting:	cohorts was 27 days and 49 days, respectively (p =	
	for patients referred to and	RDU called The Gale	0.0019). The median wait time interval from RO	
	treated with radical	and Graham Wright Prostate	consult to start of therapy (RT), the "treatment	
	radiotherapy treatment (RT)	Centre, set up at the North	interval," for patients in the RDU and community	
	at the Odette Cancer	York General Hospital (NYGH),	cohorts was 46 days and 37 days, respectively (p =	
	Centre, comparing patients	Branson Site, Toronto, Ontario,	0.52)	
	diagnosed in the RDU	Canada.		
	versus the usual community		There were statistically significant differences	
	process.	Staffing/facilities:	between the two cohorts, favouring the RDU cohort,	
		Staff include radiation oncology	for other key wait time intervals. These differences	
	Data collection methods	and urology specialists	included suspicion to DTT (p = 0.012), urologist visit	
	and dates: The first 50	0	to diagnosis (p = 0.0094), diagnosis to DTT (p =	
	patients who were seen at	Services provided:	0.018), and diagnosis to treatment (p = 0.016).	
	the RDU and the first 50 patients from the community	Unclear	Additional Findings:	
	who consented were		Among all patients, there were 22 patients (25%) with	
	accrued to the study on a		perceived delayed treatment. Among those 22	
	consecutive basis starting in		patients, most of patients identified a systematic	
	October 2011.		reason (64%) for the delay. There was no significant	
	The RDU was not equipped		difference on the cause of perceived delay between	
	to treat patients with radical		the RDU and community cohorts (p = 0.86).	
	radiotherapy treatment (RT),		, ,	
	therefore the sample of		Risk category and Gleason sum were independently	
	patients that agreed to		predictive of longer intervals from diagnosis to DTT.	
	participate in this study was		Patients with Gleason sum of 6 or 7 disease had	
	obtained at the Odette		shorter diagnosis to DTT intervals compared patients	
	Cancer Centre at		with Gleason 8-9 disease (median 41 vs. 42 vs. 94	
	Sunnybrook Health		days, respectively, p = 0.035). Patients with low-	
	Sciences Centre and not at		versus intermediate- versus low-risk disease had	
	the RDU.		median intervals of 67 vs. 41 vs. 38 days,	
			respectively (p = 0.011). Conversely, patients with	
	Outcomes reported:			

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Participant characteristics,		PSA ≥10, or with high-risk disease had shorter DTT	
	Overall wait time interval		to RT intervals: PSÃ ≥10 vs.	
	(time from suspicion of			
	prostate cancer to radiation			
	therapy)			
	Diagnostic interval (time from suspicion of prostate			
	cancer to diagnosis)			
	Time from diagnosis to			
	radiation oncology (RO)			
	consult			
	Treatment interval (time			
	from RO consult to start of			
	radiation therapy)			
	Patient perceived delays			
		0		
Oujok Diognostia Unit (ODU	) at Hospital Clínic de Barcelona	Spain		
Bosch et al (2020). What is	Study Design: Cross-	Sample size: 1,004 patients	The mean age of QDU patients and inpatients was	Cancer-related study
the relevance of an	sectional post-test only	comprising of 508 patients from	71.2 (12.8) and 72.5 (13.2) years, respectively, and	(pancreatic cancer)
ambulatory quick diagnosis	quasi-experimental	QDU and 496 inpatients	there was a slight predominance of males in both	(parior datio dariodi)
unit or inpatient admission	4		groups. No significant differences were observed in	
for the diagnosis of		Participants: Patients aged	the socioeconomic status.	potential QDU data
pancreatic cancer? A	Intervention/comparator:	≥18 years with a diagnosis of		overlap with Bosch
retrospective study of 1004	QDU vs hospitalised	pancreatic adenocarcinoma	Primary Findings:	2021 (i.e. pancreatic
patients. Medicine, 2020,	(inpatient ward at same	who had been referred to QDU	Time to admission was significantly shorter than	ca data only
vol. 99, num. 11, p.	hospital)	or hospitalised between	time to the first QDU visit (0.7 [0.2] vs 1.2 [0.3)] days;	between 2009 and
e19009.		October 2005 and November	P<0.001) and there were no differences between	2017)
	Aim: To investigate the	2018 were eligible.	admission time to diagnosis and the QDU time to	
	effectiveness and associated costs of a	Cattings ODI I becard in the	diagnosis (4.1 [0.8] vs 4.3 [0.6] days; P=0.163).	
	hospital-based ambulatory	Setting: QDU based in the Adult Day Care Centre of	Three patients were admitted to inpatient wards during the QDU assessment: 2 had a quick	
	QDU versus inpatient	Hospital Clínic, Barcelona,	deterioration of their performance status as well as	
	setting for the diagnosis of	Spain	increased jaundice and the other a pulmonary	
	pancreatic adenocarcinoma.	Opan,	thromboembolism.	
	panersano adorrocaromonia.	Staffing/facilities: Staff at		
	Data collection methods	QDU includes a full-time	The frequency of risk factors of pancreatic cancer	
	and dates: Clinical data	consultant internist, a senior	(age, smoking status, history of pancreatitis, family	
	were collected on QDU and	internal medicine resident, a	history, BMI, Long standing Type II diabetes mellitus,	
	hospitalised patients	full-time nurse, a part-time	heavy alcohol consumption) was slightly higher in	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	between October 2005 and	nurse coordinator, and 2 part-	inpatients than in QDU patients, but no significant	
	November 2018.	time administrative assistants.	differences were observed.	
		The unit is open 5hours a day,		
	Costs of all individual	5 days a week. Staff in each of	Multivariate logistic regression analysis with	
	resource items were	the 3 medical wards includes 2	adjustment for other variables, identified 4 significant	
	obtained from the	full-time consultant internists, 2	independent predictors of hospitalisation: age ≥75	
	institutional information	residents, a full-time nurse	years (OR 4.40, 95% CI: 3.31 to 8.19; p 0.012),	
	system of the hospital	coordinator, 3 teams of 3 full-	thrombophlebitis (OR 2.07, 95% CI: 1.77 to 2.86;	
		time nurses and 3 teams of 2	p0.041), jaundice (OR 9.12, 95% CI 6.58 to 16.03;	
	Outcomes reported:	full-time nursing assistants (8-	p<0.001), and an ECOG performance score ≥2 to 4	
	Risk and prognostic factors	hours daily shifts), and a full-	(1.304, 95% CI: 0.804 to 1.905; p 0.044). Having	
	of pancreatic cancer	time administrative assistant.	jaundice was the strongest predictor of admission on	
	Presenting symptoms and		multivariate analysis (OR 9.12, 95% CI: 6.58–16.03;	
	signs	Complete annual de de la lace	P<.001).	
	Wait times	Services provided: Upper	Coot analysis	
	Time to admission/first QDU	gastrointestinal endoscopic	Cost analysis	
	visit (time between referral	ultrasound (EUS), US/CT-	Considering that the mean admission time to	
	and appointment at QDU/admission of	guided biopsy, contrast- enhanced thin-slice CT scan of	diagnosis of inpatients was 4.1 (1.4) days and that	
	inpatients)	the chest, abdomen, and pelvis	the mean number of visits of QDU patients during the QDU time to diagnosis was 1.02 (0.3), the total cost	
	QDU time to diagnosis	the chest, abdomen, and peivis	per hospitalised patient was €634.36 (80.56), with	
	(defined as time elapsed		46.4% being attributable to personnel salaries and	
	between the request of the		44.2% to diagnostic tests, and the total cost per QDU	
	decisive diagnostic		patient was €347.76 (48.69), with 66.7% being	
	procedure and the		attributable to diagnostic tests, 18.2% to ambulatory	
	cyto/pathological diagnosis)		visits, and 13.7% to salaries. According to the	
	Length of stay for inpatients		analysis, the total saving with QDU was €286.6 per	
	Admission time to diagnosis		patient.	
	(defined as time elapsed		'	
	between the request of the		67.7% of inpatients versus 62.6% of QDU patients	
	decisive diagnostic		had a tumour site of the head of the pancreas,	
	procedure and the		Inpatients were also more likely than QDU patients to	
	cyto/pathological diagnosis)		have a mean tumour size >2cm (77.0 vs 72.4%;	
			P=.048), an N1 stage (75.6 vs 70.9%; P=.049), and a	
	Predictors of hospitalisation		poorer grade of histological differentiation (26.2 vs	
			21.1%; P=.031). Moreover, 61.5 vs 59.1% of	
			inpatients and QDU patients, respectively, had a	
	Mean number of visits		metastatic stage on presentation (P=.120) and 29.4	
	during the QDU evaluation		versus 29.1% of inpatients and QDU patients,	
	Cost per visit		respectively, had an unresectable, locally advanced	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Total cost per QDU patient		tumour (P=.221). Regional lymph nodes could not be	
	cost per day of hospital stay		identified in imaging studies in 8.5% of QDU patients	
	total cost per hospital		and 9.5% of inpatients. The histological differentiation	
	inpatient		in 7.9% of QDU patients and 8.5% of inpatients was	
	total saving with QDU		unknown for the pathologist. There were several	
			statistically significant differences regarding	
			laboratory results. Inpatients were more likely than	
	Charlson comorbidity index		QDU patients to have higher serum levels of CA19.9,	
			CEA, LDH, AST/SGOT, ALT/ SGPT, alkaline	
			phosphatase, total bilirubin, creatinine, and CRP. The	
			levels of albumin and haemoglobin were significantly	
			lower in inpatients.	
			Additional Findings:	
			While both QDU patients and inpatients were more	
			commonly referred from the ED, the QDU was more	
			often used by PC physicians (31.7% of QDU patients	
			versus 21.4% of inpatients were referred from PC;	
			P<.001). The mean age of QDU patients and	
			inpatients was 71.2 (12.8) and 72.5 (13.2) years,	
			respectively, and there was a slight predominance of	
			males in both groups. No significant differences were	
			observed in the socioeconomic status. Compared	
			with inpatients, QDU patients were less likely to live	
			alone and more likely to live with a partner (21.3 vs	
			26.6%; P=.024 and 69.7 vs 65.0%; P=.042,	
			respectively). Regarding symptoms and signs on	
			presentation, admitted patients were significantly	
			more likely than QDU patients to have weight loss,	
			asthenia, anorexia, abdominal pain, jaundice, and	
			palpable hepatomegaly of stony consistency.	
			Whereas some symptoms (nausea/ vomiting, change	
			in bowel habit, pruritus, and new-onset diabetes)	
			never presented solitarily, the most frequent	
			symptoms presenting solitarily were abdominal pain,	
			jaundice, back pain, and the triad weight loss,	
			asthenia, and anorexia. It is of note that 9 (1.8%)	
			QDU patients and 6 (1.2%) inpatients (all of them	
			with early-stage pancreatic adenocarcinoma) had no	
			symptoms but their tumour was detected as an	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
			incidental imaging finding on medical check-up or	
			during evaluation for other diseases.	
Brito-Zerón et al (2014).	Study Design: Cross-	Sample size: 344 patients,	A total of 344 patients were finally evaluated, 176	Unclear if controls
Diagnosing unexplained	sectional post-test only	176 from QDU and 168	QDU patients and 168 controls. QDU patients were	are same wards as
fever: can quick diagnosis	quasi-experimental	controls (hospitalised).	predominantly women and had a lower mean age	in Bosch 2020 and
units replace inpatient			than controls. Both QDU and control patients were	Bosch 2018.
hospitalization? European		Participants: All participants	predominantly referred from the ED. However, more	
Journal of Clinical	Intervention/comparator:	were consecutive patients	QDU patients than controls were referred from	Potential QDU data
Investigation, 44(8),	QDU vs hospitalised	referred to the QDU due to	primary healthcare centres (PHC), and more controls	overlap with Bosch
pp.707-718.	(internal medicine	fever of uncertain nature	than QDU patients were referred from the ED	2021, i.e. FUN data
	department)	(FUN), defined as a	B. E. I.	only between 2009
		temperature > 38 °C during at	Primary Findings:	and 2011
	Aim: To analyse the main	least 1 week and no diagnosis	Time-to-diagnosis of QDU patients was longer than	As the set of the
	causes of fever as a key or	after a previous evaluation.	length-of-stay of controls ((25.82 ± 26.14 vs. 12.89 ±	As the setup may be
	isolated symptom of disease	Cotting: ODL at Llaggital	11.33 days, P < 0.001). The mean number of visits	different, the results
	in a cohort of patients	Setting: QDU at Hospital	required to reach a diagnosis in QDU patients was	and implications of
	evaluated in the QDU of a	Clínic de Barcelona, Spain	2.66 ± 1.25 (range: 1–10 visits). 56% patients	this study cannot be
	tertiary university hospital, to examine the advantages	Staffing/facilities:	required one or two visits, while 44% required three or more visits. Patients who required < 3 visits had a	directly applicable to other countries and
	and disadvantages of this	Staff in QDU includes	higher prevalence of infectious diseases, while those	generalized, which
	unit for the diagnosis of	a consultant internist, a full-	who required ≥ 3 visits had a higher prevalence of	represents an
	fever and to compare the	time nurse and two part-time	inflammatory diseases.	intrinsic weakness.
	results with a cohort of	secretaries. Staff in each	initialitimatory discuses.	Specific QDU
	hospitalised patients.	internal medicine ward includes	QDU patients had a higher frequency of referrals in	patients with
	nospitalisea patients.	two consultants internists, four	comparison with controls. QDU patients were more	potentially serious
		residents, a nurse coordinator,	frequently referred to PHC physicians and less	conditions including
	Data collection methods	three teams of three full-time	frequently to specialized outpatient clinics. Three	unexplained fever
	and dates:	nurses and three teams of two	QDU patients required admission in the internal	may be handled
	Economic outcomes data	full-time nursing assistants (8-h	medicine department for further evaluation of	diversely elsewhere,
	collected from hospital	daily shifts), and a full-time	unresolved fever.	with the contrast
	information systems	secretary.		between
	(bottom-up micro-costing)	_	One control patient died during hospitalisation, and	hospitalisation and
		Services provided:	there were no deaths among QDU patients	ambulatory care
	November 2008 and April	Laboratory tests included,	Mean total costs per QDU patient was €644.59	depending not only
	2011	among others, acute phase	±120.18, while it was €4404.64 ±815.32 per	on local issues but
		reactants (C-reactive protein,	hospitalised patient. Mean cost per QDU visit was	also on the
	Outcomes reported:	erythron sedimentation rate),	€63.50, and mean cost per day in hospital was	implementation and
		hemogram (total leucocytes,	€117.00. Direct and Indirect costs varied but were	comprehension of
		manual white blood cell count,	generally less in QDU patients. The mean saving of	clinical guidelines.

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Number of visits required to reach a diagnosis (QDU only) Time to diagnosis (from first visit to diagnosis) (QDU only) Length of hospital stay (hospitalised only) Death during evaluation Onward referrals Economic outcomes (micro costing):  Indirect costs (general expenses, maintenance etc.) Cost per hospital stay (hospitalised only) Cost per day of stay (hospitalised only) Cost per visit (QDU only) Cost per patient (from first to last visit) (QDU only)	haemoglobin, haematocrit, platelets), liver function tests, serum lactate dehydrogenase, serum total proteins and protein electrophoresis, microbiological serologies [e.g. IgM and IgG for cytomegalovirus (CMV), Epstein–Barr virus (EBV), Toxoplasma gondii, human parvovirus B19], HIV testing, b2 microglobulin, specific serum tumour markers, specific serum autoantibodies, specific genetic studies (autoinflammatory diseases), including cultures, imaging studies, endoscopies and cytology/biopsy studies	€3760 for each QDU patient mostly reflects the differences in staffing and working hours and in number of investigations.	Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.  Costs were adjusted for inflation to 2011 Euros, the last year of data gathering, using the Consumer Price Index
Bosch, Jordán and López-Soto (2013). Quick diagnosis units: avoiding referrals from primary care to the ED and hospitalizations. The American Journal of Emergency Medicine, 31(1), pp.114-123	Study Design: Cross- sectional post-test only quasi-experimental  Intervention/comparator: QDU vs hospitalised (internal medicine department)  Aim: To determine whether quick diagnosis units	Sample size: 4,170 QDU patients and 3,030 randomly selected hospitalised patients.  Participants: QDU patients were consecutively selected, whilst hospitalised patients were retrospectively randomly selected with a diagnosis of anaemia (n = 851), cachexia-anorexia syndrome (n = 717), febrile syndrome (n = 485),	Of the 4170 patients finally evaluated, 48% (n =2,001) were male, and the mean age (SD) was 61 (17.93) years. All patients were judged stable enough for an initial QDU assessment. Sixteen patients were lost to follow-up, 15 were hospitalised, and 12 died during the QDU evaluation before reaching a diagnosis.  Primary Findings: Assessment of hospitalised patients concluded hospitalisation might have been avoided in between 84% and 91% of hospitalised patients.	QDU data overlap with Bosch 2012a (2,000 consecutive patients evaluated between 2007 and 2010)  One limitation of the study that makes it difficult to judge whether the use of
	(QDUs) can safely and efficiently avoid emergency department (ED) visits and hospitalisations.	adenopathies and /or palpable masses (n = 428), lung and/or pleural abnormalities (n = 278), and chronic diarrhoea (n =	Referral sources varied. From December 2007 to December 2009, 1,304 (66%) of 1,963 QDU patients were referred from PC to the ED and 496 (25%) of	QDUs alleviates ED crowding is the heterogeneity of patients included.

Citation Study	y Details	Participants & Setting	Key findings	Observations/Notes
Data and description of the property of the pr	collection methods dates: collected from medical rds patients: December to December 2009 (n 63 patients) and sary 2010 to January (n = 2207 patients). Ditalised patients: ember 2006 and sary 2012 phone survey evaluated seen December 2010 December 2011  comes reported: time for first visit (QDU only) to diagnosis (time from visit to ultimate mosis) (QDU only) rral patterns over time in ED to QDU vs ditalisation) ard referral/destination of the of hospital stay poitalised only) re care preferences J vs hospitalisation) — reported re preference on type of ral (QDU vs ED) — self	Participants & Setting 271) admitted to the internal medicine service between September 2006 and January 2012.  One month after evaluation, a telephone survey was conducted in 300 randomly selected QDU patients.  Additionally, one month after discharge, a random sample of 200 patients from the random cohort were asked about care preferences and referral in future.  Setting: QDU at Hospital Clínic de Barcelona, Spain.  Staffing/facilities: The QDU has a dedicated consulting room and patient/family waiting room. It is open for 5 hours from Monday to Friday and is staffed by a consultant in internal medicine and a full-time nurse, with parttime support from 2 secretaries. In addition, consultations are provided by specialists from other services as required.  Services provided:  Not reported	1,963 QDU patients from PC to the QDU. In contrast, from January 2010 to January 2012, 774 (35%) of 2,207 QDU patients were referred from PC to the ED and 1,172 (53%) of 2,207 QDU patients from PC to the QDU (P < 0.0001).  Analysis of the referral patterns from the ED over time for the 6 main reasons for consultation showed significant differences in the number of patients referred to the QDU vs hospitalisation. From December 2007 to December 2009, 683 (36%) of 1,876 patients were referred from the ED to the QDU, and 1,320 (65%) of 2,031 patients (retrospective cohort) were directly hospitalised from the ED. In contrast, from January 2010 to January 2012, 1,193 (64%) patients were referred from the ED to the QDU and 711 (35%) patients were hospitalised from the ED (P < 0.0001).  The most common diagnoses were cancer in 1,264 (30.3%) of 4,170 patients and iron-deficiency anaemia not related to malignancy in 792 of (19%) 4,170 patients. The most frequent malignancies were colorectal cancer and lymphoma: the main reason for iron-deficiency anaemia was chronic gastrointestinal bleeding (325/4170 [7.8%] patients.  Waiting times to first QDU visit from ED ranged from 0 to 3.5 days (mean 1.9 days) and from PHC ranged from 1 to 7 days (mean 3.6 days). Wait times for admission in hospitalised patients ranged from ED and between 3 to 7 days (mean 4.9 days) in those referred from ED and between 3 to 7 days (mean 4.9 days) in those referred from PHC.  Each QDU patient had a mean of 3.13 visits and a mean (SD) time to diagnosis of 8.9 (2.35) days. The mean (SD) hospital stay of the retrospective cohort of hospitalised patients was 8.76 (2.18) days.	although the review of cases was conducted according to clinical parameters, we cannot exclude the possibility of some subjectivity when determining which hospitalised patients could have been worked up safely in the QDU.  Because we did not describe the course of patients after an initial diagnosis was reached, we do not have an accurate picture of the overall costs involved.  Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.  Costs were assessed using the hospital costs and not overall Spanish National Health Service costs.

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Direct costs (diagnostic test, consumables, QDU visits and inpatient stay) Indirect costs (maintenance and general expense overheads) Cost per visit (QDU only) Cost per day (hospitalised only) Cost per hospital stay (hospitalised only) Cost per process (from admission to discharge)		Destinations of QDU and hospitalised patients, after diagnosis and hospital discharge, respectively. During the QDU evaluation, 125 (3%) patients were referred to the ED due to complications of the process under evaluation (e.g., worsening of anaemia). Overall, 15 patients were hospitalised and 12 died. In the remaining cases, the situation was resolved and the QDU evaluation proceeded. Review of these 27 cases showed that, at least initially, they were stable enough to start QDU evaluation.  The mean cost per process was €3241.11 (SD 915) in hospitalised patients and €726.47 (617) in QDU patients. Mean cost of hospitalisation per day was €369.99 and mean cost per QDU visit was €232.1.  Additional Findings:  The response rate to the survey was 96% among QDU patients. If further diagnostic tests were required, 88% of patients would prefer the QDU care model to hospitalisation. In addition, 97% would prefer direct PC referral to the QDU without the need to attend the ED first. Finally, 182 (96%) of the 190 patients from the retrospective cohort who responded to the survey would prefer the QDU care model to hospitalisation should the diagnostic workup be performed again, and 98% would prefer direct hospitalisation from the QDU or PC without attending the ED first.	
Bosch et al (2012a). Quick diagnosis units versus hospitalization for the diagnosis of potentially severe diseases in Spain Journal of Hospital Medicine, 7(1), pp.41-47.	Study Design: Cross- sectional post-test only quasi-experimental  Intervention/comparator: QDU vs hospitalised (admitted to the internal medicine department)	Sample size: 2,000 consecutive QDU patients and 1,454 control patients  Participants: Consecutive QDU patients. Control patients (comprised of patients diagnosed with anaemia n = 548; cachexia-anorexia syndrome n = 458; febrile	Of the 2000 QDU patients finally included, of whom 1106 were female, with a mean age of 60 years (18.84).  Primary Findings: The main sources of referral were the ED (1,022 patients) and PHC centres (942 patients). Waiting time for the first QDU visit ranged from 2 to 8 days (mean 3.9 days) in patients referred from PHC centres, and 0 to 4 days (mean 2.1 days) in patients	QDU data overlap with Bosch, Jordán and López-Soto 2013 (2,000 consecutive patients evaluated between 2007 and 2010)  Time to diagnosis in QDU patients was

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Aim: To describe the	syndrome n = 240 and	referred by the ED. The 2,000 first visits generated	compared to the
	functioning of a QDU in a	adenopathies or palpable	4,260 successive visits (ratio first/successive = 2.13	length of hospital
	Spanish public university	masses n = 208) randomly	visits). The average number of visits per patient was	stay in hospitalised
	hospital after evaluating	selected from 2,022	3.11 visits. The mean length of hospital stay was 8.68	patients.
	2000 consecutive patients.	consecutive patients with these	days.	
	Authors intended to	diagnoses. Participants were		Economic outcomes
	ascertain the utility and cost	unmatched.	The most frequent diagnoses were cancer (both	(micro costing) –
	of the model compared to		epithelial and hematological) in 526/2000 (26.3%)	sub-group analysis
	conventional hospitalisation	A telephone survey was carried	patients, and iron-deficiency anaemia (unrelated to	on a randomly
	and the degree of patient	out in a random sample of 225	malignancy) in 360 patients. The most common	selected cohort of
	satisfaction.	patients 3 months after the	cancers were colon cancer and lymphomas, while the	600 QDU and 600
	Data collection mathed	QDU intervention.	main cause of iron-deficiency anaemia was chronic	QDU patients, each
	Data collection methods and dates: QDU data	Sotting: ODLI at Hagnital	gastrointestinal bleeding (148/2000 [7.4%] patients).	comprised of 150 patients with iron-
	collected between	Setting: QDU at Hospital Clínic de Barcelona, Spain	Mean time to diagnosis was 9.4 days (1.78). After	patients with iron- deficiency anaemia,
	December 2007 and July	Cirric de Barceloria, Spairi	the diagnostic study was completed, 1,232 patients	150 patients with
	2010	Staffing/facilities: The QDU is	were referred to PHC centres, 712 to outpatients, and	cachexia-anorexia
	Hospitalised (control) data	composed of a specialist in	56 required hospitalisation.	syndrome, 150
	collected between	internal medicine and a	oo reganea noophanoation.	patients with fever of
	September 2006 and June	registered nurse who work in	Taking into account previously used criteria, authors	unknown origin, and
	2010	the QDU for 5 hours daily, 5	estimated that 820 (41%) patients would have been	150 patients with
		days a week (Monday-Friday),	candidates for conventional hospitalisation (for	adenopathies and/or
	Outcomes reported:	assisted by specialists from	diagnostic studies) before QDU was created.	palpable masses. All
	Time to first QDU visit (QDU	other specialties and receives	Considering mean length-of-stay of the internal	costs analysed were
	only)	administrative support from 2	medicine department (50 beds) during 2009 for	hospital costs and
	Number of visits (QDU only)	secretaries shared with other	patients admitted for a diagnostic workup was 10.3	not National Health
	Waiting time between visits	units. It has a consulting room	days, authors estimated that 12.5 beds per day	Service costs.
	(QDU only)	and a waiting room for patients	during a year were freed up (i.e., 4563 bed-days	
	Time to diagnosis (defined	and families, and functions	saved in a year). On the other hand, 45 of 1000	
	as the time from the first	daily.	(4.5%) patients required immediate or early	
	visit to a definitive		hospitalisation due to their bad health status, which	
	diagnosis) (QDU only)	Services provided:	impeded further QDU diagnosis.	
	Onward referral	Not reported		
	Charlson comorbidity index		In hospitalised patients, the total mean cost per day	
	Length of hospital stay		of hospital stay was €363.35, and the mean cost per	
	(hospitalised only)		process was €3,153.87 (910). In contrast, the mean	
	Hospital admissions avoided		cost per process in the QDU was €702.33 (610), and	
	(defined as patients who		mean cost per QDU visit was €225.83. Mean direct	
	would have been admitted		and indirect costs were all less in the QDU visits.	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	for a diagnostic workup if there no QDU)		Compliance with the patient survey was 94%. The results highlighted 3 main aspects: a) overall	
	there no QDO)		satisfaction with QDU care was high in 93% of cases;	
	Self-reported outcomes		b) repeated travel to the hospital was not a major	
	Degree of difficulty of travel		difficulty; and c) if further diagnostic tests were	
	to unit		required, 84% of patients would prefer the QDU care	
	Overall satisfaction		model to hospitalisation. The same results were	
	Preferential future care type		obtained analysing only patients with previous	
			hospital admission. The remaining 16% indicated no	
	Economic outcomes		preference for 1 type of care.	
	Direct costs Indirect costs		Additional Findings:	
	Mean cost per visit (QDU		QDU patients with anaemia were significantly	
	only)		younger than hospitalised patients with the	
	Mean cost per process		same diagnosis (P < 0.0001). Other parameters,	
	(admission to discharge)		notably age, time to diagnosis versus length-of-stay,	
	Mean cost of daily stay		and Charlson comorbidity index showed no	
	(hospitalised only)		statistically significant differences in any of the 4 main	
	Hospital bed days saved		reasons for consultation.	
	Cost per hospital stay		The type and mean number of complementary	
	Cost per process Cost per visit		The type and mean number of complementary explorations in patients with the 4 main reasons for	
	Patient satisfaction		consultation was similar between QDU and	
	Patient preferences		hospitalised patients (2.27 vs 2.33, respectively).	
			, , , , , , , , , , , , , , , , , , , ,	
Bosch et al (2012b).	Study Design: Cross-	Sample size: 169 QDU	Of the 169 patients, 20 were excluded due to	Cancer-related study
Comparison of Quick	sectional post-test only	patients (62.8%), and 53	associated conditions that made QDU management	Data wital ODU data
<u>Diagnosis Units and</u> Conventional	quasi-experimental	Hospitalised patients (control).	inappropriate. Of the 149 QDU patients finally included, 57% were males, with a mean age of 68.3 ±	Potential QDU data overlap with above
Hospitalization for the		Participants: Consecutive	14 years. Mean age of QDU patients were	studies by Bosch et
Diagnosis of Cancer in	Intervention/comparator:	QDU patients with both initially	significantly younger than those hospitalised (68.3 vs.	al.
Spain: A Descriptive	QDU vs hospitalisation	suspected and ultimately	74.7 years; p < 0.05).	
Cohort Study	(internal medicine	confirmed (pathologically		
Oncology, 83(5), pp.283-	department)	proven) cancer were evaluated	Primary Findings:	Only participants
291.		for inclusion (n=269). Control	Time to diagnosis among QDU patients compared to	with suspected and
	Aim: To compare the	patients evaluated from 164	length of stay was not significantly longer 14.4±11.3	confirmed cancer
	diagnostic value and cost of	hospitalised patients were	days vs 10.6±9.2 days respectively; p >0.05).	diagnoses were
	a QDU and conventional	newly diagnosed with cancer	The main referral courses included 470/ of ODL	included in this
	hospitalisation in assessing patients with suspected and	admitted to the internal medicine department.	The main referral sources included 47% of QDU patients were referred from the ED, 37% from PHCs,	study.
	patients with suspected and	песисте сераппент.	patients were referred from the ED, 37 % from PHCS,	

Citation	tudy Details	Participants & Setting	Key findings	Observations/Notes
cc	onfirmed cancer in a	-	7% from other hospital departments and 9% from	Authors
	panish tertiary public	Setting: QDU at Hospital	other sources. Of hospitalised patients, 87% were	acknowledged study
ho	ospital.	Clínic de Barcelona, Spain	referred from the ED, 9% from other hospital	limits including the
			departments, 2% from PHCs, and 2% from other	prospective and
	oata collection methods	Staffing/facilities: The QDU,	sources.	retrospective nature
	nd dates: November 2008	which has a dedicated	The colling for the first ODII left on Ote O	of the two participant
ar	nd April 2010	consulting room and	The waiting time for the first QDU visit was 2 to 8	groups. Since the
	Vitoomoo roportodi	patient/family waiting room, is	days in PHC referrals and 0 to 4 days in ED referrals.	disease course after
	outcomes reported:	open Monday to Friday for 5h and is	Waiting times for hospitalised patients were 0 to 2 days in ED referrals, 2 to 3 days in referrals from	the initial diagnosis was not studied,
1	Vait time for first visit (QGU	staffed by a consultant in	other departments, and 3 to 8 days in PHC referrals.	authors were unable
	nly)	internal medicine, a full-time	other departments, and 3 to 6 days in PHC referrals.	to provide a
	lumber of visits (QDU only)	nurse, and two part-time	Mean QDU visits were 2.37. The first 149 visits	complete analysis of
	Vait times between visits	secretaries. Consults are	generated 199 successive visits (ratio first/successive	all costs.
	QDU only)	provided by other specialists	= 1.335). Mean complementary tests per patient were	an oodo.
	ime to diagnosis (from first	on demand.	2.07 in QDU and 3.05 in hospitalised patients.	Time to diagnosis in
	isit to final diagnosis)		Interconsultations per patient were 0.01 in QDU and	QDU patients was
	ength of hospital stay	Services provided:	0.49 in hospitalised patients.	compared to the
(h	nospitalised only)	Not reported	·	length of hospital
	,	·	The most common diagnoses were colorectal cancer	stay in hospitalised
			(26%, n = 38) and lymphoma (22%) in QDU patients,	patients.
	DU costs (per visit and per		and lymphoma (32%, n = 17) and colorectal cancer	
	rocess)		(23%) in hospitalised patients. There were significant	Economic outcomes
	lospital costs (per day and		differences between QDU patients and hospitalised	(micro costing)
	er process)		patients in the source of referral (p < 0.00001) and	Costs were
	Pirect costs (unit costs of		destination (p < 0.00001) but not in the reason for	assessed using the
	iagnostic procedures,		consultation (p > 0.26) and diagnosis (p > 0.34).	hospital costs rather
	onsumables, QDU visits		The Milesus week are took allowed a second and	than Spanish National Health
	nd inpatient stay)		The Wilcoxon rank sum test showed a mean and	Service costs.
	ndirect costs (overheads uch as maintenance and		median time to diagnosis of QDU patients of $14.4 \pm 11.3$ and $13$ days (P25: 2.5, P75: 21.25),	Service costs.
	eneral expenses)		respectively, which was not significantly longer than	
ge	erierai experises)		the mean and median length of stay of hospitalised	
			patients of $10.6 \pm 9.2$ and 8 days (P25: 2, P75: 12),	
			respectively (p > $0.05$ ).	
			After diagnosis, 23% of QDU patients were	
			hospitalised, 72% referred to outpatients [mainly	
			oncology (36%) and haematology (17%)], 3%	
			referred to PHCs, and 2% lost to follow-up. After	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
			discharge, 63% of hospitalised patients were referred	
			to outpatients [mainly oncology (26%) and	
			haematology (25%)], 19% to home or specialized	
			residential palliative care and 18% lost to follow-up.	
			The mean cost per day of hospital stay was €382.96	
			in hospitalised patients. The mean cost per visit in	
			QDU patients was €253.94. The mean cost per	
			process was €4,059.37 8 987 in hospitalised patients	
			and €601.84 8 502 in QDU patients.	
December 21 (0040 ) 0 1 1	Otto ha Paratina C	0	0011-000-000-00-00-00-00-00-00-00-00-00-	
Bosch et al (2012c). Quick diagnosis units or	Study Design: Cross- sectional post-test only	<b>Sample size:</b> 282 consecutive patients with severe anaemia	Of the 328 patients initially included for QDU evaluation 46 were excluded from the study due to	Likely overlap of patient data with
conventional	quasi-experimental	attended by the QDU and 252	associated conditions that made outpatient QDU	above studies
hospitalisation for the	quasi-experimental	consecutive patients with the	management inappropriate. Therefore, 282 cases	above studies
diagnostic evaluation of		same diagnosis admitted to the	were finally included, of whom 182 were female	Time to diagnosis in
severe anaemia: A	Intervention/comparator:	internal medicine department	(64.5%), with a mean age of 65.63 years (17.44). A	QDU patients was
paradigm shift in public	QDU vs hospitalised	•	total of 252 hospitalised patients were included, of	compared to the
health systems?	patients (internal medicine	Participants: Prospective	whom 166 were female (65.9%), with a mean age of	length of hospital
European Journal of	department)	cohort of all consecutive	76.11 years (12.68). QDU patients were significantly	stay in hospitalised
Internal Medicine, 23(2),		patients with severe anaemia	younger than hospitalised patients (P <0.0001).	patients.
pp.159-164.	Aim: To investigate the	(defined as a haemoglobin	Duine and Finalise are	
	utility and cost of a QDU for the evaluation of patients	concentration lower than 8 g/l) attended by the	Primary Findings: The main referral sources were the ED (186 patients)	
	with severe anaemia	QDU of the internal medicine	and primary healthcare centres (88 patients) in QDU	
	(haemoglobin	department, and a	patients, and the ED (170 patients) in hospitalised	
	b8 g/l) compared with	retrospective cohort of all	patients. Waiting time for the first QDU visit ranged	
	conventional hospitalisation	consecutive patients with same	from 2 to 8 days (mean: 3.9 days) in patients referred	
	in a tertiary public hospital in	diagnosis admitted to the	from primary healthcare centres and from 0 to 4 days	
	Spain.	internal medicine department.	(mean: 2.1 days) in patients referred from the ED.	
	Data collection methods	A telephone survey was carried	QDU patients generated 902 visits with a mean of	
	and dates:	out in a random sample of 125	2.95 visits per patient (from first to last physician—	
	QDU data collected	patients three months after the	patient encounter, once all the workup was	
	between 1 January and 31	QDU intervention.	completed and a diagnosis was achieved). Once a	
	December 2010		final diagnosis was made, 61.9% of QDU patients	
	Hospitalised (control) patient	Setting: QDU at Hospital	were referred to the original primary healthcare	
	data collected between	Clínic de Barcelona, Spain	centre, 21.4% to internal medicine outpatients, 14.8%	
	September 2006 and June		to gastroenterology outpatients, and only 1.9% were	
	2010		hospitalised in the internal medicine department,	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
		Staffing/facilities: The QDU is	normally due to worsening of anaemia. Furthermore,	
	Telephone survey data	composed of a specialist in	5 patients (1.8%) were temporally referred to the ED	
	collected three months after	internal medicine and a	whilst being studied at the QDU for some acute	
	QDU intervention	registered nurse, who are	complication (e.g., uncompensated heart failure) but	
		assisted by specialists from	all returned to the Unit to continue the study.	
	Outcomes reported:	other specialities. It has a		
	Charlson morbidity index	consulting room and a waiting	The mean time to diagnosis in QDU patients was	
	Time to Cost Soit (ODII and )	room for patients and families,	7.82 days (1.36), which was not significantly different	
	Time to first visit (QDU only)	and functions daily. The QDU	from the mean stay of 8.87 (4.45) days of	
	Definitive diagnosis	internist and nurse devote	hospitalised patients. Mean haemoglobin and	
	Time to diagnosis (defined	5-hours daily, 5 days a week	haematocrit were 76.11 (21.8) and 25.03 (6.52),	
	as the time from first visit to	(Monday–Friday), to QDU	respectively, in QDU patients and 74.61 (21.1) and	
	a definitive diagnosis) (QDU	work. QDU receives	24.11 (6.43), respectively, in hospitalised patients.	
	only)	administrative support from two	The differences were not statistically significant.	
	Number of visits (QDU only)	secretaries shared with other	Moon longth of boonital atoy was 9.97 days are are	
	Length of hospital stay	units.	Mean length of hospital stay was 8.87 days among	
	(hospitalised only) Referral source	Services provided:	hospitalised patients.	
	Onward referrals	Not explicitly stated but would	Total mean cost per day of hospital stay was	
	Diagnostic tests	include double endoscopy	€2,060.63 in hospitalised patients and €90.04 euros	
	Diagnostic tests	(colonoscopy, gastroscopy),	per QDU visit. The mean cost per process was	
	Self-reported outcomes –	duodenal biopsy, endoscopic	€18,278.01 in hospitalised patients. In contrast, the	
	Perception of the care	capsule exam, imaging,	mean cost per process in the QDU was €2,920.62.	
	process	laboratory or pathology tests	Theatr cost per process in the QDO was C2,320.02.	
	Degree of difficulty of travel	laboratory or patriology tests	There was 92% compliance with the survey of patient	
	to the unit Overall		opinion. The results highlighted three main aspects:	
	satisfaction,		a) overall satisfaction with QDU care was high in 93%	
	Preferential care type in the		of cases, b) repeated travel to the hospital was not a	
	future Conditions of physical		major difficulty, and c) if further diagnostic tests were	
	space		required, 85% of patients would prefer QDU care to	
	-1,5000		conventional hospital admission. The remaining 15%	
	Economic outcomes –		did not indicate a preferential type of care. The same	
			results were obtained analysing only patients	
	Cost per day of hospital stay		with experience of hospital admission.	
	(hospitalised only)		, , , , , , , , , , , , , , , , , , , ,	
	Cost per visit (QDU only)		Additional Findings:	
	Cost per process (time		One-hundred and eighty-six (65.9%) QDU patients	
	between first and last visit		were transfused before the first QDU visit, as were	
	for QDU and admission to		162 hospitalised patients (64.3%), 131 from ED and	
			31 at the internal medicine ward. Furthermore, 5 of	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	discharge for hospitalised patients) Cost per length of stay (hospitalised only)		the 186 QDU patients who had been transfused at the ED before the first visit were subsequently retransfused in the own Unit for reagudisation of the anaemia during the study process. Likewise, 2 of the 131 hospitalised patients first transfused at the ED and 2 of the 31 first transfused at the internal medicine ward required a new transfusion at the ward. Overall, the mean number of blood units transfused was 2.0 for QDU and 2.1 for hospitalised patients.  Definitive diagnosis among QDU patients included iron-deficiency anaemia (the commonest type of anaemia in the two cohorts), 94 patients (33.3%) had benign digestive lesions, 42 (14.9%) an unknown process, 40 (14.2%) gastrointestinal malignancies and 18 patients (6.4%) heavy menstrual bleeding. Benign digestive lesions were also the main aetiology of iron deficiency anaemia in hospitalised patients (n=90; 35.7%) followed by unknown process (50 patients; 19.8%). A gastrointestinal malignancy was found in 28 (11.1%) of 252 hospitalised patients with iron deficiency anaemia (Table 4). Multifactorial anaemia was the second major diagnostic group in QDU (n=34; 12.1%) and hospitalised patients (n=38; 15.1%).  All these patients underwent a duodenal biopsy and a capsule endoscopy	
Bosch et al (2011).  Outpatient Quick  Diagnosis Units for the evaluation of suspected severe diseases: an observational, descriptive study. Clinics, 66(5), pp.737-741.	Study Design: Cross- sectional post-test only quasi-experimental  Intervention/comparator: QDU vs hospitalised patients (internal medicine department)	Sample size: 1,000 consecutive patients evaluated in the QDU during time frame  Subgroup analysis comprised of 50 randomly selected patients with iron-deficiency anaemia, 50 with fever of unknown origin and 50 with anorexia-cachexia syndrome	Median age of 60±18.84 years (range: 15 to 95 years), 447 men and 553 women and possibly 150 control patients  Primary Findings: The first 1,000 visits generated 2,233 successive visits (ratio successive/first = 2.23).  Waiting times for a first QDU visit ranged from 2 to 8 days (mean: 3.9 days) in patients referred from	Mean cost per hospital stay and mean cost per visit were directly compared  Bed days saved – estimated from LOS and hospital admissions avoided)

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
l l	Aim: To describe the	evaluated in the QDU / or	primary healthcare centres and from 0 to 4 days	
	functioning of a QDU in a	patients who were hospitalised	(mean: 2.1 days) in patients referred from the ED of	
	Spanish public university	in the hospital's two Internal	the hospital.	Looks like the only
	nospital after evaluating	Medicine wards.		outcomes being
1	1,000 consecutive patients.		The most frequent diagnosis was cancer (either	compared between
	Also aimed to ascertain the	Survey administered to 155	epithelial or hematological) in 188 patients,	QDÜ and
	costs of the QDU model	random patients attending the	representing 18.8% of diagnoses, and iron-deficiency	hospitalised patients
	compared to conventional	QDU (85% response rate)	anaemia (unrelated to malignancy) in 180 patients	are:
h	nospitalisation and the	,	(18%). The most common cancers were colon cancer	Cost per stay/visit,
	degree of satisfaction of	Participants: Patients with	and lymphomas, while the leading cause of iron-	cost per process
	QDU patients.	potentially severe diseases that	deficiency anaemia was chronic gastrointestinal	Bed days saved
	·	would normally require hospital	bleeding (74 cases; 7.4% of all 1,000 patients). The	-
	Data collection methods	admission for diagnosis, or	mean time to diagnosis was 9.2±5.86 days (range: 1	
a	and dates:	their general condition allows	to 19 days).	
	Main data collected between	for outpatient treatment, and		
	November 2008 and	they do not have physical or	After the diagnostic study was completed, 616	
J	January 2010	psychological disabilities that	patients were referred to primary health care centres,	
	Subgroup analysis collected	would make traveling to the	356 were referred to outpatient clinics and 28	
l b	between September 2007	hospital several times difficult.	required hospitalisation.	
a	and September 2008 for			
	Hospital data and during	Setting: QDU at Hospital	Considering that the mean	
	2009 for QDU data	Clínic de Barcelona, Spain.	length of stay in the internal medicine department (50	
	collection		beds) in 2009 for patients admitted for a diagnostic	
	Survey data collection three	Staffing/facilities: staffed by a	workup was 10.3 days, authors estimated that 12.5	
	months after the QGU	specialist in internal medicine	beds/day were made available over the course of a	
ii	ntervention	and a registered nurse, with	year (i.e., 4,563 bed-days were saved in a year).	
		specialists from other fields	However, 45 of 1,000 patients (4.5%) required	
	Outcomes reported:	assisting. It has a consulting	immediate or early hospitalisation due to their bad	
	Time to first visit - waiting	room and a waiting room for	health status, which impeded further QDU diagnosis.	
	time to first QDU visit from	patients and families, and it		
	either PHC or ED	functions daily. The QDU	In hospitalised patients, the total mean cost per day	
	Number of visits - calculated	physician and nurse devote	of the hospital stay was €356.59 and the mean cost	
	from first visit and	five hours a day five days a	per process was €3,416.13. In contrast, the mean	
	successive visits (ratio	week (Monday to Friday) to	cost per process in the QDU was €735.65.	
	successive/first)	QDU work.		
	Time to diagnosis - time		Additional Findings:	
	petween first visit and	Services provided: The main	Hospital admissions avoided - 410 patients (41%)	
	definitive diagnosis (and	diagnostic tests (analytical and	would have been candidates for conventional	
	usually coincided with the	microbiological tests, simple	hospitalisation (for diagnostic studies) before the	
r	results of diagnostic test)	radiology [X-ray], CT scans,	QDU was established	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Hospital admissions avoided - patients who would have been admitted for diagnostic workup if there were no QDUs (used to measure number of bed days saved) Appropriateness criteria for QDU assessment – based on predefined list of diseases  Subgroup analysis – Length of hospital stay – no definition (used to estimate number of bed days saved) Cost per visit – mean cost per QDU visit Cost per hospital stay – mean cost hospital stay Cost per process (admission to discharge episode) Hospital bed days saved (mean LOS and cost per visit)  Patient satisfaction Patient preference	echography, nuclear scintigraphy, digestive endoscopy, biopsies and lymph node fine-needle puncture aspiration [FNPA]) are normally performed within 7 days after the first visit.	Appropriateness criteria for QDU assessment – 84% of the 1,000 met the appropriateness criteria for QDU assessment according to the agreed-upon list of diseases. The remaining 16% either did not meet the established patient profile or did not have diseases suitable for QDU care.  Survey response rate was 85% and highlighted findings included overall satisfaction with QDU was high in 95% of cases, repeated travel to the hospital was not a major difficulty for the patients, and if further diagnostic tests were required, 80% of patients would prefer the QDU care model over conventional hospital admission. The same results were obtained analysing only patients who had experience with hospital admissions. The remaining 20% did not indicate a preference for any one type of care.	
Quick Diagnostic Unit (QDU		Commission 405 ODLI	Driver - Findings	Data in the LODIL state
Sanclemente-Ansó et al (2016). Cost-minimization analysis favors outpatient quick diagnosis unit over hospitalization for the	Study Design: Economic evaluation (cost-minimisation)  Intervention/comparator:	Sample size: 195 QDU patients diagnosed with severe anaemia (n=94), lymphoma (n=63) and lung cancer (n=38) selected from 1,226	Primary Findings: There was no difference in the primary clinical outcome between QDU and hospitalised patients. For the three diagnostic groups, the overall average time to diagnosis at the QDU was 11.1 days, with a total of	Potential QDU data overlap with Bosch 2018 (QDU2) Limitations
diagnosis of potentially serious diseases. Eur J Intern Med; 30:11-17. doi: 10.1016/j.ejim.2015.12.015	QDU vs hospitalised patients (internal medicine department)	consecutive patients referred to the unit during timeframe and 237 control patients who were electively hospitalised at the	195 first visits and 137 successive visits. LOS of comparable inpatients was 10.3 (+9.1) days (median, 8; range, 4–18).	The results of the cost-minimization analysis might be biased in favour of
	Aim: To evaluate the costs of QDU vs. conventional	Internal Medicine Department of the hospital for diagnostic	No significant differences in cost saving per patient according to each final diagnosis: mean cost saving	QDU. In particular, a main criterion for

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	hospitalisation for the	workup during the same period	per patient with a diagnosis of anaemia was	referral to and
	diagnosis of cancer and	and who had the same final	€4422.91 (overall saving €415,753.54), €4481.41 per	evaluation by the
	anaemia using a cost-	diagnoses.	patient with a diagnosis of lymphoma (overall saving	QDU is that patients
	minimization analysis on the		€282,328.83), and €4464.13 per patient with a	must be well-enough
	proven assumption that	Participants: Three groups of	diagnosis of lung cancer (overall saving	and be able to
	health outcomes of both	QDU patients (severe	€169,636.94).	attend several
	approaches were	anaemia; lymphoma and lung	·	outpatient
	equivalent.	cancer) were compared with	Greatest savings of specific cost items in all	appointments [33].
	·	patients who were electively	diagnostic groups were related to hospital stays.	Accordingly, there is
	Data collection methods	hospitalised for diagnostic	Taking into account the mean LOS and the mean	a possibility that
	and dates: March 2008 and	workup.	cost per hospital stay, the mean cost saving per	patients who were
	June 2012	·	patient was €2956.41. Overall, the mean estimated	admitted were older
		Setting: QDU at Bellvitge	saving per patient for the three diagnostic groups	and had more
	Medical records were	University Hospital in	related to the costs of hospital stays represented	comorbidities,
	retrieved from the	Barcelona, which is affiliated to	66% of the total cost savings per patient. Structural	requiring more
	institutional QDU database	the University of Barcelona,	and general functioning costs also generated	attendance and
	to identify the patient groups	Catalonia, Spain. The QDU is	significant QDU savings from hospitalisation.	inpatient care
	of interest. For hospitalised	integrated to the Internal		leading to a potential
	patients, the Minimum Basic	Medicine Department of the	Overall, the mean estimated saving per patient for	selection bias.
	Data Set (MBDS)	hospital.	the three diagnostic groups related to the structural	Although this would
	complemented by medical		and general functioning costs of hospitalisation was	not likely change the
	records was used using	Staffing/Facilities: The QDU	€1485.84, ranging from €1474.76 to €1494.26	results of the study
	codes of the Spanish	is internist led and open 7	depending on the diagnosis, which represented 33%	or their
	version of the ICD-9-CM.	hours a day, 2 days a week	of the total cost savings per patient.	interpretation, the
	Cost data obtained from the	(Tuesdays and Fridays).		actual cost savings
	institutional information	Analysis implies staff also	The estimated QDU savings from hospitalisation	of the QDU
	system implement in the	included attending physician,	associated with the costs of diagnostic investigations	approach might thus
	Bellvitge hospital	registered nurse, caretaker.	were lower. The mean cost saving per patient across	be lower.
			the three diagnostic groups ranged from €19.25 in	
	Outcomes reported:	Services provided: Not	patients with anaemia to €46.73 in patients with lung	By recruiting cases
	Health outcomes:	explicitly stated, but to include	cancer to €58.25 in those with lymphoma. Overall,	by diagnosis and not
	mean time to diagnosis	blood and urine analysis, X-ray	the mean QDU saving per patient for the three	by suspicion of
	(QDU patients)	CT, simple X-ray, PET-CT,	groups related to the costs of diagnostic	diagnosis, the cost
	mean length of stay	biopsy, bronchoscopy,	investigations was only 1% of the total cost savings	of workup of patients
	(hospitalised patients)	cytology, microbial culture,	per patient. These findings suggested that, to reach a	who turn out to be
	QDU Cost outcomes	scintigraphy, mammography,	specific diagnosis of anaemia, lung cancer, and	negative for the
	(actual):	specialist consultation,	lymphoma in equivalent waiting times (i.e. time to	suspected diagnosis
	total cost per patient until	ultrasonography, colonoscopy,	diagnosis/LOS), the attending physician at the QDU	are left out of the
	reaching a diagnosis -	electrocardiography, lower and	ordered slightly fewer diagnostic tests than the two	analyses, and bias
	calculated from the sum of	upper gastrointestinal series,	physicians assigned to every patient at the Internal	might also result

Citation Study Details	Participants & Setting	Key findings	Observations/Notes
diagnostic tes procedures, structural and functioning of depreciation. Direct costs of included pers material, diag investigations each type cal according to of established Of therapeutic procedure of Average outp consultation ( calculated accofficially estables) Non-direct constructural and functioning of (administrative) maintenance and cleaning consultation of associated per medical mate therapeutic process).  Hospitalisation outcomes: Direct costs of hospitalisation cost of hospit (comprising of	edical material, sts, therapeutic blood marrow aspiration cytometry  digeneral sts, and of QDU — sonnel, medical gnostic si (unit cost for loulated officially CHS fees), rocedures. steint (unit cost scording to blished CHS sts of QDU — digeneral sts ve costs, costs, laundry services, costs, ersonnel, erial and rocedures  ion cost  of n — tal stays of personnel — caretaker staff material and		capable patients with better physical ('healthier') status at the QDU.  Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Costs based on an			
	analytical cost performed			
	internally by the Department			
	of Economics of the			
	Bellvitge Hospital and was			
	based on admission in			
	standard wards.			
	cost of physicians [attending			
	and resident] - fraction of			
	salary equivalent to 30			
	minutes per day			
	cost of diagnostic			
	investigations - average of			
	the unit costs for diagnostic			
	tests in the hospitalisation			
	approach, based on the			
	same unit costs of the QDU.			
	Non-direct costs of			
	hospitalisation -			
	structural, general			
	functioning costs excluding			
	consultations costs,			
	personnel (attending and			
	resident physician).			
	Other outcomes:			
	Number of visits			
		,		
Barriel Bia arra atia Carter (Bl	DO) of North Book Talker Hearth	UK		
	DC) at Neath Port Talbot Hospit		Patrican lung 2017 and May 2019, 190 patients	Consor related at the
Sewell et al (2020). Rapid	Study Design: Economic	Sample size: 1,000 (simulated	Between June 2017 and May 2018, 189 patients	Cancer-related study
cancer diagnosis for	evaluation	based on real-life data for	attended the RDC. Of these patients, 46% were male	Dationt laval
patients with vague	Intervention/Comparator:	intervention and control group)	and the mean age was 70 years (SD = 12.9 years;	Patient-level discrete-event
symptoms: a cost- effectiveness study. British	Intervention/ Comparator: Pilot RDC vs standard	Participants: Adults aged >10	minimum = 26; maximum = 95).	
Journal of General		Participants: Adults aged ≥18 years in the pilot area	Primary Findings:	simulation (DES) and decision analytic
	clinical practice			
Practice; 70 (692): e186- e192.	Aim. To explore the cost	who were referred by their GP to the RDC at Neath Port	Time to diagnosis	modelling were used to estimate the time
	Aim: To explore the cost-			
DOI: https://doi.org/10	effectiveness of the RDC	Talbot Hospital (NPTH) for		from referral to

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
.3399/bjgp20X708077	compared with standard clinical practice.  Data collection methods and dates: Data collected between June 2017 and May 2018. Routinely collected, fully anonymised service data from the RDC provided model data inputs. NPTH records were manually searched for control patients.  Outcomes reported: Time to diagnosis Quality adjusted life years (QALYs) Mean cost per patient Cost of diagnostic tests Personnel costs Cost-effectiveness	further investigation of non- specific and/or vague symptoms that could be due to cancer between June 2017 and May 2018  Setting: RDC at Neath Port Talbot Hospital, Wales, UK  Staffing/facilities: Consultant physician, a radiologist, a clinical nurse specialist (CNS), and a healthcare support worker (HCSW). Management and clinical guidance are provided by the RDC coordination manager and GP project lead. Two half-day clinics a week with five available clinic slots  Services provided: Physical examination, CT scans	Mean time to diagnosis was 84.2 days (SD = 65.3) in the control group. This was reduced to 5.9 days (SD = 3.4) in patients who were diagnosed directly at the RDC clinic and to 40.8 days (SD = 30.0) if further investigations following RDC were warranted.  Cost-effectiveness At between 80% and 100% capacity, the RDC produces more QALYs and is less costly, and thus outperforms standard clinical practice.  Below 80% capacity, the RDC is not cost-effective at a £20 000 willingness-to-pay threshold.  Additional Findings: Total staff costs per half-day clinic were calculated as £2640 with CT scan and other test costs amounting to £118.21 per patient	diagnosis and the cost-effectiveness of the RDC compared with standard clinical practice.  According to the study authors, data used to populate the model were taken from the first year of the RDC pilot operation, and therefore unable to allow extrapolation of the longer-term impact of the RDC on healthcare resource use, patient outcomes, or survival. This could underestimate the cost-effectiveness of the RDC.
Rapid Diagnostic Clinic (RD	C) at St Barts Health NHS Trus	t	l	11011201
Choudhury et al (2013). A multidisciplinary audit of head and neck referrals: considerations for patients' timelines and outcomes. European Archives of Oto-Rhino-Laryngology, 270(12), pp.3121-3126.	Study Design: Cross- sectional post-test only quasi-experimental  Intervention/ Comparator: Rapid Diagnostic Clinic (RDC period) vs head and neck clinics (pre-RDC period)  Aim: To critically appraise the efficacy of a RDC with respect to its impact on	Sample size: A total of 212 new patients were seen during the pre-RDC period, with complete data on 197 new patient episodes. A total of 313 new patients were seen during the RDC period, with complete data on 299 patient episodes.  Participants: All new target referrals for patients that were seen in weekly head and neck clinics	Primary Findings: During the pre-RDC period, the mean time taken for patients referred via the 2WW referral system was 11.2 ± 0.6 day (range 1–37 days). The mean time taken for all other target referrals (non-2WW) was 33.5 ± 3.3 days (range 2–145 days). During the RDC period, the mean time taken for patients referred via the 2WW referral system was 9.2 ± 0.4 day (range 1–27 days), and for non-2WW referrals was 23.3 ± 1.9 days (range 1–105 days).  A comparative data analysis for the timelines from referral to the patients being seen between the pre-RDC and RDC period confirmed a statistically significant reduction in the time from referral to	Cancer-related study (Head and neck cancer)

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	patients' timelines and outcomes	Setting: A RDC within the ENT department of Barts Health	patients first clinic consultation, between the two study periods [referred via the 2WW referral system	
	Data collection methods	NHS Trust, London, UK	11.2 to 9.2 days (P = 0.0002); all other referral sources 33.5 to 23.3 days (P = 0.0015)].	
	and dates:	Staffing/facilities: ENT head	Common	
	Retrospective audit of all	and neck specialist, either a	Additional Findings:	
	new target referrals for patients that were seen in	consultant or specialist registrar, consultant head and	During the RDC period, over one-third of patients utilised the provision of ultrasound ± FNAC, and	
	weekly head and neck	neck radiologist, consultant	consequently, the majority reached a definitive	
	clinics between 1 October	histopathologist.	outcome (discharged or scheduled for surgery)	
	2009 and 31 March 2010	0	following their first consultation.	
	(pre-RDC period), and a prospective audit the RDC	Services provided: Ultrasonography, and fine		
	during a similar time	needle aspiration cytology		
	period, from 1 October 2010	(FNAC)		
	to 31 March 2011			
	Outcomes reported:			
	Time to first visit			
	Number of visits Time from consultation to			
	treatment			
Community Diagnostic Servi Pallan et al (2005).	Study Design: Cross-	Sample size: Random	The response rates for the surveys were 52.9 per	The study authors
Evaluation of an	sectional post-test only	samples of 200 and 193 adult	cent for the community service patient survey	reported the
independent, radiographer-	quasi-experimental	patients who underwent	(100/189, 11 patients had died or moved address),	likelihood of biases
led community diagnostic	' '	diagnostic ultrasound in	44.6 per cent for the hospital service patient survey	in the study findings
ultrasound service	Intoniontion/ Comments	2001/2002 with the community	(82/184, nine patients had died or moved address),	including recall bias
provided to general practitioners. Journal of	Intervention/ Comparator: Radiographer-led	and NHS Trust services respectively	and 80.6 per cent for the GP survey (29/36). There was little variation between the two groups that	and observer bias. Similarly, due to the
Public Health. 27 (2) 176-	community diagnostic	1 copositively	responded to the patient surveys with regard to	retrospective design
181	ultrasound service vs local	Participants: Random	gender, age profile, or ethnicity.	of the study, the
	NHS Trust diagnostic	samples of 200 and 193 adult	Duine and Einstinger Many 2010 at 10 at 10 at 10	patients were not
	ultrasound service	patients who underwent diagnostic ultrasound in	Primary Findings: Mean waiting time for an ultrasound scan appointment was 17.44 (95% CI	randomly allocated to the two services,
	Aim: To assess the benefits	2001/2002 with the community	15.86–19.02) and 44.53 days (95% CI 38.83–50.23)	so it is possible that
	and disadvantages of a	and NHS Trust services	for the community and NHS Trust services	there were inherent
	radiographer delivered,	respectively	respectively.	differences in the
	primary care-based mobile			

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	diagnostic ultrasound	Setting: Community based,	Additional Findings:	two patient study
	service by comparing it to	mobile diagnostic ultrasound	Location of ultrasound appointment was reported as	groups.
	an NHS Trust diagnostic ultrasound service.	service, in a primary care area in the West Midlands, England,	convenient by 93 (93 per cent) of community service respondents and 78 (95.1 per cent) of hospital	
	uitiasouria service.	UK	service respondents. Time of appointment was	
	Data collection methods	OK .	reported as convenient by 95 (95 per cent) and 76	
	and dates: Data was	Staffing/facilities: The service	(92.7 per cent) of community service and hospital	
	collected on adult patients	is staffed by an independent	service patients respectively.	
	who had undergone	radiographer	·	
	diagnostic ultrasound		Patients were highly satisfied with both services. GPs	
	following referral by their GP	Services provided:	were markedly less satisfied with the NHS Trust	
	between April 2001 and	Ultrasound scans included	service compared to the community service. Quality	
	March 2002. Data on time	abdominal, pelvic,	of stored ultrasound images and reports were	
	between referral and	transvaginal, renal, and	comparable for the services. Cost per abnormality	
	appointment for the community service study	prostate	detected was higher for the community service (£107.69 compared to £77.35 for the NHS Trust	
	sample were collected from		service, not statistically significant).	
	GP referral forms, and for		Service, not statistically significantly.	
	the NHS Trust service			
	sample, data on time from			
	receipt of referral to			
	appointment were collected			
	from the computerised			
	patient management			
	system. Postal surveys were			
	designed to evaluate patient and GP access to the two			
	services, patient and GP			
	satisfaction with the			
	services, and some aspects			
	of service quality.			
	1 11 11 11			
	Outcomes reported:			
	Time to examination			
	Diagnostic investigation			
	costs			
	Average cost per			
	abnormality detected			
	Patient satisfaction			
	Patient preferences			

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Physician satisfaction			
	Service quality			
Demyelinating disease diagr	nostic clinic (DDC) at University	College London	I	L
Porter et al (2003).  Diagnosis of MS: a comparison of three different clinical settings Multiple Sclerosis Journal, 9(5), pp.431-439.	Study Design: Cross- sectional post-test only quasi-experimental  Intervention/ Comparator: DDC vs general neurology clinic (GNC) vs inpatient investigation unit (IIU)  Aim: To compare a newly established diagnostic clinic with two existing clinical settings in the management of the diagnostic phase of MS  Data collection methods and dates: An audit questionnaire was designed and used in a retrospective review of patients' case notes, identified from the DDC, GNC and the IIU over a 12-month period (April 1999 – April 2001)  Outcomes reported: Time to first visit Number of visits Time to examination Time to receiving results Length of hospital stay Mean cost per visit Mean cost per patient	Sample size: 50 patients (DDC = 20, GNC = 10, IUU = 20)  Participants: Patients with written evidence of a confirmed diagnosis of MS during the period April 1999 – April 2001  Setting: DDC at the National Hospital for Neurology and Neurosurgery, University College London Hospitals, UK  Staffing/facilities: The clinic is staffed by a consultant neurologist and a MS nurse specialist  Services provided: Evoked potential (VEP) testing, magnetic resonance imaging (MRI), and blood screening	The profile of the 50 patients in this study was representative of the general MS population; the majority of patients in each group were Caucasian, the age ranged from 21-68 years and there was a female predominance.  Primary Findings:  The time between referral and first appointment favoured the DDC with a mean time of 5.9 weeks, compared to 7.7 weeks for the GNC and 10.0 weeks for the IIU. The mean times between the first appointment and receipt of results were 4.7 weeks (DDC), 18.8 weeks (GNC) and 21.2 weeks (IIU). The price per patient ranged from £395 to £790 (DDC), £95 to £380 (GNC) and £1940 to £2700 (IIU).	The study authors highlighted the potential of bias and a retrospective methodology as limitations of this study.

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
One-stop breast lump clinic a	at The Breast Care Centre, Bris	tol		
	Intervention/ Comparator: One-stop breast lump clinic (providing same-day diagnosis) vs two-stop clinic (conventional system involving two appointments)  Aim: To compare the impact on patients of a onestop clinic with conventional clinic arrangements involving a minimum of two separate clinic appointments and a delay of several days or weeks before test results are provided.  Data collection methods and dates: Data were collected via semi-structured interviews and questionnaires. Dates data were collected is unclear.  Outcomes reported: Time to diagnosis Support offered after diagnosis Cost-effectiveness Patient satisfaction Patient anxiety and	Sample size: 791 (One-stop clinic = 416, Two-stop clinic = 375)  Participants: Women with no previous diagnosis of breast cancer, living within a reasonable travelling distance of the hospital and whose GP referral letter stated the presence of a breast lump were eligible for inclusion.  Setting: One stop clinic in a hospital (location not given but likely to be study author's centre - The Breast Care Centre, Frenchay Healthcare Trust, Bristol, UK)  Staffing/facilities: All clinics were conducted by the same two surgeons (one consultant, one staff grade)  Services provided: Triple assessment (consisting of clinical examination, ultrasound scanning and cytology). Mammography, when needed, was then carried out by radiologists in the hospital's general X-ray department.	The mean age of the 791 women consenting to join the study was 42.75 years (SD = 12.90 years; range 16-85 years). No significant differences in demographic variables or baseline HADS scores existed between the two clinic groups or between women eligible and ineligible for randomisation.  Primary Findings:  Six days after first clinic attendance the one-stop group showed significantly lower levels of anxiety (P < 0.05). However, the sub-group who had breast cancer had become more distressed in both groups, more so in the one-stop group. A benign diagnosis in the one-stop group was associated with fewer symptoms of anxiety (t = -5.47; d.f. = 489; P < 0.001), depression (t = -2.68; degrees of freedom (d.f). = 489; P < 0.01), improvements on VAS measures of worry about the breast problem (t = 6.08; d.f. = 481; P < 0.001), concern about future health (t = 3.13; d.f. = 474; P < 0.001), sleeping patterns (t = -5.47; d.f. = 481; P < 0.001), ability to carry on with normal daily activities (t = -3.62; d.f. = 479; P < 0.001) and EORTC subscales of quality of life (t = 2.39; d.f. = 471; P < 0.05), emotional (t = 4.93; d.f. = 471; P < 0.001) and cognitive functioning (t = 2.55; d.f. = 470; P < 0.005).  Eight weeks later, women receiving a speedier diagnosis of cancer reported higher levels of depression than women given this diagnosis in the two-stop system (P < 0.05).	Cancer-related study (Breast cancer)
	Patient satisfaction	radiologists in the hospital's general X-ray department. Cytology specimens were analysed in the pathology		
		department sited elsewhere in the hospital.	There was no significant difference in the consumption of resources between the two clinic groups.	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Citation	Ciday Details	- artioiparito & Cetting	Troy infamge	Observations/1votes
		Diagnostic centre vs Diag	nostic centre	
		Spain	100tio Ochia C	
ODI Lof Hospital Clínic de B	arcelona vs usual care vs the Q			
Bosch et al (2018). Time to	Study Design: Cross-	Sample size: 688 patients	Patients had a mean age of 63.4 years and 55.4%	Cancer-related study
diagnosis and associated	sectional post-test only	from QDU 1, 589 patients from	were males. Inpatients were older and more likely to	(lymphoma)
costs of an outpatient vs	quasi-experimental	QDU 2, 535 inpatients	be males than outpatients. Nearly 65% of patients	(1)
inpatient setting in the		, , , , , , , , , , , , , , , , , , , ,	presented with lymphadenopathy, which was more	The Author's
diagnosis of lymphoma: a	Intervention/comparator:	Participants: Patients aged ≥	frequent in outpatients than in inpatients. The main	acknowledge there
retrospective study of a	QDU1 (Hospital Clínic)	18 years with classical Hodgkin	referral source of inpatients was ED (i.e. emergency	were some missing
large cohort of major	patients vs inpatients at	lymphoma, large B-cell	admissions) (68.4%) and it was PCs in outpatients	data in the cost
lymphoma subtypes in	Hospital Clínic vs QDU2	lymphoma, follicular	(75.5%).	analysis, such as
Spain BMC cancer, 18(1),	(Bellvitge Hospital) patients	lymphoma, and		diagnostic tests,
pp.1-15.		mature nodal peripheral T-cell	Primary Findings:	therapeutic
	Aim: To investigate the time	lymphoma (comprising	Inpatients waited less than 24 h to be admitted,	procedures,
	to diagnosis of a hospital-	peripheral T-cell lymphoma,	whereas time to first visit in outpatients was	pharmaceuticals and
	based outpatient or inpatient	not otherwise specified [NOS],	significantly longer (0.6 [0.3] vs 1.7 [1.1) days; P <	consumables, and
	setting in four major	angioimmunoblastic T-cell	.001). The admission time for diagnosis of inpatients	consultations.
	subtypes of lymphomas and	lymphoma, and anaplastic	was significantly shorter than the QDU time for	
	the costs incurred by both	large cell lymphoma, anaplastic	diagnosis of outpatients (12.3 [3.3] vs 16.2 [2.7] days;	QDU time to
	clinical settings in the	lymphoma kinase [ALK]	P < .001).	diagnosis was
	diagnostic process. A further	negative).		compared to
	goal was to investigate the	Ontine The ODI of the	The mean time to biopsy was substantially longer in	admission time for
	frequency, clinical, and	Setting: The QDU of the	outpatients (7.4 [1.8] days) than in inpatients (3.5	diagnosis (instead of
	prognostic features of each	Hospital Clínic (QDU 1), an	[1.1] days) (P < 0.001).	length of hospital
	lymphoma subtype	adult day-care centre in a public 855-bed tertiary	After diagnosis, most patients were referred to	stay) because length of stay may not be a
	according to an outpatient or inpatient diagnosis	university hospital in Barcelona	outpatient specialist clinics and inpatients more often	precise reflection of
	inpatient diagnosis	(Spain), the in-patient wards of	received direct palliative care after discharge than	the time needed to
	Data collection methods	the internal medicine	outpatients.	evaluate and
	and dates: Data were	department of this hospital, and	outpationio.	diagnose a patient
	collected between January	the QDU of the Hospital of	Considering that the mean admission time for	with lymphoma
	2006 and September 2016	Bellvitge (QDU 2), a public	diagnosis of inpatients was 12.3 (3.3) days and that	
	for all groups.	750-bed tertiary university	the mean number of visits of outpatients	
	3 - 1 -	hospital near Barcelona, Spain	(corresponding to the mean QDU time for diagnosis)	
	Outcomes reported:	, , , , , ,	was 3.26 (1.2). The total cost per hospitalised patient	
	Time to first visit, number of	Staffing/facilities:	was €4039.56 (513.02), with 69.5% being attributable	
	visits, Time to examination,	QDU 1 staff included a full-time	to personnel salaries and 25.4% to diagnostic tests,	
	Time to diagnosis, Mean	consultant internist, a senior	and the total cost per outpatient was €1408.48	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	cost per hospital stay, Mean	internal medicine resident, a	(197.32), with 50.6% being attributable to diagnostic	
	cost per visit, Mean cost per	full-time nurse, a part-time	tests, 29.5% to outpatient visits, and 18.6% to	
	patient, Cost of diagnostic	nurse coordinator, and two	personnel salaries. According to the analysis, the	
	tests per patient, Cost	part-time secretaries. The unit	total saving from hospitalisation was €2631.08 per	
	saving from hospitalisation,	is open 5 h a day, 4 days a	patient.	
	personnel costs.	week.	Additional Findings:	
		QDU 2 staff included a part-	An FNAC was performed in 935 (54.4%) patients	
		time consultant internist and a	(766 [64.7%] outpatients and 169 [31.6%] inpatients)	
		part-time nurse. This unit is	yielding an overall suspicious/compatible lymphoma	
		open 7 h a day, 2 days a week.	diagnosis in 65.3% with no false positive result in any	
			patient after considering the biopsy findings	
		In the inpatient setting (three		
		wards) staff included two full-		
		time consultant internists, three		
		residents, a full-time nurse		
		coordinator, three tams of three nurses and three teams of two		
		full-time nursing assistants and		
		a full-time secretary.		
		a rain time dedictary.		
		Services provided:		
		The full range of services		
		provided may not be fully		
		reported in the text but		
		included laboratory tests, Fine		
		needle aspiration cytology		
		(FNAC), excisional biopsies, Positron emission		
		tomography–computed		
		tomography (PET-CT)		
	arcelona vs QDU of Hospital Pl			
Bosch et al (2021). <u>A</u>	Study Design: Economic	Sample size: 407 consecutive	More patients from the Secondary Unit were women	Overlap with
comparative cost analysis	evaluation (micro-costing	patients evaluated at the	and no significant differences were observed in mean	Montori-Palacín
between two quick	analysis)	Secondary Unit and a random	age between the two units.	2017 comparing the
diagnosis units of different	Intervention/servents	sample of 407 from 6960	Drimon, Findings	same centres and
levels of complexity.	Intervention/comparator:	consecutive patients evaluated	Primary Findings:	the data collection
Journal of Comparative Effectiveness	QDU of tertiary unit (Hospital Clínic) vs QDU of	at the Tertiary Unit	Patients from the Tertiary Unit were significantly more likely to be referred from the ED (61.2 vs 17.0%,	period is completely covered by Bosch
LIIECUVEHESS	T (Flospital Cillic) vs QDU 01		I likely to be reletted from the ED (01.2 vs 17.0%,	COVERED BY BUSCII

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Research, 10(5), pp.381-	secondary unit (Hospital	Participants: All patients aged	respectively; p < 0.0001), whereas patients from the	2021 data collection
392.	Plató)	≥18 years who attended the	Secondary Unit were mostly referred from primary	period. This study
		two QDUs at least once	care centres (69.0%). The rate of referrals for	also has economic
	Aim: To compare by micro-	between 1 January 2009 and	symptoms suggestive of cancer was 33.2% in the	outcomes and so
	costing the costs incurred by	1 January 2017 were	Tertiary and 26.0% in the Secondary Unit (p =	offers more
	quick diagnosis units of	potentially eligible to be	0.0012) and patients from the former unit were more	information.
	tertiary and second-level	included in the study.	likely to have a final diagnosis of malignancy (19.7 vs	
	hospitals.		14.3%, respectively; p = 0.0020).	The authors
		Setting: The Tertiary Unit is	Although the total number of visits in the Tertiary	acknowledged some
	Data collection methods	located in an adult daycare	Unit was significantly higher than that in the	limitations of the
	and dates: Data were	centre of the hospital (hospital	secondary centre unit (3.098 ± 0.6584 vs 2.123 ±	study, In addition to
	collected on patients that	Clínic).	0.2171, respectively; $p = 0.0064$ ) (ratio of	its retrospective
	attended both QDUs at least		successive/first visits [2.07 ± 0.2241 vs 1.12 ±	nature, costs related
	once between 1st January	The secondary unit is located	0.1034; p = $0.0070$ , respectively]), the mean time to	to the miles driven
	2009 and 1st January	in a second-level district	diagnosis was significantly shorter in the former (8	by the patient or
	2017.Data were retrieved	hospital (hospital Plató).	[IQR 4–13] vs 12 [IQR 1–28], respectively; p <	anyone
	from computerised medical	D 41 OD11	0.0001).	accompanying them
	records stored in the	Both QDUs were located in	Out a transa	or the contribution of
	information systems of both	Barcelona, Spain.	Cost outcomes	patients' and
	hospitals.	Ctaffing/facilities, Ctaff at the	The mean total cost per patient of the Tertiary Unit	caregivers' time (i.e.,
	Outcomes reported.	Staffing/facilities: Staff at the	was €577.50 ± 219.60, varying from a minimum of	a societal
	Outcomes reported: Number of visits, Time to	unit of the tertiary hospital	€353.2 to a maximum of €975.8 per patient and year,	perspective) were not included in the
	· ·	included a consultant general	while the mean cost of the Secondary Unit was	
	diagnosis, Diagnosis, Mean cost per visit, Mean cost per	internist, a senior internal medicine resident, nursing, and	€394.70 ± 92.58 per patient, ranging from a minimum of €289.6 to a maximum of €539.1 per patient and	cost estimates. An additional limitation
	patient, Direct and structural	administrative staff. The unit is	year. The mean cost per visit of both units was	of the study is the
	costs, Indirect costs,	open 5 days a week and is	similar (€182.8 ± 41.47 in the Tertiary vs €184.6 ±	fact that study data
	Personnel costs, Diagnostic	equipped with armchairs and	29.41 in the Secondary Unit; p = 0. 0.9056). An	were obtained from
	investigation costs.	recovery rooms for procedures	analysis of general costs revealed that direct and	two urban medical
	investigation costs.	requiring sedation.	structural costs per patient of the two units were not	centres in a single
		requiring sectation.	significantly different. Conversely, indirect costs of	geographic region
		Staff at the unit of the	the Tertiary Unit were significantly higher than those	therefore limiting the
		secondary hospital included	of the secondary centre unit (€49.93 ± 19.90 vs	generalisability of
		two part-time general internists	€12.42 ± 2.344, respectively; p = 0.0018).	the findings
		as well as administrative		
		personnel.	In both units, Direct costs accounted for the largest	
			proportion of cost per patient without significant	
		Services provided:	differences (79.13 percent [95% CI, 77.12–81.14] in	
		The full range of services	the Tertiary vs 81.15 percent [77.53–84.76] in the	
		provided may not be fully	Secondary Unit; p = 0.3327). In addition, no	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Citation	Study Details	Participants & Setting reported in the text but included endoscopies, ultra- sonographies, cytology/biopsy, CT scans, and MRI	significant differences were found in the average contribution of structural costs to the cost per patient of both units. However, the contribution of indirect costs was significantly greater for the unit of the tertiary centre (8.595 [8.377–8.813] vs 3.284 percent [2.618–3.950], respectively; p < 0.0001)  When looking at the mean share of each direct cost component relative to the mean total cost per patient, laboratory and pathology costs along with imaging and endoscopy costs accounted for the largest share, with a significantly greater contribution of imaging and endoscopy costs of the secondary versus tertiary centre unit. Whereas costs of biopsy and cytology techniques and specialist consultation and referral accounted for a tiny fraction of the cost per patient of both units without relevant differences, personnel or staff costs of the Tertiary Unit accounted, on average, for a significantly greater amount (12.58 percent [10.64–14.51] vs 9.746 percent [8.029–11.46], respectively; p = 0.0373)  The overall average costs of the two units in both groups of patients were higher than those in the baseline population. Specifically, for referrals for symptoms suggestive of cancer, mean cost per patient of the Tertiary Unit was €782.52 ± 191.56 and it was €562.21 ± 94.55 in the Secondary Unit (p = 0.0537). For patients with a final diagnosis of malignancy, mean cost per patient of the Tertiary Unit was €1069.17 ± 218.64 while it was €827.65 ± 151.83 in the other unit (p = 0.0871). Consistent with the results of the principal analysis, both for patients referred for suspected cancer and those with an eventual cancer diagnosis, cost differences continued to lie in personnel and indirect costs with significant	Observations/Notes
			differences between the two units Personnel costs per patient of the tertiary hospital	
			unit were found to be significantly higher than those	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
			of the other unit (€68.75 ± 14.90 vs €36.90 ± 3.28 p = 0.0011). Laboratory and pathology costs were higher in the tertiary unit however this was not significant, and no significant differences were reported for other costs such as, imaging and endoscopy, biopsy and cytology techniques and specialist consultation and referral.	
Montori-Palacín et al (2017). Quick outpatient diagnosis in small district or general tertiary hospitals: A comparative observational study. Medicine 96 (22).	Study Design: Cross- sectional post-test only quasi-experimental  Intervention/comparator: QDU1(Hospital Plató) vs QDU2 (Hospital clínic)  Aim: To comparatively describe the diagnostic performance of the QDU of an urban district hospital (QDU1) and the QDU of its reference general hospital (QDU2).  Data collection methods and dates: Data from all the patients evaluated were recorded onto case report forms and codified in a database. Data were collected for patients referred to both QDUs between November 2009 and February 2016  Outcomes reported: Time to first visit, Number of visits, Time to examination, Time to diagnosis,	Sample size: 336 consecutive patients referred to QDU1, 530 patients who were referred to QDU2 randomly chosen retrospectively.  Participants: Patients aged ≥18 years with potentially serious diseases referred to both QDUs between November 2009 and February 2016  Setting: The QDU of Hospital Plató (QDU1) integrated in the internal medicine department of this hospital. It is an urban district hospital in Barcelona providing care to a reference population of 140,000 and QDU2 is its reference centre. The QDU of Hospital Clínic (QDU2) integrated in the internal medicine department of this hospital and, in particular, in an adult day-care centre.  Staffing/facilities: QDU1 has 120 beds for acute patients. The attending physician in charge of the unit is a general internist who dedicates 4 hours	QDU1 patients were predominantly referred from PCCs (69%), and EDs were the main referral source of QDU2 patients (59%). The most frequent reasons for referral to QDU1 were unintentional weight loss (UWL) (21%), tests detected at referral sites (14%), anaemia (14%), abnormal peripheral lymphadenopathy and/or palpable masses (10%), and gastrointestinal symptoms (10%). In QDU2, the most common referral reasons were anaemia (21%), gastrointestinal symptoms (19%), UWL (16%), fever (12%), and adenopathies and/or palpable masses (11%).  Primary Findings:  The median time to first visit was longer in QDU1 than in QDU2 patients (5 [2–8] vs 3 [1–5] days; P=0.008) and the median number of visits was lower in QDU1 patients (2 [1–3] vs 2.5 [1.5–4], respectively; P=0.003). The 336 first visits in QDU1 generated 375 successive visits with a successive-to-first visit ratio of 1.12, which was lower than the QDU2 ratio 2.13 (P<0.001).  At first visit, nearly all the patients underwent laboratory tests and plain X-rays (98 and 87%, respectively, in QDU1 and 97 and 90%, respectively, in QDU2). The QDU2 patients underwent significantly more ultrasonographies, endoscopies, and cytology/biopsy studies than the QDU1 patients. Furthermore, significant differences were observed in the waiting times to CT scan and cytology/biopsy studies, which were longer in QDU2 patients, and in	Overlap with Bosch 2021 comparing the same centres and the data collection period is completely covered by Bosch 2021 data collection period.  The authors' acknowledged several limitations including the relatively small sample size, some relevant data from the QDU2 group might not have been fully captured, and the handling of patients referred to hospital-based outpatient clinics such as those reported here or hospitalised for evaluating similar conditions can be different in other clinical settings, a situation relying on factors such as the

Citation Study Details	Participants & Setting	Key findings	Observations/Notes
Diagnosis, Diagnostic tests, Onward referral.	per week to this clinical duty. QDU2 staff includes a consultant general internist full- time, a senior internal medicine resident, a nurse part-time, a nurse coordinator part-time, and 2 secretaries part-time. The unit is open 5 hours a day, 4 days a week.  Services provided: CT scan, MRI, Ultrasonography, Endoscopy, Scintigraphy, Body FDG-PET, Cytology/biopsy, and Bone marrow aspiration	the waiting times to ultrasonography, endoscopy, scintigraphy, and body FDG-PET, which were longer in QDU1 patients.  While QDU1 patients were more likely than QDU2 to require ≤2 visits to achieve a diagnosis (73 vs 57%; P<0.001). the median time-to-diagnosis was longer in the former (12 [1–28] vs 8 [4–14] days, respectively; P<0.001).  Although a final diagnosis of no malignancy prevailed over malignancy in both QDU1 and 2 patients (83 and 79%) malignancy was more common among the latter (19 vs 13%, respectively; P=0.001)  After diagnosis, most QDU1 patients were referred to outpatient clinics of Hospital Plató and PCCs (42% each), with 8% being referred to specialist outpatient clinics of the reference Hospital Clínic. In addition, 60% of QDU2 patients were referred onward to PCCs and 35% to the hospital outpatient clinics.	institution traditions, the available resources, or the type of centre. Consequently, the findings and potential implications of this study cannot be generalised. Lastly, although matching was indeed done, the resulting sample was too small to perform a logistic analysis.

## 3. DISCUSSION

## 3.1 Summary of the findings

Our rapid review sought to identify community diagnostic centres, however our search only identified one diagnostic service located within the community, while the remaining studies covered diagnostic centres located in hospitals with direct access from primary care. There is evidence to suggest that diagnostic centres can be an effective alternative model of care, capable of reducing waiting times, and reducing pressure on hospitals by avoiding hospitalisations, reducing the number of visits required to receive a definite diagnosis, and increasing the number of patients in whom a definite outcome is reached. However, the costs incurred by a diagnostic centre can be impacted by the diagnostic and clinical complexity of the patients managed at the unit, as well as the characteristics of the unit including the number of staff and contribution of staff time. Overall cost-effectiveness of diagnostic centres may be dependent on whether or not the centre is running at full capacity.

However, much of the evidence was derived from quasi-experimental studies, with only three economic evaluations. We identified one RCT, however this study did not contribute to the evidence base used in this review because it was old and primarily focussed on patient anxiety. While it did report some economic outcomes these were superseded by more recent studies. Considerable methodological limitations across included studies, as well as structural differences in healthcare systems across international studies, could limit the applicability of these findings. However, we did identify five studies that were conducted in the UK, three of which were specific to cancer diagnosis, one specific to the diagnosis of MS, and one assessed the effectiveness of a mobile diagnostic ultrasound service.

### 3.2 Limitations of the available evidence

This RR has highlighted several evidence gaps including the paucity of robust study designs in this area of research. The majority of study designs included in this review utilised weak methodologies that may not be appropriate for inferring effectiveness. This RR did not identify any studies exploring equity of access to diagnostic centres and only three economic evaluations were identified, one of which was conducted in the UK.

The quality of reporting in the included studies was oftentimes poor. Key details pertaining to outcome measures or information about diagnostic centres, were often lacking or poorly described. In addition, key statistical parameters, such as confidence intervals, were not reported in some study results, making it difficult to determine the magnitude of effect of some diagnostic centres.

Most of the evidence identified in this review were derived from diagnostic centres located within hospital sites. Only one study included in this review examined a diagnostic service located within the community (a mobile ultrasound service). Whilst siting a diagnostic centre within the hospital setting is likely to provide greater availability to already established and functioning diagnostic equipment and services, it may not be accessible to certain groups of patients, and further worsen health inequalities.

Only five UK studies were identified, with the remaining studies conducted in a variety of other countries. A large number of these studies were conducted in Spain, and these measured many of the relevant outcomes included in this RR. As a result, the generalisability of our findings to Wales could be limited due to differences in healthcare systems and healthcare provision between both countries.

Furthermore, many of the studies conducted in Spain reported data from the same set of diagnostic centres - some with similar data collection periods, thereby creating the potential for double counting (see Appendix 2 for details about the potential for data overlap). To reduce the likelihood of double counting, where multiple studies reported on the same diagnostic centre, we only reported findings from the most recent study in the narrative synthesis (if a comparison to usual care was provided) and highlighted whether any of the other studies identified any other relevant outcomes not reported in the more recent publication. Although this is not a usual approach to take, we believe this was a pragmatic approach, given the timescale.

The majority of included studies compared patients attending diagnostic centres with a range of comparators including hospitalised patients and historical controls. These comparisons may not be appropriate considering the fact that hospitalised patients are generally more acutely unwell and require more clinical input and longer care than those eligible to attend a diagnostic centre. In addition, unlike hospital wards, diagnostic centres are generally not open 24 hours a day, and the infrastructure and operational functioning of these centres were inconsistently reported.

## 3.3 Implications for policy and practice

This RR has highlighted possible benefits of diagnostic centres, particularly with regards to their impact on waiting times and pressure on secondary care. Although inferences around the effectiveness of community diagnostic centres cannot be made due to the paucity of evidence from diagnostic centres located outside of hospital settings, the information extracted from these studies provide valuable information into the potential benefits of establishing these centres within Wales.

In light of the paucity of robust evidence, further well-designed, higher quality research from the UK and similar countries is needed to better understand the effectiveness of community diagnostic centres within Wales. Research around diagnostic centres sited outside of hospital locations is particularly needed to investigate the impact on equity of access. In addition, further research is required to evaluate the effectiveness of diagnostic centres for conditions other than cancer, and full economic evaluations of these centres are also needed to better understand how diagnostic centres can be efficiently utilised.

Comparative impact evaluations should be incorporated into service development plans from the onset, to assess the effectiveness of newly opened diagnostic centres in the UK over time.

## 3.4 Strengths and limitations of this rapid review

The studies included in this RR were identified through an extensive search of electronic databases, trial registries, grey literature, as well as consultation of content experts in the field. Despite making every effort to capture all relevant publications and reduce the risk of bias, it is possible that additional eligible publications may have been missed or we may have introduced some biases to this RR through our inclusion criteria. Efforts were made to reduce this risk of introducing bias and have highlighted this where possible, for example in the investigation into the potential risk of multiple studies reporting the same data.

We identified a large number of studies during the initial stages of this review (prior Rapid Evidence Map), many of which were descriptive in nature. To overcome this potential limitation, we made the decision to include only studies that had some sort of comparator and utilised a study design algorithm developed by Leatherdale (2019), to assign an accurate description of the methods employed.

We made the pragmatic decision to report the findings from the most recent studies when multiple studies were reporting on the same diagnostic centre and outcome. However, this may have introduced some bias in the reporting as there is a potential that the studies could have had different aims and objectives and may also have been focussed on different health conditions. Therefore, the findings may have differed between studies, specifically for the economic evaluations.

As no date or country of study limits were set, and the data collection dates of included studies are wide ranging, it is possible that the diagnostic centres we have included here may not be the same as the proposed diagnostic centres within Wales. It is also possible that as many of the diagnostic centres included were from other countries where the healthcare system is different to that of the UK, the results may not be generalisable to the UK.

## 4. REFERENCES

BBC News (2022) Rapid cancer diagnosis centre rollout in Wales a UK first. Available at: Rapid cancer diagnosis centre rollout in Wales a UK first - BBC News [Accessed 06 October 2022].

Department of Health and Social Care (2021) Available at: 40 community diagnostic centres launching across England - GOV.UK (www.gov.uk). [Accessed 13 July 2022].

Health Education England (2022). 'Community Diagnostic Centres (CDC)'. Available at: https://www.hee.nhs.uk/our-work/cancer-diagnostics/community-diagnostic-centres-cdc. [Accessed 31 October 2022].

Jensen H, Tørring M.L, Olesen F, et al. (2015). Diagnostic intervals before and after implementation of cancer patient pathways-a GP survey and registry based comparison of three cohorts of cancer patients. *BMC cancer*, 15(1), pp.1-10.

Leatherdale S.T. (2019) Natural experiment methodology for research: a review of how different methods can support real-world research, International Journal of Social Research Methodology, 22:1, 19-35, DOI: 10.1080/13645579.2018.1488449.

NHS England (2020) Diagnostic: Recovery and Renewal. Report of the Independent Review of Diagnostic Services for NHS England. Available at: https://www.england.nhs.uk/wpcontent/uploads/2020/11/diagnostics-recovery-and-renewal-independent-review-of-diagnosticservices-for-nhs-england-2.pdf [Accessed 12 July 2022].

NHS England (2022) One million checks delivered by NHS 'one stop shops'. News. Available at: NHS England » One million checks delivered by NHS 'one stop shops' [Accessed 12 July 2022].

NHS (2022) Document 3 - Community Diagnostic Hub (CDH) Draft Qualification Specification. Available at: https://www.ardengemcsu.nhs.uk/media/2585/document-3-cdh-framework-specificationv111.pdf [Accessed 12 July 2022].

The King's Fund (2022). 'Are community diagnostic centres really moving care closer to home?' Available at: https://www.kingsfund.org.uk/blog/2022/10/are-community-diagnostic-centres-reallymoving-care-closer-home. [Accessed 03 November 2022].

Welsh Government (2021) NHS activity and performance summary: July and August 2021. Statistics. Available at: https://gov.wales/nhs-activity-and-performance-summary-july-and-august-2021-html [Accessed 12 July 2022].

Welsh Government (2022) Our programme for transforming and modernising planned care and reducing waiting lists in Wales. Available at: https://gov.wales/sites/default/files/publications/2022-04/our-programme-for-transforming--and-modernising-planned-care-and-reducing-waiting-lists-inwales.pdf [Accessed 13 July 2022].

StatsWales (2022) Waiting times by month. Available at: https://statswales.gov.wales/Catalogue/Health-and-Social-Care/NHS-Hospital-Waiting-Times/Diagnostic-and-Therapy-Services/waitingtimes-by-month [Accessed 24 October 2022].

## 5. RAPID REVIEW METHODS

## 5.1 Eligibility criteria

We searched for primary sources to answer the review question "What is the effectiveness of community diagnostic centres?"

The following eligibility criteria were used to identify studies for inclusion in the RR:

Table 2. Fligibility criteria

	Inclusion criteria	Exclusion criteria
Participants	Symptomatic patients, all conditions being referred to diagnostic centres via primary care settings	
Settings	Diagnostic centres in any setting	Exclude screening programmes, or where there is treatment undertaken but no diagnostics.
Intervention / exposure	Diagnostic centres/units/hubs and clinics accepting referrals from primary care (as a minimum)	Community diagnostic centres accepting referrals exclusively from other routes
Comparison (if applicable)	Usual care/other diagnostic centres	
Outcomes	All outcomes, with a focus on:  - capacity - pressure on secondary care - waiting times - equity of access - and all economic outcomes	
Study design	Any design that contains a comparison that can infer effectiveness	
Countries	All countries	
Language of publication	Studies published in English	Any study not published in English
Publication date	No date limits set	
Publication type	Published and preprint primary literature	All publication types other than primary literature

## 5.2 Literature search

The studies included in this RR were identified through the literature search conducted in our preliminary work. COVID-19 specific and general repositories of evidence reviews noted in our resource list were searched on 6th July 2022 by three reviewers and an updated search was conducted on the 3<sup>rd</sup> of August 2022 for the REM. An audit trail of the search process is provided within the resource list (Appendix 3). Searches were limited to English-language publications and included searches for primary studies. References of secondary sources

identified during preliminary work were scanned for relevant primary studies and forward and backward citation tracking was also conducted on the secondary sources.

Search concepts and keywords around diagnostic units, centres, hubs, and clinics were utilised. The searches combined free text words and descriptors when available. We deliberately kept our search strategy broad to capture as much evidence on diagnostic centres as possible. Resources searched are outlined in Appendix 3 and the search strategy used to search Medline is available in Appendix 4.

## 5.3 Study selection process

Our prior Rapid Evidence Map included 50 primary studies, all of which were screened for inclusion in the Rapid Review using the updated eligibility criteria in 5.1 by two independent reviewers.

#### 5.4 Data extraction

One researcher performed the data extraction and a second researcher carried out consistency checks. Information extracted includes:

- Reference (author, year, country)
- Study design
- Intervention / comparator
- Δim
- Data collection methods (and dates)
- Outcome(s) measured
- Study participants (e.g., sample size, age range, sex, any other specifics)
- Setting
- Staffing/facilities
- Services provided (e.g. MRI, ultrasound, etc.)
- Key findings
- Additional notes/comments

An observations/notes column was added to report key information that was not captured above and to record any limitations of the included sources (see Table 1).

### 5.5 Study design categorisation

Studies were categorised by research design and additional analytic techniques if applicable, using the study design classification system developed by Leatherdale (2019) by a single reviewer, with verification of all judgements by a second reviewer (see Tables 3, 4 and 5). The Leatherdale tool includes a series of questions on the methodological characteristics of a natural experimental study to identify an accurate description of the research design, in particular the characterisation of designs by the frequency and points at which data is collected.

### 5.6 Quality appraisal

A range of JBI quality appraisal checklists (which were selected based on the study design used) were used to assess the methodological quality of each included study. Quality assessment was undertaken by a single reviewer, with verification of all judgements by a second reviewer. Any discrepancies were discussed and resolved amongst the review team. The results of the quality appraisals can be seen in Tables 3, 4, and 5.

## 5.7 Synthesis


The effectiveness of diagnostic centres was compared to a comparator (most often usual care) on a range of outcomes including, pressure on secondary care, capacity, wait times and cost-effectiveness. Following on from the REM, a narrative synthesis was conducted reporting the results of selected studies that included diagnostic centres accepting referrals from primary care and that had a comparative element. Stakeholders highlighted the importance of finding out if diagnostic centres can impact waiting times and current pressures on secondary care, as well as the economic impact. With this in mind, we categorised the outcomes identified into 'impact on waiting times', 'impact on pressure' and 'economic outcomes' and reported findings using these categories. In an attempt to highlight the more robust methodological studies (economic evaluations), we reported these findings first. Where multiple studies reported outcomes on the same diagnostic centre, we chose to report only the findings form the most recent study to avoid the risk of double counting.

### 6. EVIDENCE

## 6.1 Study selection

Due to the large number of studies identified it was decided, in conjunction with stakeholders, to include only studies that included a diagnostic centre accepting referrals from primary care as a minimum and included a comparator group. Of the initial 50 studies screened 42 included diagnostic centres that accepted referrals from primary care and of these, 21 were comparative and 20 reported on our outcomes of interest. The study selection process is outlined below.

# 6.2 Study selection flow chart



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

## 6.3 Quality appraisal tables

Table 3 Quality appraisal results for economic evaluations

Study		JBI Appraisal Items – Economic evaluations									
	Q1   Q2   Q3   Q4   Q5   Q6   Q7   Q8   Q9   Q10   Q11										
Bosch et al 2021	Υ	Υ	Υ	U	Υ	Υ	Υ	U	N	Υ	N
Sanclemente-Ansó et al 2016	Υ	Υ	Υ	Υ	Υ	Υ	Υ	U	N	Υ	N
Sewell et al 2020	Υ	Υ	Υ	Υ	Υ	Υ	N	N	Υ	Υ	N
Key: Y=Yes, N=No, U=Unclear,	N/A=r	not app	olicable	e							·

- Q1. Is there a well-defined question?
- Q2. Is there comprehensive description of alternatives?
- Q3. Are all important and relevant costs and outcomes for each alternative identified?
- Q4. Has clinical effectiveness been established?
- Q5. Are costs and outcomes measured accurately?
- Q6. Are costs and outcome valued credibly
- Q7. Are costs and outcomes adjusted for differential timing?
- Q8. Is there an incremental analysis of costs and consequences?
- Q9. Was sensitivity analysis conducted to investigate uncertainty in estimates of cost or consequences?
- Q10. Do study results include all issues of concern to users?
- Q11. Are the results generalizable to the setting of interest in the review?

Table 4. Quality appraisal results for randomised controlled trials

Study	JBI A	JBI Appraisal Items – Randomised Controlled Trial											
	Q1	21 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13											
Harcourt et al 1998	Υ	Y Y N N N Y Y Y Y Y											
Key: Y=Yes,	N=No,	U=Und	clear, N	/A=not	applica	ble							

- Q1. Was true randomization used for assignment of participants to treatment groups?
- Q2. Was allocation to treatment groups concealed?
- Q3. Were treatment groups similar at the baseline?
- Q4. Were participants blind to treatment assignment?
- Q5. Were those delivering treatment blind to treatment assignment?
- Q6. Were outcomes assessors blind to treatment assignment?
- Q7. Were treatment groups treated identically other than the intervention of interest?
- Q8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analysed?
- Q9. Were participants analysed in the groups to which they were randomised?
- Q10. Were outcomes measured in the same way for treatment groups?
- Q11. Were outcomes measured in a reliable way?
- Q12. Was appropriate statistical analysis used?
- Q13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?

Table 5. Quality appraisal results for quasi-experimental studies

Study	JBI Appraisal Items – Quasi-experimental studies									
	Q1.	Q2.	Q3.	Q4.	Q5.	Q6.	Q7.	Q8.	Q9.	
Arnaout et al 2013	Υ	U	Υ	Y	N	N/A	Υ	Y	Y	
Bosch et al 2011	Υ	U	Υ	Υ	N	N/A	Υ	Υ	N/A	
Bosch et al 2012a	Υ	N	Υ	Υ	N	N/A	N	Υ	Υ	
Bosch et al 2012b	Υ	N	Υ	Υ	N	N/A	Υ	Υ	Υ	
Bosch et al 2012c	Υ	N	Υ	Υ	N	N/A	N	Υ	Υ	
Bosch, Jordán and López- Soto 2013	Y	N	Y	Y	N	N/A	N	Y	Υ	

Bosch et al 2018	Υ	N	Υ	Υ	N	N/A	Υ	Υ	Υ
Bosch et al 2020	Υ	N	Υ	Υ	N	N/A	Υ	Υ	Υ
Brito-Zerón et al 2014	Υ	N	Υ	Υ	N	N/A	N	Υ	Υ
Choudhury et al 2013	Υ	U	Υ	Υ	N	N/A	Υ	Υ	Υ
McKevitt et al 2017	Υ	U	Υ	Υ	N	N/A	Υ	Υ	Υ
Montori-Palacín et al 2017	Υ	N	Υ	Υ	N	N/A	Υ	Υ	Υ
Nixon et al 2019	Υ	U	Υ	Υ	N	N/A	Υ	Υ	Υ
Pallan et al 2005	Υ	U	Υ	Υ	N	N/A	Υ	U	U
Porter et al 2003	Υ	N	Υ	Υ	N	N/A	Υ	U	N/A
Sethukavalan et al 2013	Υ	Υ	Υ	Υ	N	N/A	Υ	Υ	Υ
Kev: Y=Yes N=No U=Uncle	ar N/A	\=not an	nlicable						

- Key: Y=Yes, N=No, U=Unclear, N/A=not applicable1. Is it clear what is the cause and what is the effect?
- 2. Were the participants included in any comparisons similar?
- 3. Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest?
- 4. Was there a control group?
- 5. Were there multiple measurements of the outcome both pre and post the intervention/ exposure?
- 6. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analysed?
- 7. Were the outcomes of participants included in any comparisons measured in the same way?
- 8. Were outcomes measured in a reliable way?
- 9. Was appropriate statistical analysis used?

## 7. ADDITIONAL INFORMATION

### 7.1 Conflicts of interest

The review team declares no conflicts of interest.

## 7.2 Information available on request

The protocol for this RR is available on request from Hannah Shaw, Public Health Wales, E-mail: Hannah.shaw@wales.nhs.uk.

## 7.3 Acknowledgements

The authors would like to thank Brendan Collins, Delia Ripley, Jennifer Morgan, Joanna Charles, Leon Wong, Rob Orford and Sally Anstey for their contributions during stakeholder meetings in guiding the focus of the review and interpretation of findings.

# 8. ABOUT THE WALES COVID-19 EVIDENCE CENTRE (WCEC)

The WCEC integrates with worldwide efforts to synthesise and mobilise knowledge from research.

We operate with a core team as part of Health and Care Research Wales, are hosted in the Wales Centre for Primary and Emergency Care Research (PRIME), and are led by Professor Adrian Edwards of Cardiff University.

The core team of the centre works closely with collaborating partners in <u>Health Technology</u> Wales, Wales Centre for Evidence-Based Care, Specialist Unit for Review Evidence centre, SAIL Databank, Bangor Institute for Health & Medical Research/ Health and Care Economics Cymru, and the Public Health Wales Observatory.

Together we aim to provide around 50 reviews per year, answering the priority questions for policy and practice in Wales as we meet the demands of the pandemic and its impacts.

#### **Director:**

**Professor Adrian Edwards** 

#### **Contact Email:**

WC19EC@cardiff.ac.uk

#### Website:

https://healthandcareresearchwales.org/about-research-community/wales-covid-19evidence-centre

# 9. APPENDIX

**APPENDIX 1: Characteristics of included diagnostic centres** 

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre			
	Canada										
Lymphoma I	Lymphoma Rapid Diagnosis Clinic (LRDC) at Princess Margaret Cancer Centre, Toronto, Ontario										
Nixon et al (2020).	Lymphoma Rapid diagnosis clinic (LRDC) based in a tertiary cancer centre (Princess Margaret Cancer Centre), part of University Health Network (UHN), Toronto, Ontario, Canada.	The goal of the centre was to provide specialised comprehensive assessment and timely and appropriate investigations to reduce wait times to a definitive biopsy to establish histologic diagnosis and initiation of treatment.	The clinic was led by a Nurse practitioner; however, it appears weekly dedicated operating rooms for lymphoma biopsies were used by head and neck, thoracic, and general surgeons, and biopsy material from outside facilities were reviewed by hemapathologists when available.	Laboratory tests, peripheral blood flow cytometry, tuberculosis skin testing, abdominal ultrasound, computed tomography scans, bone marrow biopsy, or FNA. Referral to surgical services for consideration of excisional lymph node biopsy or radiology for image guided core biopsy was requested based on location and size of lymphadenopathy.	Lymphadeno pathy and suspected lymphoma	Primary care or medicine, ER, or community specialists	Lymphadenopathy on the basis of clinical assessment or imaging, biopsy results suspicious for lymphoma, or peripheral blood abnormalities.  Patient symptoms included: symptoms of viral infection, "B" symptoms, new pain, pruritus, palpable lymph nodes, lymphocytosis (ALC > 4.0 X 109/L)	The clinic was Nurse practitioner-led  The optimal approach to lymphoma diagnosis is multidisciplinary, and our data suggest that even a modest additional investment in personnel and resources would be expected to significantly improve delivery of care for patients with suspected lymphoma.			
The Gale an	d Graham Wright	Prostate Centre, No	orth York General Hospi	ital Toronto, Ontario		•					
Sethukaval an et al (2013).	Rapid diagnostic unit (RDU) called The Gale and Graham Wright Prostate Centre, set up at the North	The Wright Prostate Centre is a diagnostic assessment programme and multidisciplinar y clinic where both radiation oncology and urology specialists see	Staff include radiation oncology and urology specialists	Unclear	Prostate cancer	Urologists or family physicians (primary care)	Patients with suspicion of cancer either (based on a prostate-specific antigen (PSA) test), because of symptoms, or an abnormal digital rectal exam (DRE), which warranted further testing or				

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	York General Hospital (NYGH), Branson Site, Toronto, Ontario, Canada.	every patient on the same day after obtaining their biopsy results					referral to a specialist to definitively diagnose or rule out cancer	
Rapid Acce	ss Diagnostic and	Support (RADS) at	The Women's Breast H	ealth Center, Ottawa Hospital, (	Ottawa, Ontario			
Arnaout et al (2013).	The Women's Breast Health Center of the Ottawa Hospital in Ottawa, Ontario, Canada (a university- affiliated tertiary care centre)	The Rapid Diagnosis and Support (RADS) Program initiative was a pilot programme which aimed to accommodate the increasing patient volume, reduce wait times, decrease fragmentation of care, and enhance a patient's overall experience.	A multidisciplinary team of breast cancer specialists (five radiologists, five surgeons, two pathologists, one nurse manager, two nurse navigators, and a diagnostic imaging manager)	Routine screening mammography, initial diagnostic imaging workup (mammogram and/or breast ultrasound) for a breast problem (e.g., palpable mass, breast pain, nipple discharge), or additional diagnostic imaging and biopsy workup following an abnormal mammogram performed at another institution	Breast cancer	Primary care	Patients are routinely referred to the breast centre for either:  1. Routine screening mammogram  2. Breast symptoms requiring diagnostic imaging workup  3. Abnormal outside imaging needing additional diagnostic workup/biopsy	Coordination of diagnostic imaging workup and nursing support were provided by a nurse navigator. The nurse navigator was assigned to track all patients within the programme to help expedite and inform them of additional diagnostic imaging workup appointments, provide psychosocial support to the patients during their diagnostic care, and provide a telephone hotline service for which patients can call if they had any questions or concerns.  RADS program patients were labelled as such on imaging and pathology requisitions to help avoid delays. Interventions, such as coordinating same day tests and changing biopsy schedules and calling pathologists to accommodate faster access to pathology, were implemented as much as possible.  Through this prospective pilot project, we have learned that we can efficiently triage patients at highest risk of having breast cancer and therefore initiate strategies to reduce diagnostic wait times for these patients and prevent fragmentation of care. Most of these interventions were aimed at tracking the diagnostic journey of these patients so that their workup can be appropriately expedited and unnecessary gaps in scheduling can be avoided.

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre			
Rapid Acces	Rapid Access Breast Clinic (RABC) at Mount St Joseph Hospital, Vancouver										
McKevitt et al (2017).	Rapid Access Breast Clinic (RABC) at Mt St Joseph Hospital, British Columbia, Canada	The RABC was established to offer a single site for coordinated clinical and radiological assessment of breast problems	Clerical staff, radiologists, surgeons, nurse navigator and clinic family physician (FP)	Offers on-site mammography, breast ultrasound, ultrasound-guided biopsy, and mammographic and ultrasound-guided fine wire localisation. Patients requiring stereotactic core biopsy, MRI or MRI-guided biopsy have those investigations coordinated by the RABC at regional imaging sites offering those investigations.	Breast cancer	Family physician (primary care)	Abnormal screening mammogram or presenting with a new breast problem.	The Rapid Access Breast Clinic (RABC) was established following the guidelines for breast centres outlined by the European Society of Mastology (EUSOMA).  The clinic <b>provided triple evaluation</b> of patients with close collaboration between clinicians and radiologists, facilitated by clinical pathways and nurse navigation. The development of the RABC in conjunction with the radiology department at the centre created a unique situation in which the breast surgeons saw patients managed by two separate diagnostic pathways.			
				Sp	ain	1					
		lospital Clínic, Barc									
Bosch et al (2020). Brito-Zerón et al (2014). Bosch, Jordán and López-Soto (2013). Bosch et al (2012a). Bosch et al (2012b). Bosch et al (2012c). Bosch et al (2011c).	Quick Diagnosis Unit (QDU) based in the Adult Day Care Centre which is situated within the General Internal Medicine Department of a public tertiary university hospital (Hospital Clínic), Barcelona, Spain.	The QDUs implemented in Spain are mainly led by general internists and aim to provide patients with serious disease with the prompt and effective diagnosis and treatment they deserve and require	Staff at QDU includes a full-time consultant internist, a senior internal medicine resident, a full-time nurse, a part-time nurse coordinator, and 2 part-time administrative assistants. The unit is open 5hours a day, 5 days a week. In addition, consultants from other services are provided as required.  It has a consulting room and a waiting room for patients	Upper gastrointestinal endoscopic ultrasound (EUS), US/CT-guided biopsy, contrast-enhanced thin-slice CT scan of the chest, abdomen, and pelvis  Laboratory tests included, among others, acute phase reactants (C-reactive protein, erythrosedimentation rate), hemogram (total leucocytes, manual white blood cell count, haemoglobin, haematocrit, platelets), liver function tests, serum lactate dehydrogenase, serum total proteins and protein electrophoresis, microbiological serologies [e.g. IgM and IgG for cytomegalovirus (CMV),	Most studies were non- specific but including potentially severe diseases such as cancer and severe anaemia (some studies had a specific focus including severe anaemia, pancreatic cancer, unexplained fever).	Primary care and emergency department	The QDU evaluates stable patients with suspected serious disease who require expeditious workup and who, in many instances, would be admitted to hospital for diagnostic testing. Thus, patients must be physically and mentally capable of attending several outpatient appointments.  Symptoms may include: Anaemia, cachexia-anorexia syndrome, febrile syndrome, adenopathies and/or	The operation of the QDU is based on an urgent first visit, followed by the preferential scheduling and coordination of complementary tests and subsequent visits until a diagnosis is made.			

Deference	Lagation 0	Aim of the	Staff & facilities	Investigative	Diagnosis of	Deferrel	Deferral exiteria	Voy underning elements of discressis
Reference	Location & setting	centre	Staff & facilities	Investigative procedures/services	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	Setting	Centre		conducted	interest			Centre
			and families, and	Epstein–Barr virus (EBV),			palpable masses,	
			functions daily.	Toxoplasma gondii, human			unexplained severe	
				parvovirus B19], HIV testing,			abdominal pain,	
				b2 microglobulin, specific			chronic diarrhoea,	
				serum tumour markers,			recent severe	
				specific serum			constipation,	
				autoantibodies, specific			rectorrhagia,	
				genetic studies			jaundice, lung and/or	
				(autoinflammatory diseases),			pleural abnormalities,	
				including cultures, imaging			unexplained dyspnea,	
				studies, endoscopies and			dysphagia, ascites,	
				cytology/biopsy studies			anasarca, bone pain with suspicion of	
				The main diagnostic tests			malignancy, arthritis,	
				(analytical and			hemogram	
				microbiological tests, simple			abnormalities	
				radiology [X-ray], computed			suggestive of primary	
				tomography [CT],			hematologic disorder,	
				echography, nuclear			splenomegaly and/or	
				scintigraphy, digestive			hepatomegaly,	
				endoscopy, biopsies and			monoclonal	
				lymph node fine-needle			paraprotein band with	
				puncture aspiration [FNPA])			or without suspicion	
				are normally performed			of multiple myeloma,	
				within 7 days after the first			neurologic disorders	
				visit.			(central, spinal, and	
							peripheral nervous	
							system)	
Quick Diagn	ı ostic Unit (QDU) a	ı at Bellvitge Hospital,	Barcelona	<u> </u>				<u> </u>
Sanclemen	QDU at	Not stated	The QDU is	Not explicitly stated, but to	Non-specific	Primary	Anaemia, cachexia-	Hospital-based QDUs are normally led by
te-Ansó et	Bellvitge		internist led and	include blood and urine	but including	care and	anorexia syndrome,	internists and are a distinct model of
al (2016).	University		open 7 hours a day,	analysis, X-ray CT, simple X-	potentially	the	febrile syndrome,	outpatient care delivery almost exclusively
` ′	Hospital in		2 days a week	ray, PET-CT, biopsy,	serious	emergency	adenopathies and/or	reported in Spain, most notably in Catalonia.
	Barcelona,		(Tuesdays and	bronchoscopy, cytology,	diseases	department	palpable masses,	The driving reason explaining the important
	which is		Fridays). Analysis	microbial culture,			unexplained severe	role of internists leading QDUs is the common
	affiliated to the		implies staff also	scintigraphy, mammography,			abdominal pain,	presence of nonspecific symptoms such as
	University of		included attending	specialist consultation,			chronic diarrhoea,	weight loss, fatigue, malaise or fever of
	Barcelona,		physician,	ultrasonography,			recent severe	unknown origin in patients referred to
	Catalonia,			colonoscopy,			constipation,	

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	Spain. The QDU is integrated to the Internal Medicine Department of the hospital.		registered nurse, caretaker.	electrocardiography, lower and upper gastrointestinal series, esophagogastroduodenosco py, blood marrow aspiration, flow cytometry			rectorrhagia, jaundice, lung and/or pleural abnormalities, unexplained dyspnea, dysphagia, ascites, anasarca, bone pain with suspicion of malignancy, arthritis, hemogram abnormalities suggestive of primary hematologic disorder, splenomegaly and/or hepatomegaly, monoclonal paraprotein band with or without suspicion of multiple myeloma, neurologic disorders (central, spinal, and peripheral nervous system)	these units. The versatility of these physicians for the diagnosis of a wide range of serious disorders together with their integral, global view of the patient contrast with the more specialized approach of physicians at other units such as the UK onestop diagnostic clinics.  The requirements for evaluation by the QDU at Bellvitge Hospital are: 1) clear referral criteria based on a pre-established list of suspected serious disorders; 2) the first visit has to occur as soon as possible after referral (≤15 days); 3) patients must have preferential access to a wide range of diagnostic tests; and 4) patients should be able to attend several appointments for outpatient visits and diagnostic tests.
Quick Diagn	ı nosis Unit (QDU), I	Hospital Plató						
Bosch et al (2021). Montori- Palacín et al (2017).	QDU of a second-level district hospital (Hospital Plató) with 160 beds and providing healthcare for a population of 140,000 inhabitants.	The unit works as an ambulatory clinic evaluating patients with suspected severe conditions whose physical performance allows them to travel from home to hospital and back for visits and examinations.	The unit is staffed with two part-time general internists each working 4 hours per week, as well as administrative personnel.	Not described but appear to include CT scan, MRI, ultrasonography, endoscopy, scintigraphy, body FDG-PET, cytology/biopsy, bone marrow aspiration.	Suspected severe conditions	Primary care, emergency department, outpatient clinics, and inpatient wards.	Not described in detail, but included unintentional weight loss, adenopathies and/or palpable mases, anaemia, fever, gastrointestinal symptoms, test abnormalities, osteoarticular symptoms, respiratory symptoms, unexplained tiredness, neurological	The general working protocol of the unit consists of a rapid first appointment after referral from primary care centres or the emergency departments of the hospitals (usually within 5 days), followed by preferential programming of diagnostics tests and subsequent visits until a diagnosis is made.

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
							disorders, ascites and other reasons (not defined).	
T 5	<u> </u>	,		United	Kingdom			
Harcourt et al (1998).	Care Centre, Bristo One stop clinic in a hospital (location not given but likely to be study author's centre - The Breast Care Centre, Frenchay Healthcare Trust, Bristol, UK)	Not stated	All clinics were conducted by the same <b>two surgeons</b> (one consultant, one staff grade)	Triple assessment (consisting of clinical examination, ultrasound scanning and cytology) and mammography, when needed.	Breast cancer	GP (primary care)	Women with no previous diagnosis of breast cancer, living within reasonable travelling distance of the hospital and whose general practitioner (GP) referral letter stated the presence of a breast lump	Triple assessment of each woman was conducted by either member of staff in the initial appointment. Mammography, when needed, was then carried out by radiologists in the hospital's general X-ray department. Cytology specimens were analysed in the pathology department sited elsewhere in the hospital. This system was constant over the course of the study.
Choudhury et al (2013).	A 'Rapid Diagnostic Clinic' (RDC) within the ENT department (of Barts Health NHS Trust, London)	The RDC provides multi-modality specialist assessment for new referrals, with on-site sonography and cytology.	NHS Trust, London  ENT head and neck specialist, either a consultant or specialist registrar, consultant head and neck radiologist, consultant histopathologist. This clinic is run on a weekly basis.	Ultrasonography, and fine needle aspiration cytology (FNAC)	Head and neck cancer	GPs and other specialities within the hospital	Not clearly stated. (Targeted referrals included patients revered via the 2WW scheme and non- 2WW referrals)	The RDC in this study was established based on National Institute of Clinical Excellence (NICE) recommendations for improving healthcare services for head and neck cancers. The RDC is a <b>one-stop diagnostic service</b> where all new target referrals for patients with suspected malignancy can receive <b>multi-modality specialist assessment</b> .
Demyelinatii	ng disease diagno		University College Lond			•		
Porter et al (2003).	Demyelinating disease diagnostic clinic (DDC) at the National Hospital for Neurology and Neurosurgery, University	The DDC aims to minimize the time between referral and completion of tests by carrying out tests on the same day and	The clinic is staffed by a consultant neurologist and a multiple sclerosis nurse specialist	Evoked potential (VEP) testing, magnetic resonance imaging (MRI), and blood screening	Multiple sclerosis	GP or another neurologist	GPs tend to refer patients with new neurological symptoms, lasting days or weeks with no obvious explanation. Neurologists refer difficult diagnostic	The DDC was modelled on the UK multiple sclerosis Society standards of healthcare set for the diagnostic phase.  The structure of the DDC provides an appropriate setting and experienced professional support to deal with the initial psychological impact of the diagnosis and offers ongoing support through patient/family

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	College London Hospitals	providing follow-up within four weeks.					cases including suspected primary progressive disease, those with an atypical presentation and those with nonorganic symptoms	health promotion and self-management programmes.  The clinic is designed to allow a 45-minute new patient appointment with the consultant neurologist and MS nurse, followed by access to visual evoked potential (VEP) testing, magnetic resonance imaging (MRI) and blood screening, as appropriate. Follow-up appointments to all patients are scheduled to allow 30 minutes with the neurologist and MS nurse followed by a further 30 minutes with the MS nurse in a quiet room. All newly diagnosed are followed up with one to one appointments with their families and have access to a structured educational programme entitled 'Working together to understand MS'.
			lbot Hospital, Neath, Wa			100	15	
Sewell et al (2020).	Rapid diagnostic centre (RDC), Neath Port Talbot Hospital, Wales, UK	Not stated	Consultant physician, a radiologist, a clinical nurse specialist (CNS), and a healthcare support worker (HCSW). Management and clinical guidance are provided by the RDC coordination manager and GP project lead. Two half-day clinics a week with five available clinic slots	It is unclear if the full range of investigative procedures available at the centre was reported but includes physical examination and computed tomography (CT)	Cancer	GP (primary care)	Patients with vague and/or non-specific symptoms suspicious of cancer, who do not meet criteria for referral under an urgent suspected cancer (USC) pathway	This pilot rapid diagnosis centre (RDC) allows GPs within targeted clusters to refer adults with vague and/or non-specific symptoms suspicious of cancer, who do not meet criteria for referral under an urgent suspected cancer (USC) pathway, to a multidisciplinary RDC clinic where they are seen within a week. Patients leave the clinic with either a diagnosis and management plan or further investigations booked.

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
Pallan et al (2005).	Community based, mobile diagnostic ultrasound service, in a primary care area in the West Midlands, England, UK	Not stated	The service is staffed by an independent radiographer	Ultrasound scans included abdominal, pelvic, transvaginal, renal, and prostate	Not specified	GP (primary care)	Not stated	The mobile diagnostic ultrasound service was radiographer-led and was provided to GPs by an independent radiographer.

## Appendix 2: Potential overlap of data for the studies conducted in Spain

Includes 11 individual studies investigating four diagnostic centres  NB: Groupings are by hospital site	
INIB. (ELUTIDIDUS SIG DA DOUGHIST SIG	
	nformation on
	ootential data
· · · · · · · · · · · · · · · · · · ·	crossover
Hospital Clínic de Barcelona – Barcelona - described as an 885 bed tertiary hospital with a reference population of around 550,000. Earlier sources describe it as a 8	340 bed tertiary hospital
with a reference population of around 540,000	
	Jnclear
<u>comparative cost analysis</u> QDUs between January 2009 Referral source vs QDU of <b>Hospital Plató</b> (secondary	
between two quick and January 2017 Referral reason unit)	
diagnosis units of different Number of visits	
levels of complexity. Sample size: 407 patients from Time to diagnosis	
Journal of Comparative each unit (the tertiary unit sample Diagnosis	
Effectiveness were randomly selected from Mean cost per visit	
Research, 10(5), pp.381- 6,960 consecutive patients) Mean cost per patient	
Direct and structural costs	
Indirect costs	
Personnel costs	
Diagnostic investigation costs	
	Potential QDU data
	overlap with Bosch 2021
	i.e pancreatic ca data
	only between 2009 and 2017)
pancreatic cancer? A Predictors of hospitalisation	2017)
retrospective study of 1004  Mean tumour size	
patients. Medicine, 2020, Tumour site	
vol. 99, num. 11, p. Cancer stage on presentation	
e19009. Charlson comorbidity index	
Surgical characteristics	
Mean cost per hospital stay	

Montori-Palacín et al (2017). Quick outpatient diagnosis in small district or general tertiary hospitals: A comparative observational study. Medicine 96 (22).  Bosch et al (2018). Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain BMC cancer, 18(1), pp.1-15.	2009 to 2016  2006 to 2016	Aged ≥18 referred to both settings (chosen randomly) Sample size: 866 participants, 336 from QDU1 and 530 from QDU2  Aged ≥18 years with lymphoma (4 types) Sample size: 1,779 patients. 1,184 outpatients (688 from QDU1 and 496 from QDU 2) and 535 inpatients	Time to diagnosis Diagnostic tests Diagnosis Onward referral Mean cost per hospital stay	(Hospital Clínic)	Potential QDU1 and 2 data overlap with Bosch 2021 (i.e patient data between 2009 and 2016) – note that cases were chosen randomly  Potential QDU1 data overlap with Bosch 2021 (i.e lymphoma data only between 2009 and 2016)
			Mean cost per visit  Mean cost per patient  Cost of diagnostic tests  Cost saving from hospitalisation  Personnel costs		
Brito-Zerón et al. (2014). <u>Diagnosing unexplained</u> <u>fever: can quick diagnosis</u> <u>units replace inpatient</u> <u>hospitalization?</u> European Journal of Clinical	2008 to 2011	All consecutive patients referred to the QDU between November 2008 and April 2011 due to undiagnosed fever Sample size: 344 patients, 176 from QDU and 168 controls (internal medicine department)	Participant characteristics Referral source Referral reason Number of visits Time to diagnosis Diagnosis Length of hospital stay	QDU (Hospital Clínic) vs internal medicine department (unclear if same wards as in Bosch 2020 and Bosch 2018)	Potential QDU data overlap with Bosch 2021, i.e FUN data only between 2009 and 2011

Investigation, 44(8),			Diagnostic tests		
pp.707-718.			Death during evaluation		
			Onward referrals		
			Mean cost per hospital stay		
			Mean cost per visit		
			Mean cost per patient		
Bosch, Jordán and López-	2006 to 2012		Participant characteristics		QDU data overlap with
Soto (2013). Quick		the QDU and patients admitted to			Bosch 2012a (2,000
diagnosis units: avoiding			Referral reason	medicine service	consecutive patients
referrals from primary care			Referral appropriateness		evaluated between 2007
to the ED and			Time to first visit		and 2010 <b>)</b>
hospitalizations The			Number of visits		
American Journal of		Sample size: 4,170 QDU patients			
Emergency		and 3.030 hospitalised patients	Time to diagnosis		
Medicine, 31(1), pp.114-			Diagnosis		
123			Length of hospital stay		
			Death during evaluation		
			Onward referrals		
			Mean cost per hospital stay		
			Mean cost per process		
			Mean cost per visit		
			Patient preferences		
Bosch et al (2012a). Quick	2006 to 2010	Consecutive QDU patients		QDU patients vs patients admitted to	QDU data overlap with
diagnosis units versus				the internal medicine department	Bosch, Jordán and
hospitalization for the		2007 and July 2010 and patients			López-Soto 2013 (2,000
diagnosis of potentially			Time to first visit		consecutive patients
severe diseases in Spain		548), cachexia-anorexia	Number of visits		evaluated between 2007
Journal of Hospital		syndrome (n = 458), febrile	Time to diagnosis		and 2010)
Medicine, 7(1), pp.41-47		syndrome (n = 240), and	Diagnosis		
		adenopathies or palpable masses			
			Charlson comorbidity index		
			Hospital bed days saved		
		•	Onward referrals		
		Sample size: 2,000 QDU patients			
			Cost per process		
		the internal medicine department			
			Patient satisfaction		
			Patient preferences		

Bosch et al (2012b). Comparison of Quick Diagnosis Units and Conventional Hospitalization for the Diagnosis of Cancer in Spain: A Descriptive Cohort Study Oncology, 83(5), pp.283-291.	2008 to 2010	suspected and ultimately confirmed (pathologically proven) cancer evaluated between November 2008 and April 2010. Also included patients newly diagnosed with cancer admitted to the internal medicine department Sample size: 169 (62.8% of 269 consecutive patients evaluated	Patient characteristics Referral source Reason for referral/consultation Time to first visit Number of visits Time to diagnosis Length of hospital stay Diagnosis Onward referral Mean cost per hospital stay Mean cost per visit Mean cost per process	QDU (Hospital Clínic) vs internal medicine department	potential QDU data overlap with above studies by Bosch et al.
Bosch et al (2012c). Quick diagnosis units or conventional hospitalisation for the diagnostic evaluation of severe anaemia: A paradigm shift in public health systems? European Journal of Internal Medicine, 23(2), pp.159-164.	2006 to 2010		Referral source	QDU (Hospital Clínic) vs internal medicine department	Likely overlap of patient data with above studies
Bosch et al (2011).  Outpatient Quick  Diagnosis Units for the  evaluation of suspected  severe diseases: an  observational, descriptive	2008 to 2010	Sample size: 1,000 QDU patients and ?150 patients admitted to	Participant characteristics Referral source Referral reason	QDU (Hospital Clínic) vs internal medicine department	Likely overlap of patient data with above studies

study. Clinics, 66(5), pp.737-741.			Time to diagnosis Diagnosis Length of hospital stay Diagnostic tests Hospital bed days saved Onward referral Mean cost per hospital stay Mean cost per process Mean cost per patient Patient satisfaction Patient preference		
Bellvitge Hospital – Barcelor	na - described as a	750 bed tertiary hospital with a refe	erence population of around 350,000		
Sanclemente-Ansó et al (2016). Cost-minimization analysis favors outpatient quick diagnosis unit over hospitalization for the diagnosis of potentially serious diseases. Eur J Intern Med; 30:11-17. doi: 10.1016/j.ejim.2015.12.015	2008 to 2012	Patients diagnosed with severe anaemia, lymphoma, and lung cancer selected from consecutive patients referred to the unit between March 2008 and June 2012 and those electively hospitalised at the Internal Medicine Department of the hospital for diagnostic workup during the same period and who	Referral source Number of visits	QDU (Bellvitge) vs internal medicine department	Potential QDU data overlap with Bosch 2018 (QDU2)

## **APPENDIX 3: Resources searched during Rapid Review Searching**

## Table 6: Resources searched

Resource Resource	Success or relevancy of the retrieval
Priority COVID resources for reviews	
Cochrane COVID Review Bank (Browse list of titles) https://covidreviews.cochrane.org/search/site	Searched, nothing found
WHO Global Coronavirus Database - secondary evidence (Use filter options to limit search results to secondary evidence under "Type of Study" and English language under "Language") https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/	Searched, results found
L*OVE COVID - systematic reviews (Links to the systematic reviews section) https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?population=5e7fce7e3d05156b 5f5e032a&classification=systematic-review	Searched, nothing found
VA-ESP (Use "search this page" to limit to a concept. A second (or subsequent) concept can be applied to the results list by using "search this page" again.) https://www.covid19reviews.org/index.cfm	Searched, nothing found
Additional COVID resources for reviews (Tailor the list according to the topic and potential evidence base. In some cases, it may be scan the main (generic) source rather than COVID-19 specific product; listed under second	dary research)
LitCovid (Subset of PubMed. Abstracts do not download, but if using EndNote or Mendeley you can use the 'Find Reference Updates' feature to import the abstracts from PubMed. Covered by VA-ESP for reviews) https://www.ncbi.nlm.nih.gov/research/coronavirus/	Not searched, not relevant
EPPI-Centre - Living map of the evidence of studies on COVID-19 identified in MEDLINE and EMBASE, that groups the evidence into broad themes (Select "Access current version" below first picture) https://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingsystematicmapoftheevidence/tabid/3765/Default.aspx	Not searched, not relevant
EUnetHTA – COVID 19 response (Not a searchable database but lists of evidence reviews covering diagnostics and treatments) https://eunethta.eu/services/covid-19/	Not searched, not relevant
Trip – for guidelines (TripPro can be accessed by an institutional based subscription based via institution, otherwise use Trip) As a COVID-19 resource for guidelines – search for (covid-19 OR covid19 OR sars-cov-2 OR sars-cov2 OR sarscov2) and the topic/concept of interest, then filter by UK guidelines, covers NICE and SIGN. Can also filter for non-UK guidance. https://www.tripdatabase.com/	Not searched, not relevant
For topic specific / focused review questions  COVID-END — Evidence summaries (McMaster Health Forum)  (Incorporates multiple COVID-19 resources, including many listed here. May be useful for topic specific/focused questions; may not be useful for border questions)  https://www.mcmasterforum.org/networks/covid-end	Not searched, not relevant
COVID-19 Evidence Alerts from McMaster PLUS <sup>TM</sup> Usefulness dependent on topic; may not be user friendly for broad/complicated questions https://plus.mcmaster.ca/COVID-19/	Not searched, not relevant
Additional COVID resources for primary studies	

	T
WHO Global Coronavirus Database - primary studies	Not searched,
(Use filter options to limit search results to primary evidence under "Type of Study" and	not relevant
English language under "Language")	
https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/	
<u>L*OVE COVID - primary studies</u>	Not searched,
https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?population=5e7fce7e3d05156b 5f5e032a&classification=primary-study	not relevant
Cochrane COVID-19 Study Register	Not searched,
https://covid-19.cochrane.org/	not relevant
LitCovid	Not searched,
(Subset of PubMed. Abstracts do not download, but if using EndNote or Mendeley you	not relevant
can use the 'Find Reference Updates' feature to import the abstracts from PubMed)	
https://www.ncbi.nlm.nih.gov/research/coronavirus/	
Secondary resources for reviews relevant to local/UK context	
United Kingdom Health Security Agency (UKHSA) – COVID-19 Rapid Reviews	Searched,
https://ukhsalibrary.koha-ptfs.co.uk/covid19rapidreviews/	nothing found
The part of the pa	Tiothing round
NICE resources for COVID reviews	Searched,
https://www.nice.org.uk/guidance/conditions-and-diseases/respiratory-	nothing found
conditions/covid19/products?Status=Published	
Any queries regarding ongoing or planned reviews contact Chris Connell:	
Chris. Connell @nice.org.uk	
Healthcare Improvement Scotland – COVID-19: Evidence for Scotland	Searched,
(not a searchable database but a lists Once for Scotland guidance, rapid evidence	nothing found
reviews, NICE rapid guidelines evidence covering diagnostics and treatments)	Tiothing round
http://www.healthcareimprovementscotland.org/our_work/coronavirus_covid-	
19/evidence_for_scotland.aspx	
Ireland, HSE Library, COVID-19 Summaries of Evidence	Searched.
Ireland, HSE Library, COVID-19 Summaries of Evidence not a searchable database but a list of all summaries of evidence that HIQA have been	Searched,
not a searchable database but a list of all summaries of evidence that HIQA have been	Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address)	
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/	nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) – Rapid reviews	nothing found Searched,
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology-	nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology-assessments?tid_1=All&field_hta_topics_target_id=112	nothing found Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE	nothing found  Searched, nothing found  Not searched,
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant)	nothing found Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies	nothing found  Searched, nothing found  Not searched,
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations	nothing found  Searched, nothing found  Not searched, not relevant
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada)	nothing found  Searched, nothing found  Not searched,
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations	nothing found  Searched, nothing found  Not searched, not relevant
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs)	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched,
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US)	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found  Searched, searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html	nothing found  Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found  Searched, searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US)	Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found  Searched, nothing found  Searched, searched, nothing found  Searched, searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living	Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living review: "Antibody Response Following SARS-CoV-2 Infection and Implications for	Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found  Searched, nothing found  Searched, searched, nothing found  Searched, searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology-assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living review: "Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review"	Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found  Searched, nothing found  Searched, searched, nothing found  Searched, searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living review: "Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review" https://www.ahrq.gov/coronavirus/health-systems-research.html	Searched, nothing found  Not searched, not relevant  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living review: "Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review" https://www.ahrq.gov/coronavirus/health-systems-research.html NASEM The National Academy of Sciences Engineering Medicine - Coronavirus	Searched, nothing found  Not searched, not relevant  Searched, nothing found  Searched, nothing found
not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/ HIQA Health Information and Quality Authority (Ireland) — Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology- assessments?tid_1=All&field_hta_topics_target_id=112  SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies  Secondary resources for reviews produced by key international organisations  NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service  ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data  CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html  AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living review: "Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review" https://www.ahrq.gov/coronavirus/health-systems-research.html	Searched, nothing found  Not searched, not relevant  Searched, nothing found

Australian National COVID-19 Clinical Evidence Task Force - Living Guidelines; mainly treatment https://covid19evidence.net.au/ (also incorporated in Trip)	Searched, nothing found
Secondary research resources for (non-COVID-19) reviews (Tailor the list according to the topic and potential evidence base, talk to stakeholder before with this type of search)	ore proceeding
Trip (TripPro can be accessed by an institutional based subscription based via institution, otherwise use Trip) https://www.tripdatabase.com/	Searched, results found
Cochrane Database of Systematic Reviews (CDSR) https://www.cochranelibrary.com/cdsr/reviews	Searched, results found
Campbell Collaboration https://www.campbellcollaboration.org/better-evidence.html	Searched, nothing found
JBI (via OVID) (Subscription based service – WCEBC has a subscription)	Not searched, maybe relevant
Epistemonikos https://www.epistemonikos.org/en/advanced_search https://www.epistemonikos.org/ (for the simple search)	Searched, results found
International HTA database (INAHTA-HTA) (for technology & intervention questions only) https://database.inahta.org/	Searched, nothing found
PROSPERO https://www.crd.york.ac.uk/prospero/	Searched, nothing found
PubMed/MEDLINE Filter by systematic reviews, reviews or meta-analysis once search undertaken https://pubmed.ncbi.nlm.nih.gov/	Searched, results found
Additional resources searched (Add in any additional resources that have been used, e.g. Scopus, HMIC, Social Care O	nline)
Google Advanced Search https://www.google.co.uk/advanced_search	Not searched, maybe relevant
Google Scholar https://scholar.google.com/	Searched, results found
Google	Searched, results found
EMBASE	Searched, results found

Appendix 4: Search strategy used for MEDLINE

Set#	Searched for	Results
S1	((TI,AB("community diagnos* centre*")))	1
S2	((TI,AB("community diagnos* clinic*")))	1
S3	((TI,AB("community diagnos* hub*")))	1
S4	((TI,AB("community diagnos* unit*")))	0
S5	((TI,AB("rapid diagnos* unit*")))	16
S6	((TI,AB("rapid diagnos* clinic*")))	12
S7	((TI,AB("rapid diagnos* centre*")))	4
S8	((TI,AB("rapid diagnos* hub*")))	0
S9	((TI,AB("mobile diagnos* hub*")))	0
S10	((TI,AB("mobile diagnos* clinic*")))	0
S11	((TI,AB("mobile diagnos* centre*")))	0
S12	((TI,AB("mobile diagnos* unit*")))	8
S13	((TI,AB("multidisciplinary diagnos* unit*")))	0
S14	((TI,AB("multidisciplinary diagnos* hub*")))	0
S15	((TI,AB("multidisciplinary diagnos* centre*")))	4
S16	((TI,AB("multidisciplinary diagnos* clinic*")))	2
S17	((TI,AB("mobile healthcare unit*")))	2
S18	((TI,AB("accelerate coordinate evaluate")))	3
S19	S18 OR S17 OR S16 OR S15 OR S14 OR S13 OR S12 OR S11 OR S10 OR S9 OR S8 OR S7 OR S6 OR S5 OR S4 OR S3 OR S2 OR S1	52
S20	((TI,AB("diagnos* centre*")))	408
S21	((TI,AB("diagnos* clinic")))	282
S22	((TI,AB("diagnos* clinics")))	86
S23	((TI,AB("diagnos* hub*")))	7
S24	((TI,AB("diagnos* unit*")))	462
S25	S24 OR S23 OR S22 OR S21 OR S20 OR S19	1247°
S26	(MJMESH.EXACT("Diagnostic Services"))	1211°
S27	S26 OR S25	2436°